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SUMMARY 
Laminin-α2 deficient congenital muscular dystrophy, classified as MDC1A, is a severe 
progressive muscle-wasting disease that leads to death in early childhood. MDC1A is caused by 
mutations in lama2, the gene encoding the laminin-α2 chain being part of laminin-2, the main 
laminin isoform present in the extracellular matrix of muscles and peripheral nerves. Via self-
polymerization, laminin-2 forms the primary laminin scaffold and binds with high affinity to α-
dystroglycan on the cell surface, providing a connection to the cytoskeleton via the 
transmembranous protein β-dystroglycan. Deficiency in laminin-α2 leads to absence of laminin-2 
and to upregulation of laminin-8, a laminin isoform that cannot self-polymerize and does not bind 
to α-dystroglycan. Therefore, in laminin α2-deficient muscle the chain of proteins linking the 
intracellular contractile apparatus via the plasma membrane to the extracellular matrix is 
interrupted. Consequently, muscle fibers loose their stability and degenerate what finally leads to 
a progressive muscle wasting. 
In previous studies, we have shown that a miniaturized form of the extracellular matrix protein 
agrin, which is not related to the disease-causing lama2 gene and was designed to contain high-
affinity binding sites for the laminins and for α-dystroglycan, was sufficient to markedly improve 
muscle function and overall health in the dyW-/- mouse model of MDC1A. In a follow-up study we 
provided additional evidence that mini-agrin, both increases the tolerance to mechanical load but 
also improves the regeneration capacity of the dystrophic muscle. 
We now report on our progress towards further testing the use of this approach for the treatment 
of MDC1A. To test whether mini-agrin application after onset of the disease would still ameliorate 
the dystrophic symptoms, we have established the inducible tetracycline-regulated “tet-off” 
expression system in dyW-/- mice to temporally control mini-agrin expression in skeletal muscles. 
We show that mini-agrin slows down the progression of the dystrophy when applied at birth or in 
advanced stages of the disease. However, the extent of the amelioration depends on the 
dystrophic condition of the muscle at the time of mini-agrin application. Thus, the earlier mini-
agrin is applied, the higher is the profit of its beneficial properties. 
In addition to gene therapeutical approaches, the increase of endogenous agrin expression levels 
in skeletal muscles by pharmacologically active compounds would be a safe and promising 
strategy for the treatment of MDC1A. To evaluate the potential and pave the way to further 
expand on the development of such a treatment, we determined whether full-length agrin 
ameliorates the dystrophic phenotype to a comparable extent as it was observed by application of 
mini-agrin. We provide evidence that constitutive overexpression of chick full-length agrin in dyW-/- 
muscle ameliorates the dystrophic phenotype, although not as pronounced as mini-agrin does.  
In conclusion, our results are conceptual proof that linkage of laminin to the muscle fiber 
membrane is a means to treat MDC1A at any stage of the disease. Our findings definitely 
encourage to further expanding on this therapeutic concept, especially in combination with 
treatment using functionally different approaches. Moreover, these experiments set the basis for 
further developing clinically feasible and relevant application methods such as gene therapy4 
and/or the screening of small molecules able to upregulate production of agrin in muscle. 
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I GENERAL INTRODUCTION 
1 Adult Skeletal Muscle Characteristics 
Three different kinds of muscles are found in vertebrate animals: cardiac muscle, smooth muscle 
and skeletal (or striated) muscle. The contraction of skeletal muscle is controlled by the nervous 
system and thus underlies voluntary control. In this respect, skeletal muscle differs from smooth 
and cardiac muscle, both able to contract without being stimulated by the nervous system. 
1.1 Structure and functional units of skeletal muscle 
A skeletal muscle consists of thousands of cylindrical muscle fibers, which are assembled by 
connective tissue and constitute the basic contractile units. The extensive connective tissue in 
skeletal muscles is responsible to combine the contractile myofibers into functional units (bundles 
or fascicles) and transform the contraction into movement. This force transduction is mediated via 
the myotendinous junctions (MTJ) at either end of the muscle, where myofibers attach to the 
skeleton by tendons. 
Each muscle fiber comprises myofibrils that are aligned in parallel, contains many nuclei and 
mitochondria that both are located just beneath the plasma membrane and dispose of an 
extensive endoplasmic (sarcoplasmic) reticulum that extends between the myofibrils. Myofibrils 
consist of a chain of repeating units called sarcomeres, which involve two kinds of filaments 
arranged in parallel. The thick filaments with a diameter of ~15nm are composed of the protein 
myosin and the thin filaments having a diameter of ~5nm are composed of the protein actin along 
with smaller amounts of the proteins troponin and tropomyosin. Sarcomeres impose the striated 
appearance and are the force generators in skeletal muscles.  
 
Individual adult skeletal muscles are composed of a mixture of myofibers with different 
physiological properties, Type I and Type II fibers, whereas a single motor unit always contains 
one type or the other, never both. The proportion of each fiber type within a muscle determines its 
overall contractile property. Type I fibers, also known as "slow-twitch" fibers, are resistant to 
fatigue and thus are dominant in muscles that depend on tonus, for instance those responsible for 
posture. They are loaded with mitochondria, depend on cellular respiration for ATP production 
and are rich in myoglobin and hence red in color. Type II fibers, known as "fast-twitch" fibers, 
fatigue easily and are dominant in muscles used for rapid movement. They contain few 
mitochondria, few myoglobin, but are rich in glycogen and depend on glycolysis for ATP 
production. 
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The number of muscle fibers is probably fixed early in life. In adults, muscle trophy is the balance 
between anabolic processes (the synthesis of contractile proteins and, to a minor extent, the 
proliferation and recruitment of progenitor cells) and catabolic processes (protein degradation due 
to calcium leakiness and the activation of proteases). Thus, increased strength and muscle mass 
is achieved by an increase in the thickness of the individual fibers as well as an increase of 
connective tissue.  
1.2 Sources of Energy  
The immediate source of energy for muscle contraction is ATP. Creatine phosphate is used as a 
storage of "high-energy" phosphate bonds and thus is produced when ATP levels are high. 
During exercise, creatine phosphate can donate the high-energy phosphate back to ADP to form 
and replenish ATP. This reversible reaction is catalyzed by the enzyme creatine kinase (CK). A 
limited source of ATP in skeletal muscle fibers is glycogen. Glycogen can degrade by 
glycogenolysis and is used to keep the muscle functioning in case it fails to receive sufficient 
oxygen to cover its ATP needs by respiration. Cellular respiration not only is required to cover the 
ATP needs of a muscle engaged in prolonged activity (thus causing more rapid and deeper 
breathing), but is also required afterwards to enable the body to re-synthesize glycogen from the 
lactic acid produced earlier. 
1.3 Molecular Basis of Force Transduction 
1.3.1 The "actin-myosin sliding mechanism" 
Muscle contraction is produced by converting the chemical energy of ATP into mechanical work, 
which is executed by the sarcomeric units of the myofibrils. Shortening of the sarcomeres 
produces the shortening of the myofibril what in turn shortens the muscle fiber resulting in muscle 
contraction. Tightening of the sarcomere itself occurs by sliding of actin filaments against myosin 
filaments. Each molecule of myosin in the thick filaments contains a globular subunit, the myosin 
head, which contains binding sites for the actin molecules in the thin filaments and for ATP. 
Activation of the muscle fiber causes the myosin heads to bind to actin. An allosteric change 
occurs which draws the thin filament a short distance (~10nm) past the thick filament. Then the 
linkages break (for which ATP is needed) and reform farther along the thin filament to repeat the 
process. As a result, the filaments are pulled past each other.  
1.3.2 From Activation to Contraction 
Skeletal muscle cells are electrically excitable. Thus, the induction for contraction arrives as an 
electrical signal from the motor neuron contacting the muscle fiber at the highly specialized 
neuromuscular junction (NMJ). The terminals of motor axons contain thousands of vesicles filled 
with acetylcholine (ACh). When an action potential reaches the axon terminal, hundreds of these 
vesicles discharge their ACh onto the specialized area of the postsynaptic membrane containing 
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clusters of acetylcholine receptor channels (AChR). AChRs are 300kDa glycoproteins composed 
of five transmembranous polypeptides; α2, β, γ or ε, δ, together forming a cation channel. Binding 
of ACh molecules to the two α-subunits of each AChR, opens the channels and leads to a locally 
large Na+ influx into the muscle fiber creating an end plate potential. If the end plate potential 
reaches the threshold voltage (~ −50 mV), sodium ions flow in with a rush and an action potential 
is created and propagates down the length of the fiber. 
Immediately following the action potential, the enzyme acetylcholinesterase (AChE)5 breaks down 
the ACh in the synaptic cleft, the sodium channels close and the resting potential of the fiber is 
restored by an outflow of potassium ions. The muscle fiber is ready to receive and process a next 
nerve impulse. 
Calcium ions (Ca2+) link the action potentials in a muscle fiber to contraction. In resting muscle 
fibers, large quantities of Ca2+ are stored in the endoplasmic (sarcoplasmic) reticulum. Along the 
plasma membrane (sarcolemma) of the muscle fiber, invaginations of the membrane form tubules 
of the "T-system". These tubules plunge repeatedly into the interior of the fiber and terminate 
near the calcium-filled sarcoplasmic reticulum. Each action potential propagates quickly along the 
sarcolemma, hence is carried into the T-system and triggers the release of Ca2+ ions. The Ca2+ 
diffuses among the thick and thin filaments where it binds to troponin that is connected to 
tropomyosin located on the thin actin filaments. Ca2+-binding to troponin allows the tropomyosin 
molecules to shift their position so that myosin heads can bind to the actin filament and the 
sarcomere can contract. When the process is over, the calcium is pumped back into the 
sarcoplasmic reticulum using a Ca2+ ATPase. 
 
One muscle can be driven by many motor neurons, but each muscle fiber is innervated by a 
single axon terminal of a motor neuron that in turn can branch and innervate several muscle 
fibers.  
The compound of muscle fibers innervated by the same motor neuron is called a motor unit. 
Although the response of a motor unit is all-or-none, the strength of the response of the entire 
muscle is determined by the number of motor units activated. A motor unit is small in muscles 
over which we have precise control. For example, a single motor neuron triggers fewer than 10 
fibers in the muscles controlling eye movements, in contrast, a single motor unit for a muscle like 
the gastrocnemius muscle may include 1000–2000 fibers scattered uniformly through the muscle. 
1.3.3 Formation of the Neuromuscular Junction (NMJ) 
To ensure speed and reliability of transmission, the mature NMJ has to be highly specialized and 
organized. It is a morphologically complex structure formed by the presynaptic motor neuron, the 
Schwann cells, the interposed basal lamina and the postsynaptic muscle fiber, all tightly 
connected to each other. The postsynaptic muscle fiber membrane is depressed into shallow 
gutters, which in turn are invaginated into 1μm deep junctional folds, whose openings are directly 
opposite the presynaptic active zones enhancing transmission. 
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Formation of the neuromuscular junction depends on inductive interactions between the 
developing nerve and muscle6,7. At the NMJ, several proteins are highly concentrated, specialized 
and organized compared to extrasynaptic regions. Underneath the neuromuscular synapse, 
aggregates of muscle nuclei selectively express mRNA encoding postsynaptic proteins such as 
rapsyn and AChRs8,9. Moreover, highly influential postsynaptic organizers have the ability to 
aggregate and organize postsynaptic proteins. Nerve-derived agrin (7.4.8) turned out to play a 
key role in pre- and postsynaptic differentiations10,11-14,7,15. During development, neural agrin 
(7.4.8) is synthesized by motoneurons, transported down axons and released by the motor axon 
terminal into the synaptic cleft. Its N-terminus binds with high affinity to all laminins present in the 
synaptic basal lamina16,17. By interacting with a yet undefined receptor on the myotube surface, it 
initiates clustering of preexisting AChRs and other postsynaptic molecules under the nerve 
terminal. Thus, the uniformly distributed AChRs become highly concentrated in the postsynaptic 
membrane (~10,000/µm2 synaptically versus <10/µm2 extrasynaptically). A cytoskeletal 
apparatus associated with the cytoplasmic domains of AChRs helps to generate and maintain this 
high AChR density at synaptic sites. 
2 Muscle Integrity: The Major Proteins in Skeletal Muscle 
2.1 The Extracellular Matrix 
The intramuscular connective tissue (the interstitium) is extensively filled with blood vessels18-20 
what provides the contracting muscle with oxygen and substrate for energy production. It 
accounts for 1–10% of the skeletal muscle mass and varies quite substantially between different 
muscles21,22. The interstitium is organized into three discrete but continuous sheets. The 
epimysium encircles the whole muscle, whereas the perimysium ensheats bundles of muscle 
fibers (fascicles) including blood vessels. The endomysium encloses each individual muscle fiber 
with a random arrangement of collagen fibrils and further harbors fibroblasts, mast cells and 
macrophages23,24.  
Beneath the endomysium there is a highly structured sheet, the so-called basement membrane, 
which considerably contributes to the structural integrity of the host tissue25-28. Basement 
membranes are composed of two layers. The external reticular lamina mainly accounts for 
muscle's elasticity based on its proteoglycan-rich ground substance embedding fibrillar collagens 
and elastin. The internal basal lamina (50-100nm) is directly linked to the plasma membrane and 
surrounds each muscle fiber, is fused to Schwann cells, passes the 50nm wide synaptic cleft and 
extends into junctional folds. It provides a structural and regulatory environment for the muscle 
fibers.  
2.1.1 The Basal Lamina 
Basal laminas are adhesive substrates, which provide mechanical support and harbor signalling 
components variously promoting proliferation, survival, differentiation and gene expression in 
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neighboring cells. A basal lamina is composed of several collagenous glycoproteins, non-
collagenous glycoproteins, and proteoglycans. Its major constituents are collagen IV, laminins, 
nidogen, perlecan and fibronectin29,7,15. 
 
In the extrasynaptic basal lamina, the major structural component is the non-fibrillar collagen IV. 
Laminins constitute the major non-collagenous glycoproteins, while in adult muscle the 
predominant isoform is laminin-2 (α2, β1, γ1)30. Both, collagen and laminin self-assemble and 
form networks which are linked to each other by nidogen31,32,33. This basic structure of the basal 
lamina provides the extracellular scaffold to which muscle fibers are tightly anchored through 
interactions with membrane-associated and transmembranous receptors, in turn interacting with 
the cytoskeleton. Most importantly, laminin-2 interacts with the dystrophin-glycoprotein complex 
(DGC) and both collagen IV and laminins interact with transmembranous integrins. Deficiency or 
dysfunction in one of the proteins implicated in the tight basal lamina-sarcolemma-cytoskeleton 
linkage, impairs the essential structural muscle integrity and leads to muscular dystrophy34-36. 
 
Additionally, basal lamina components play active roles in myogenesis and synaptogenesis as 
well as in regenerative processes. Laminin and collagen IV provide binding sites for 
proteoglycans, in turn able to aggregate and present bioactive polypeptides critical for 
myogenesis such as fibroblast growth factors (FGF) and transforming growth factors (TGF)37. 
Moreover, the basal lamina is supposed to orient the formation of new muscle during satellite cell-
mediated regeneration. Indeed, muscles do regenerate in the absence of the basal lamina, but 
myotubes are not oriented in parallel what markedly affects the resulting stability and force 
generation.  
 
At NMJ, the basal lamina is structurally and functionally highly specialized. Several protein 
isoforms are concentrated or specific for the synaptic basal lamina38. It is supposed to markedly 
contribute to the tight adhesion at the neuromuscular junction39. 
a. Laminins 
Laminins constitute large heterotrimeric glycoproteins of nearly 800kDa and ~100nm in length40. 
At least 15 different heterotrimers are known to be formed out of 5 α, 3 β and 3 γ chains, each 
encoded by a different gene41-45,46. Three chains, one of each subtype, bind together via their 
central coiled-coil domains and finally constitute a molecule with one long arm and up to three 
short arms47. The α−chain of laminin extends beyond the long arm coiled-coil to form the G-
domain, which typically consists of five globular modules (LG1-LG5)48 important for interactions 
with cell surface binding partners. 
 
Several laminin isoforms (laminin-1, -2, -3, -4, -10, -11, and -12) are able to self-assemble via 
their short arms and thus form a network to which other basal lamina constituents can bind49-52. In 
contrast, laminin-6, -7, -8, -9, -14 and -15 fail to polymerize due to lack of most of the α-subunit 
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short arm. These truncated laminins might offer an advantage in a situation where large 
rearrangements in basement membrane are required as it is the case during development or 
regeneration processes53. 
Laminins are implicated in multiple interactions with other extracellular matrix or cell-surface 
proteins and thus play a crucial role in basal lamina integrity54,27,28. The short-arm of the laminin 
γ1 chain (the predominant γ-chain in muscle) is involved in nidogen binding and thus provides for 
the important connection of the laminin and collagen IV networks32,33. Moreover, the basal lamina- 
proteoglycan agrin, binds strongly to the long arm of all laminin isoforms17. The G-domains of 
several laminin isoforms interact with β1-integrins, heparin and heparan sulfates. Some laminin 
isoforms additionally bind to α-dystroglycan40,55,56 ,57. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure and isoform-specific interactions mediated by laminins 
(from Miner and Yurchenco, 2004)3
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Laminin isoforms have restricted distributions within the basal lamina, especially in regard to 
extrasynaptic and synaptic regions, what attributes highly specific functions to the different 
isoforms. Moreover, the expression of distinct laminin chains is tightly regulated during 
myogenesis, pointing to laminin's implication in myofiber formation and synaptogenesis58-60. 
 
Initially, during embryonic development in mice, the laminin α2, α4 and α561 chains are present in 
muscle basal lamina53. These α-chains all assemble to heterotrimers together with the β1 and γ1 
chains, giving rise to laminin-2 (α2, β1, γ1), laminin-8 (α4, β1, γ1) and laminin-10 (α5, β1, γ1). 
Postnatally, the laminin α4 and α5 chains disappear from the extrasynaptic but not from the 
synaptic region. Consequently, laminin-2 (α2, β1, γ1) becomes the predominant laminin isoform 
present in extrasynaptic basal lamina of the adult skeletal as well as in cardiac muscle and 
peripheral nerves57,62-64.  
 
Laminin-2 (Fig. 2) self-polymerizes to form a laminin network in the basal lamina. Moreover, the 
G-domain of laminin-2 (constituted by the laminin-α2 chain) binds to α-dystroglycan on the cell 
surface (LG4, LG5), as well as to the transmembranous integrin α7β1 (LG1-LG3), the principal 
integrin isoform in striated muscle65-68. Both of these laminin-2 receptors interact with the 
cytoskeleton and are thought to be critical to maintain normal muscle function since they control 
cellular activities such as adhesion or migration, differentiation and polarity, proliferation or 
apoptosis, and gene expression56,69-77. Thus, Laminin-2 provides for the extracellular scaffold 
allowing the anchorage of muscle fibers to the basal lamina and at the same time serves as an 
extracellular ligand for membrane-associated and transmembranous receptors in turn interacting 
with the cytoskeleton. In conclusion, laminin-2 has an essential role in maintaining the structural 
integrity of the skeletal muscle. 
 
Previously, laminin isoforms containing a laminin-α2 chain, namely laminin-2 (α2, β1, γ1), laminin-
4 (α2, β2, γ1) and laminin-12 (α2, β1, γ3) were denoted as merosin. The importance of laminin-α2 
subunits in the development and maintenance of muscle and nerve is demonstrated by mutations 
that affect this chain78-83. Laminin-α2 deficiency causes a severe muscular dystrophy, termed 
MDC1A.  
 
The synaptic basal lamina is rich in β2-containing trimers, which were shown to stop motor axon 
growth and to initiate differentiation into nerve terminals in vitro84,85. The presence of laminin α2, 
α4, and α5 chains in the synaptic basal lamina give rise to laminin-4 (α2, β2, γ1), laminin-9 (α4, 
β2, γ1) and laminin-11(α5, β2, γ1), all of which might be involved in presynaptic differentiation.  
Laminin-11 promotes presynaptic differentiation and repels Schwann cell processes; laminin-9 
promotes the precise alignment of pre- and postsynaptic specializations; and laminin-4 may be 
important for structural integrity60,86-88. 
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b. Collagen 
Proteins of the collagen family are the major structural components of the extracellular matrix24,89. 
They are responsible for tissue strength and elasticity and also play dynamic roles in promoting 
cell growth and differentiation.  
 
The structure of collagen constitutes a long and thin rod-like protein consisting of 3 coiled 
subunits. The triple helix gives collagen a rigid structure and renders it resistant to proteolysis. 
Collagen is principally produced by fibroblasts and their synthesis is regulated by complex 
interactions between growth factors, hormones and cytokines, whereas TGFβ and PDGF play a 
stimulating and glucocorticoids an inhibiting role. 
 
Several collagen types (up to 7) have been identified in intramuscular connective tissue90-92. The 
fibrillar collagen types I, II, and III are major components of the epimysium and the perimysium, 
whereas the non-fibrillar type IV collagen constitutes the principal collagenous material in the 
myofiber basal lamina. In contrast to fibrillar collagens, the non-fibrillar type IV collagen has a 
more flexible structure. Hence, self-polymerization of collagen type IV does not form ordered 
fibrillar structures, rather than a flexible filamentous meshwork93,94 that is stably linked to the 
laminin network by interactions with nidogen and likely provides stability at sites or moments of 
mechanical stress27,50,95,96.  
 
Isoforms of collagen IV are differentially distributed with regard to the synaptic basal lamina, 
suggesting distinct isoforms to exhibit unique functions. Extrasynaptic portions of muscle contain 
the α1(IV) and α2(IV) chains, whereas synaptic portions primarily contain the α3 – α5(IV) 
chains97,98. 
Figure 2: Interactions of laminin-2. 
Laminin-2 is the predominant laminin 
isoform present in the extracellular 
matrix of matured muscle and 
peripheral nerves. 
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c. Nidogen 
Nidogen, also known as entactin, is a ubiquitous component of basal laminas. Most importantly, 
nidogen provides the primary link between the laminin and collagen IV networks99-101. It is a 
glycoprotein of about 150kDa  composed of three globular domains (G1–3)102,103. The G2 domain 
binds collagen IV, perlecan and fibronectin, whereas the G3 domain binds with high affinity to the 
laminin-γ1 chain104-106. However, nidogen-deficient animals appear to develop normally and there 
is no evidence of structural deformity in the basement membrane107, suggesting either that 
nidogen has no structural role in the basement membrane or more likely that its absence is 
compensated for by other proteins, such as nidogen-2108. 
d. Heparan Sulfate Proteoglycans (HSPG) 
Proteoglycans are complex macromolecules consisting of a protein core to which one or more 
glycosaminoglycan (GAG) moieties are covalently attached. GAGs are linear polymers of 
repeating disaccharides. They constitute highly negatively charged, viscous molecules, whose 
low compressibility provides structural integrity to cells.  
Heparan sulphates are the GAG chains of heparan sulphate proteoglycans (HSPG), which exist 
as integral membrane proteins or as secreted extracellular matrix proteins109. The affinity for a 
large number of proteins has implicated HSPG in many cellular processes such as cell 
proliferation, cell differentiation, angiogenesis, metastasis, tissue repair, cell adhesion, 
sequestering of growth factors110-113, lining blood vessels114, and serving as a structural 
component of basal laminas115-119. In muscle, three main basement membrane HSPGs have 
been well characterized, agrin120,121, perlecan122 and Collagen XVIII120,121. 
 Agrin 
Agrin, isolated by Nitkin et al. (1987)12 is a HSPG with a protein core of ~225kDa in size. 
Attachment of GAG chains at two different sites elevate the molecular weight of agrin to 400 to 
600kDa 16,120,123,124. It comprises nine follistatin-like domains resembling protease inhibitors, EGF-
repeats and laminin-like globular domains125,126.  
Agrin is synthesized by different tissues such as kidney, lung, brain, spinal cord, muscles and 
neurons. As a large multidomain protein, agrin interacts with many basal lamina and cell surface 
proteins, including collagen type IV, laminin17, tenascin, neural cell adhesion molecules (N-CAM), 
α-dystroglycan127 and integrins7 as well as with carbohydrates such as heparin, heparan 
sulphates and sialic acid128. 
The mRNA of agrin undergoes tissue-specific alternative splicing at several sites129. Amino acid 
inserts at the carboxy-terminus (4.8) are termed A and B in chicken or y and z in rodents. The 
insert of eight amino acids at B/z site is responsible for agrin‘s ability to induce a signalling 
cascade resulting in AChR-aggregation as well as clustering of AChE and voltage-gated sodium 
channels at the NMJ130,131,10,132-134. The insert of four amino acids at A/y site is required for agrin 
binding to heparin via the second laminin-like globular domain132. In contrast, non-neuronal agrin 
isoforms including muscle-derived agrin, lack amino acid inserts at the C-terminus and fail to 
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cluster AChRs 131,135,127. Instead, muscle-derived agrin binds with a 10 times higher affinity to α-
dystroglycan than nerve-derived agrin132, suggesting an organizing and stabilizing function 136-138. 
 Perlecan 
Perlecan is a large HSPG with a 270-467kDa core protein consisting of various domains122,139. In 
muscle, perlecan is present in both extrasynaptic and synaptic basal lamina, but is concentrated 
at synaptic sites116,117,140. Perlecan may promote the stability of basal lamina through a broad 
spectrum of protein interactions, including laminin, collagen IV, nidogen, fibronectin and itself141-
144. It is also involved in the adhesion of the basal lamina to the cell surface, since it binds to and 
co-localizes with α-dystroglycan on the muscle membrane145. Moreover, perlecan may regulate 
the activity of growth factors146, since its heparan sulphate chains bind fibroblast growth factors 
(FGF) and enhance their activity147. In the synaptic basal lamina, perlecan mediates the 
anchoring of AChE148.  
2.2 Membrane-associated and Cytoplasmic Proteins 
The muscle fiber plasma membrane (sarcolemma) is a highly specialized cellular structure. It 
constitutes the physical boundary to the cell and acts as the surface through which the cell 
interacts with its environment. The sarcolemma contains a very close and highly organized 
contact with the extracellular matrix. 
2.2.1 The Dystrophin-Glycoprotein Complex (DGC) 
The dystrophin-glycoprotein complex (DGC) is a specialization of cardiac and skeletal muscle 
membrane149-153. The DGC is composed of transmembranous, cytoplasmic, and extracellular 
proteins, including dystrophin, dystroglycan, sarcoglycans, sarcospan, syntrophins, dystrobrevins, 
caveolin-3, and neuronal nitric oxide synthase (nNOS). It provides for the tight link of the 
cytoskeleton via the sarcolemma to the basal lamina56,71,154. This linkage is essential for muscle 
stability, since during muscle contraction, the contractile machinery inside the myofibers has to 
remain connected with the sarcolemma and the extracellular matrix to maintain muscle integrity. 
Without this association, proper movement would be hampered and muscle fibers would risk 
damage. Hence, mutations or lack in members of this complex lead to more or less severe 
muscular dystrophies155,156. In addition to structural support, signal transduction properties are 
attributed to the DGC157-159. At the NMJ, the DGC is concentrated and specialized, implying its 
role for synaptic maturation as well as for maintenance of the NMJ160.  
a. Dystrophin 
Dystrophin is a 427kDa cytoplasmic protein161,162  that serves as a molecular link between the 
contractile elements of muscle cytoskeleton and the muscle fiber membrane, which in turn is 
linked to the surrounding basal lamina by further components of the DGC155.  Dystrophin's N-
terminus interacts with the filamentous γ-actin of the contractile apparatus of the muscle163-166, 
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whereas its C-terminus interacts with the intracellular portion of the transmembranous protein β-
dystroglycan71,167-170.   
Genetic disruption of dystrophin leads to Duchenne muscular dystrophy (DMD) and the milder 
Becker muscular dystrophy (BMD)149. In the absence of dystrophin, the transmembranous DGC 
elements as well as the sarcoglycan complex are unstable and are reduced at the sarcolemma. 
This renders the muscle abnormally susceptible to damage from contraction171. 
 
At the NMJ, the dystrophin homologue utrophin is part of the DGC. Utrophin is localized with 
AChRs at the crests of postsynaptic junctional folds172,173 and is supposed to function in 
neuromuscular synapse maturation174-176,177. 
b. Dystroglycan 
Dystroglycan acts as an essential core component of the DGC by connecting the cytoplasmic 
components via the sarcolemma to the extracellular matrix of the muscle fiber 71,76,178,179.  
Dystroglycan is transcribed from a single gene and is posttranslationally processed into two 
subunits, namely α- and β-dystroglycan with a core molecular weight of 43kDa and 156kDa, 
respectively180. Dystroglycan is heavily glycosylated, what determines much of its binding 
properties and hence gives rise to different isoforms conferring distinct functions.  
 
β-dystroglycan is a single-pass transmembranous protein that intracellularly binds to 
dystrophin/utrophin, whereas the extracellular N-terminus is non-covalently anchored to its 
extracellular binding partner α-dystroglycan. Thus, β-dystroglycan tightly links the muscle 
membrane to its intra- and extracellular environment73,181,182.  
In turn, α-dystroglycan provides an important connection to the muscle fiber basal lamina scaffold 
by binding to different laminin isoforms. Moreover, α-dystroglycan interacts with agrin, perlecan, 
biglycan and neurexin134,160,183-188. Glycosylation defects of α-dystroglycan disrupts the binding to 
extracellular ligands such as laminin and leads to muscular dystrophy 189-196. 
 
At the NMJ, dystroglycan is involved in the maturation and maintenance of the postsynaptic 
membrane in adult animals. β-dystroglycan interacts with rapsyn, a cytoplasmic protein required 
for acetylcholine receptor clustering at NMJ197,198. Consequently the dystroglycan complex is 
necessary for stabilization of acetylcholine receptor clusters at NMJ199 as well as the localization 
of perlecan and subsequently AChE200,201. Moreover, ß-dystroglycan binds to Grb2, what links the 
DGC to the Ras/MAPK signalling pathway202.  
 
c. The Sarcoglycan-Complex and Sarcospan 
Sarcoglycans are glycosylated transmembranous proteins. In cardiac and skeletal muscle, they 
form a heterotetrameric complex composed of α−, β−, γ−, and δ-sarcoglycan, whereas the core is 
formed by β− and δ-sarcoglycan which are joined by the other subunits203. β− and δ-sarcoglycan 
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are also supposed to mediate the association of the sarcoglycan-complex to α-dystroglycan, thus 
fixing the complex to the rest of the DGC204. Moreover, the sarcoglycan complex binds to α-
dystrobrevin205 and stabilizes sarcospan206 at the membrane. Nevertheless, there is no direct 
association with dystrophin.  
 
The precise function of the sarcoglycan-complex has remained unclear. However, it stabilizes the 
dystrophin–dystroglycan interaction and may regulate the adhesion to laminin-2 in the 
extracellular matrix. The extracellular domains of α-sarcoglycan may be involved in signalling 
critical for muscle cell survival207. Mice lacking sarcoglycan genes effectively model human 
mutations leading to different types of limb girdle muscular dystrophy.  
  
d. Syntrophins and Dystrobrevin  
Three syntrophin isoforms exist in skeletal muscle, α−, β1- and β2-syntrophin208-210. Syntrophins 
are cytoplasmic adaptor proteins thought to recruit signalling proteins to the muscle fiber 
membrane. The linkage to the DGC is mediated via binding to dystrophin/utrophin and α-
dystrobrevin211. For this reason, syntrophins are secondarily abnormal in Duchenne muscular 
dystrophy212,213. Moreover, α-syntrophin binds neuronal nitric oxide synthase214,215 (nNOS), 
sodium channels212,216,217, aquaporin-4218,219, kinases220,221, the growth factor receptor bound 
adapter protein Grb2222, and ErbB4, a signalling protein implicated in promoting transcription from 
sub-synaptic nuclei in skeletal muscle223.  
 
In skeletal muscle, α-dystrobrevin-1, -2 and -3 are localized in the cytoplasm and, like 
syntrophins, are thought to serve as a scaffold for signalling proteins224-227. Moreover, α-
dystrobrevin binds to syntrophins, the sarcoglycan–sarcospan complex and directly interacts with 
dystrophin228,229. 
 
2.2.2 Integrins 
Integrins are integral receptor proteins which are of crucial importance for cell-extracellular matrix 
and cell-cell interactions230,231. Functional integrins consist of a α and a β subunit, both 
transmembranous glycoproteins that are non-covalently linked to each other.  
Integrin molecules are major structural components of adhesion complexes at the cell 
membrane232,233. Extracellular matrix ligands for integrins are known to be collagens, fibronectin, 
tenascin and laminin, while the β-subunit cytoplasmic domain of integrin is interacting with the 
cytoskeleton234,235. In this way, integrins establish a mechanical continuum along which forces can 
be transmitted from the outside to the inside of the cell, and vice versa236-239.  
 
Integrin α7β1 is the predominant integrin isoform found in skeletal and cardiac muscle. It is 
concentrated at MTJs but is also present along the sarcolemmal membrane and constitutes an 
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important receptor for laminin-1, -2 and –4. Integrin α7β1 mediates indispensable interactions 
between the cytoskeleton and the extracellular matrix that are independent of the DGC-mediated 
connection240-243,244. 
3 Laminin and its Receptors in the Peripheral Nervous System  
The speed and efficiency of propagation of action potentials along peripheral neurons are 
increased by insulating myelin sheaths formed by Schwann cells, which wrap around axons and 
form segments of about 1mm length. In between these segments, small regions of axon 
membrane remain bare, so-called nodes of Ranvier. Thus, the signal propagates along the axon 
by leaping from node to node. At site of muscle fiber contact, the axonal branch of a motor 
neuron loses its myelin sheath and makes a spray of fine boutons, which are capped by synapse-
associated Schwann cells. 
 
The peripheral nervous system (PNS) contains two distinct types of basement membranes. The 
perineurial basement membrane surrounds bundles of Schwann cell axon units and mainly 
contains laminin-9 (α4, β2, γ1) and laminin-11 (α5, β2, γ1)60,97,245. The endoneurial basement 
membrane surrounds each individual Schwann cell and contains a complex system of laminin 
isoforms and receptors that are differentially expressed in a precise temporal and spatial 
distribution. Its major laminin isoforms during development are laminin-2 (α2, β1, γ1) and laminin-
8 (α4, β1, γ1), whereas matured endoneurial basement membrane predominantly contains 
laminin-2, similar to muscle fiber basal lamina60,246. Laminins in the endoneurial basement 
membrane are strictly required for Schwann cell survival, interaction with axons, myelination, 
myelin maintenance and nerve regeneration. 
 
Aberrant laminin signalling induces pathogenesis such as for instance MDC1A and leprosy. For 
instance, mutations in the lama2 gene, coding for the laminin-α2 chain, cause both a muscular 
dystrophy and a peripheral neuropathy in human and mice (MDC1A). Null-mutants of laminin-α2 
chain showed presence of initial myelination. However, Schwann cells that lack laminin-2 (α2, β1, 
γ1), cannot send processes within axonal bundles, proceed with radial sorting, nor achieve a 1:1 
relationship with axons247. The sorting abnormalities are more severe in the proximal than in the 
distal PNS. Thus, the neuropathy derives from demyelination, mainly in the proximal part of the 
PNS, and results in a reduced nerve conduction velocity248. 
 
Laminin receptors in the peripheral nervous system are collagens, integrins and dystroglycan. 
Schwann cell-specific inactivation of the β1-integrin gene, prevented radial sorting of axons, 
similar to the phenotype observed in laminin-α2 mutants. Hence, the defect may arise from 
disrupted signalling from laminin to the cytoskeleton due to lack of its receptor. This elevates the 
abundant α6β1-integrin to the putative laminin receptor involved in radial axonal sorting by 
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Schwann cells. Conclusively, signals from laminins allow Schwann cells to radially sort axons 
during development, by mediating the main regulatory events via β1-integrin-mediated 
cytoskeletal rearrangements.  
 
Glycosylation of α-dystroglycan is very important for its function as a laminin receptor. Indeed 
Largemyd mice, bearing a deletion of the LARGE glycosyltransferase leading to hypoglycosylation 
of dystroglycan193,249, have both a muscular dystrophy and a peripheral neuropathy. Moreover, 
Largemyd neuropathy also includes unsorted naked axons suggesting that another substrate of 
LARGE may be β1-integrin. In contrast, Schwann cell-specific inactivation of dystroglycan causes 
a late onset neuropathy, involving hypomyelination and abnormally folded myelin sheaths. 
However, there are no abnormalities in radial sorting. 
 
Leprosy is one of the leading causes of non-traumatic peripheral neuropathy worldwide. The 
Mycobacterium leprae has a special tropism for Schwann cells because it binds laminin-2 in 
endoneurial basal lamina and uses laminin receptors, in particular α6β4-integrin and 
dystroglycan, to enter Schwann cells. When the mycobacterium binds these receptors, it is able 
to cause Schwann cell de-differentiation, causing demyelination250.  
4 Development of Skeletal Muscle: A Short Overview 
All vertebrate skeletal muscles (apart from head muscles) derive from mesodermal precursor 
cells originating from the somites. During embryonic development, mesodermal precursor cells 
receive signals from surrounding tissues, which induce (Wnts, Sonic hedgehog, Noggin) or inhibit 
(BMP4) the expression of the primary myogenic regulatory factors (MRFs) Myf5 and MyoD. Myf5 
and MyoD both are transcriptional activators and their upregulation specify the precursors to the 
myogenic lineage. Proliferative myogenic cells that are MyoD and/or Myf5 positive are termed 
myoblasts. Committed myoblasts migrate laterally to form the myotome, which eventually forms 
the skeletal musculature. Pax3 promotes myogenesis in the lateral myotome. To induce terminal 
differentiation of myoblasts into myocytes, proliferating myoblasts withdraw from the cell cycle by 
upregulation of the secondary MRFs, myogenin and MRF4. Subsequently, myocytes start to 
express muscle-specific genes such as myosin heavy chain (MHC) and muscle-specific creatine 
kinase (MCK). Finally, mononucleated myocytes specifically fuse to each other to form a 
multinucleated syncytium, the myofibers, which mature into contracting muscle fibers. After 
sexual maturity, skeletal muscle is a stable tissue characterized by multinucleated postmitotic 
muscle fibers with their postmitotic myonuclei located at the periphery. 
 
A distinct subpopulation of myoblasts fails to differentiate, but remains associated with the surface 
of the developing myofiber as quiescent undifferentiated muscle satellite cells. Satellite cells are 
characterized by their high Pax7 expression, which is essential for the specification and 
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expansion of the satellite cell population. Satellite cell nuclei can be distinguished from myonuclei 
by their abundant heterochromatin reflecting their mitotic quiescence.  
 
Only recently the muscle precursor cells accounting for muscle growth were identified251. This 
newly identified population of muscle progenitor cells ingress the primary myotome directly from 
the central dermomyotome, express the transcription factors Pax3 and Pax7 and are maintained 
as a proliferating population in embryonic and fetal muscles throughout development. 
Subsequently, the Pax3/Pax7-positive cells become myogenic to form and contribute to the 
formation and growth of muscles during embryonic and fetal life. Thus, Pax3 and Pax7 have an 
important role in conferring myogenic potential on the muscle progenitor cells and thus assuring 
skeletal muscle formation252. The same studies provide evidence that satellite cells derive from 
the same novel population of muscle progenitor cells251,252. 
5 Regeneration of Skeletal Muscle  
Adult mammalian skeletal muscle is a stable tissue and elicits only a slow turnover of its 
constituent multinucleated muscle fibers (1–2 % of myonuclei are replaced every week). However, 
mammalian skeletal muscle has the ability of rapid and extensive regeneration in response to 
severe damage, resulting either from direct trauma such as extensive physical activity or from 
innate genetic defects. 
Damage of muscle is generally accompanied by disruption of the muscle fiber integrity. It is 
believed that damage of the sarcolemma or the sarcoplasmic reticulum promotes increased 
calcium influx, resulting in a loss of calcium homeostasis and increased calcium-dependent 
proteolysis that drives tissue degeneration.  
5.1 The Regeneration Process 
The muscle regeneration process is characterized by an early degenerative followed by a 
regenerative phase. The initial degenerative phase upon muscle injury is characterized by 
necrosis and an increased number of non-muscle mononucleated cells within the damaged site. 
Factors released by the injured muscle activate inflammatory and mononucleated myogenic cells. 
Neutrophils are the first inflammatory cells to invade the injured muscle, followed by 
macrophages becoming predominant about 2 days postinjury253. Macrophages infiltrate the 
injured site to phagocytose cellular debris and to activate myogenic cells.  
Muscle degeneration is followed by the activation of a muscle repair process. Myofiber 
regeneration is characterized by the activation of myogenic satellite cells to proliferate, 
differentiate, and fuse to necrotic fibers for repair or to each other for new fiber formation. 
Regenerating fibers are characterized by their small caliber and their centrally located myonuclei. 
Newly formed myofibers are often basophilic (reflecting high protein synthesis) and express 
embryonic/developmental forms of myosin heavy chain (MHC), reflecting de novo fiber 
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formation254. Once fusion of myogenic cells is completed, newly formed myofibers increase in 
size, and myonuclei move to the periphery of the muscle fiber. Under normal conditions, the 
regenerated muscle is morphologically and functionally indistinguishable from undamaged 
muscle.  
5.2 Satellite cells 
5.2.1 Localization and Identification of Satellite Cells 
Muscle satellite cells were first described in 1961255. Recent studies suggest that satellite cells 
derive from the same Pax3/Pax7 expressing cell population as muscle progenitor cells 251,252. 
Satellite cells constitute a population of undifferentiated mononuclear myogenic cells that remain 
localized in the periphery of myofibers within the basal lamina, hence their name256. They are 
present in all skeletal muscles and are associated with all muscle fiber types, albeit unequally 
distributed. Within the same muscle, higher numbers of satellite cells are found associated with 
slow type I muscle fibers than with fast type II fibers. The satellite cell population varies also with 
age and decreases in density over time. 
 
Pax7 is a transcription factor implicated in development of the skeletal muscle and is expressed 
only at low levels in adult muscle fibers. In contrast, it is a reliable marker of satellite cells, since it 
is specifically expressed in quiescent and activated muscle satellite cells up to myogenic 
differentiation when its expression is rapidly down-regulated257,258. Mice deficient in Pax7 in 
skeletal muscles (Pax7–/–), appear normal at birth but fail to grow postnatally. They show a 
decreased skeletal muscle mass resulting from a fiber size decrease rather than a decrease in 
fiber number. Pax7–/– animals fail to thrive and usually die within 2 wk after birth258,259. As 
expected, skeletal muscles have a striking absence of satellite cells and normal skeletal muscle 
regeneration is dramatically reduced258. 
5.2.2 Activation, Proliferation, Migration and Differentiation of Satellite Cells 
In the course of muscle regeneration, the myogenic program of satellite cells is activated. They 
exit their normal quiescent state and start to proliferate. Activation of satellite cells requires a 
temporally controlled upregulation of muscle transcription factors and muscle specific genes260-262. 
This process is regulated through mechanisms involving cell-cell and cell-matrix interactions as 
well as extracellularly secreted factors. Muscle injuries have been shown to cause the release of 
biologically active molecules into the extracellular space. Such molecules include the hepatocyte 
growth factor (HGF), shown to be the primary muscle factor capable of inducing quiescent 
satellite cell activation, fibroblast growth factor (FGF)263, insulin growth factors (IGF) and 
transforming growth factors (TGF) of the TGF-β family, such as myostatin which inhibits both 
proliferation and differentiation. 
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Satellite cell activation is not restricted to the damaged site. Damage at one end of a muscle fiber 
will activate satellite cells all along this fiber leading to the proliferation and migration of the 
satellite cells to the regeneration site264. In a moderate injury, the satellite cells use the basement 
membranes of necrotic fibers as a scaffold to ensure a similar position of the new muscle fibers. 
 
The process of satellite cell proliferation and differentiation during muscle regeneration is 
reminiscent of embryonic muscle development. In particular, the critical role of the MRFs is 
observed in both processes. At the molecular level, proliferation is characterized by the rapid 
upregulation of the two early MRFs, Myf5 and/or MyoD, followed by the co-expression of these 
two MRFs. Myf5 is supposed to promote satellite cell self-renewal, whereas MyoD promotes 
satellite cell progression to terminal differentiation265. 
 
After several rounds of proliferation, the majority of the satellite cells differentiates and fuse to 
form new syncytial myofibers or to repair damaged one. This requires expression of the late MRF 
members Myogenin and MRF4, upregulated in cells beginning their terminal differentiation 
program263,266. The differentiation program is then completed with the activation of muscle-specific 
proteins, such as myosin heavy chain (MHC), and the fusion to repair damaged muscle. Repaired 
or new myofibers grow to resemble original myofibers267.  
5.2.3 The Satellite Cell Pool 
Satellite cell self-renewal is a necessary process without which recurrent muscle regeneration 
would rapidly lead to the depletion of the satellite cell pool. Therefore a small proportion of 
satellite cells that has undergone proliferation returns to the quiescent state, thereby replenishing 
the satellite cell pool267,268. The molecular mechanisms underlying the satellite cell self-renewal is 
unclear, although several lines of evidence suggest a role for Myf5 in facilitating satellite cell self-
renewal.  
 
Whatever the cellular mechanisms for satellite cell self-renewal are, they do not compensate for 
the chronic loss of myonuclei throughout a lifetime as reflected by the reduction in satellite cell 
number with aging, nor do they compensate for the depletion of the satellite cell pool resulting 
from continuous activation of muscle repair in dystrophic muscles269,270.  Exhaustion of the mitotic 
potential of satellite cells, or replicative senescence, may be responsible for the decrease in the 
satellite cell pool with age270.   
6 Muscular Dystrophies 
Muscular dystrophies are clinically and molecularly heterogeneous diseases of a genetic origin. 
They are characterized by a progressive wasting of skeletal muscle starting at any age from birth 
to middle years and resulting in significant disability. Frequently, respiratory and cardiac functions 
are affected, leading to respiratory failure and premature death. Most of the dystrophies have a 
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very poor prognosis. The underlying mutations often affect the proteins implicated in the tight 
physical linkage of the actin cytoskeleton and the extracellular matrix, namely members of the 
DGC and associated proteins such as laminin-2. The entire structure of proteins protects the 
integrity of the muscle tissue against physical damage during repeated rounds of contraction and 
relaxation. Disruption of this link by deficiency in one of its constituents leads to a decreased 
mechanical stability and an increased fragility of the sarcolemma, especially during intense 
contractile activity34-36. This, in turn, results in increased calcium entry (although the molecular 
mechanisms have not been elucidated in detail) and focal or diffuse damage to the fiber. 
Damaged or dead fibers can be repaired or replaced by satellite cells, responsible for muscle 
growth and regeneration in postnatal life. However, the satellite cells of patients with muscular 
dystrophy share the same molecular defect and produce fibers that are also prone to 
degeneration. With time, the population of satellite cells is exhausted and the muscle tissue is 
progressively replaced by non-muscle tissue.  
It has proven very difficult to set up an accurate and clinically useful classification of the muscular 
dystrophies. Nevertheless, advances in the understanding of the molecular defects of these 
disorders have permitted a foundation for classification based on molecular biology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Overview of muscular dystrophies and their corresponding animal models.  
Muscular dystrophies implicated in the alteration of proteins involved in the basal lamina-sarcolemma-
cytoskeleton linkage are represented. 
 
(from Allamand et al., 2000) 1,2  
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6.1 Congenital Muscular Dystrophies 
Congenital muscular dystrophies (CMD) represent a clinically and molecularly heterogeneous 
group of autosomal recessively inherited neuromuscular disorders271,272. The incidence of CMD is 
4.65 in 100,000 and thus represents the most frequent autosomal recessive neuromuscular 
disease273. Various forms of congenital muscular dystrophies have been identified and attributed 
to mutations in several genes. 
 
 
Disease Gene Product 
MDC1A lama2 Laminin-α2 
MDC1B Unknown Unknown 
MDC1C FKRP Fukutin-related protein 
MDC1D LARGE Glycosyltransferase-like protein LARGE 
Walker-Warburg syndrome (WWS) POMT1/2 Protein O-mannosyl-transferase 1 
Muscle-eye-brain disease (MEB) POMGnT1 O-mannoside N-acetylglucosaminyl transferase 
Fukuyama CMD (FCMD) FCMD Fukutin 
Congenital myopathy274 ITGA7 Integrin α7 
CMD with early spine rigidity (RSS) SEPN1 Selenoprotein N 
COL6A1/2 α1 collagen VI + α2 collagen VI 
Ullrich CMD 
COL6A3 α3 collagen VI 
 
 
 
CMD is caused by mutations directly or indirectly interfering with the interaction of extracellular 
ligands and α-dystroglycan. These include cell surface receptors, such as integrins274,275 
(congenital myopathy), basal lamina proteins, such as laminin-2 (MDC1A), and extracellular 
matrix proteins, such as collagen VI (Ullrich CMD)276. Recently, post translational modification of 
proteins has been defined as a new area of focus for congenital muscular dystrophy research by 
the identification of a group of disease genes that encode known or putative glycosylation 
enzymes190,194,277,278. Walker-Warburg Syndrome (WWS279-284) and muscle-eye-brain disease 
(MEB280,285-287) are caused by mutations in 2 genes involved in O-mannosylation, POMT1 and 
POMGnT1, respectively. Fukuyama muscular dystrophy (FCMD288) is due to mutations in fukutin, 
a phospholigand transferase. MDC1C and LGMD2I are allelic, due to mutations in fukutin-related 
protein (FKRP289-291). Disruption of the glycosyltransferse-like protein LARGE is responsible for 
MDC1D192 caused by aberrant glycosylation of a-dystroglycan192,292. A common feature of 
MDC1C, WWS, MEB and FCMD is hypoglycosylation of α-dystroglycan189,293. Thus, a major 
feature in these pathologies is abnormal glycosylation of α-dystroglycan, impairing interactions 
Table 1: Congenital muscular dystrophies and their mutated genes
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with its normal extracellular matrix partners and giving rise to progressive muscle degeneration 
and abnormal neuronal migration189. 
For most of the mutations causing CMD, corresponding animal models are available, effectively 
imitating human pathology and allowing for molecular investigations in regard to therapeutic 
interventions. 
6.1.1  Laminin α2-deficient Congenital Muscular Dystrophy (MDC1A) 
The first report of a MDC1A patient derived from a French research group in 199481,294. In 
European populations, laminin-α2- or merosin-deficient congenital muscular  dystrophy (MDC1A) 
is one of the most frequent neuromuscular diseases in children, as it accounts for about 50% of 
all congenital muscular dystrophies78,80-82. 
a. Molecular and Cellular Basis of MDC1A  
The predominant laminin isoform in the extracellular matrix of skeletal muscles and peripheral 
nerves is laminin-2 (α2, β1, γ1). The three short arm N-terminals of laminin-2 allow self-
polymerization providing for a supporting laminin network in the basal lamina. The C-terminal 
globular domains of the α2 chain mediate the linkage to the sarcolemma mainly by interactions 
with the cell surface receptor α-dystroglycan which is part of the DGC56,69-77 and α7β1 integrin. In 
MDC1A the laminin-α2 chain is disrupted what consequently leads to absence of laminin-2 in the 
extracellular matrix of muscles and peripheral nerves. This leads to upregulation of the laminin-α4 
chain to yield laminin-8 (α4, β1, γ1)246,295. The laminin α4 chain lacks the short N-terminal arm 
what impedes the ability to self-polymerize. In addition, laminin α4 does not interact with the cell 
surface receptors α-dystroglycan and α7β1 integrin. These properties are likely to be important 
for the integrity of the muscle. Hence, the tight basal lamina-sarcolemma-cytoskeleton linkage is 
disrupted, what decreases the mechanical stability of the muscle and evokes cycles of de- and 
regeneration34-36. With time, this leads to replacement of muscle with fibrous tissue and thus to 
the muscle waste typical for this disease. 
 
MDC1A is caused by mutations in lama2, the gene encoding the laminin-α2 chain. Its cDNA 
spans 9.5kb and harbors 64 exons296 giving rise to a polypeptide chain of 3110 amino-acid 
residues. In human, the lama2 gene is located on 6q22–23. Most mutations in the lama2 gene 
result in complete absence of laminin-α2 protein; however, rare allelic mutations can result in 
partial protein reduction297. Analysis of the laminin-α2 chain cDNA or the lama2 gene itself 
showed that small deletions or insertions mostly localized in the N-terminal domain (exons 1–31), 
induce complete merosin deficiency and a severe phenotype298. Mutations in the last exons of the 
G domain (exons 58 to 64) result in the expression of partially functional laminin-α2 chain, 
retaining at least some of its normal functions and thus are often associated with somewhat 
milder forms of CMD80,298,299. 
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In addition to absence of laminin-2 (α2, β1, γ1), mutations in the gene for laminin α2 leads to lack 
of the laminin-4 (α2, β2, γ1) at the NMJ60. Laminin-4-deficient synapses fail to develop proper 
postsynaptic folds300,301. The mechanism by which laminin-4 regulates fold formation likely 
includes activation of α7-integrins. Splice variants of integrin-α7 are concentrated at NMJs and 
MTJs, but absent from junctions in laminin-4 deficient mice. 
 
In addition to the progressive muscular dystrophy, deficiency in laminin-α2 chain cause a 
peripheral neuropathy resulting in reduced nerve conduction velocity predominantly involving 
motor or sensory motor nerves. The neuropathy in MDC1A is of the demyelinating type. In large 
part, this abnormality is due to the inability of Schwann cells to send processes around axons as 
well as a decrease in number and proliferation of Schwann cells. The presence of naked axons is 
more evident in the proximal part of the PNS (especially roots) than in the distal part. This 
difference may result from compensation or redundancy by other laminin isoforms specific to the 
distal PNS. For example, laminin α1 is upregulated in distal nerves, but not roots, of dystrophic 
mice. Some fibers in the proximal PNS and most fibers in the distal PNS achieve the pro-
myelinating state, and myelinate. But the dystrophic myelin is not normal: Thickness is reduced or 
increased, internodes are up to 50% shorter, nodes of Ranvier can be abnormally wide with nodal 
gaps up to 10µm and voltage-gated sodium channel clustering at nodes of Ranvier is reduced. 
b. Mouse Models of MDC1A  
Laminin-2 performs important functions in muscle53,302 and mouse models have been 
instrumental in elucidating these functions. As many as five mouse models for laminin α2-
deficiency are available303-307. Naturally occurring models include the dy-/-, dy2J-/- and dyPAS-/- mice, 
while dy3K-/- and dyW-/- mice constitute genetically engineered mouse models of MDC1A.  
The dy-/- mice express a laminin-α2 polypeptide of apparent normal size but in very small 
amounts, and the mice suffer from a very severe form of MDC1A. The mutation in the dy-/- mice 
has not yet been identified. The mutation in the lama2 gene responsible for the dy2J-/- mouse 
phenotype, is an in-frame deletion within the polymerizing N-terminal globular domain of the 
laminin-α2 chain304,305. Although defective in self-assembly, the α2-laminins remain within the 
basal lamina, probably tethered through nidogen, agrin, integrin, dystroglycan and other cell-
surface binding molecules40,308,309. The partial laminin-α2 deficiency in dy2J-/- mice results in a mild 
phenotype. Both, the dyPas-/- and the dy3K-/- mice completely lack laminin-α2 and represent a 
severe phenotype310. For generation of dyW-/- mice, a cassette containing the LacZ and neo genes 
was inserted shortly downstream the lama2 gene ATG initiation site by homologous 
recombination in embryonic stem cells. The dyW-/- mouse is not a null mutant, since a small 
amount of a truncated laminin-α2, which lacks domain VI but contains the G domain, is 
expressed. The severe phenotype in dyW-/- mice may be related more to the low amounts of 
laminin-α2 than to the lack of domain VI in the protein.  
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The pathology in these mouse models resembles human MDC1A pathology. In all MDC1A mice, 
muscle development is seemingly normal, but a more or less severe muscular dystrophy is 
manifested postnatally303-305,311. α7β1 remains localized to the MTJs, whereas the sarcolemmal 
distribution of α7β1 integrin is disturbed. Both at the synapse and in the extrasynaptic 
sarcolemmal basement membranes, lack of laminin-α2 is compensated by expression of the 
functionally different laminin α4 chain giving rise to laminin-8 isoform that is neither able to self-
polymerize nor to interact effectively with α-dystroglycan. Similarly, the progressive lameness of 
hindlegs is characteristic of mice from all dy strains and is likely due to deficiency of laminin-α2 in 
peripheral nerves312 Unlike in human MDC1A pathology, in none of the mouse models, changes 
of the white matter in the brain could be observed307.  
c. Clinical and Pathological Features of MDC1A 
The 'classical form' of MDC1A is associated with complete loss of laminin-2 and presents with 
early onset of a severe and progressive muscular dystrophy, hypotonia, peripheral neuropathy 
and characteristic white matter hypodensity on cerebral magnetic resonance imaging313-315. 
Children can sit without support but almost never achieve independent ambulation. Progressive 
joint contractures, rigidity and scoliosis of the spine are common, making ambulation more 
difficult. Respiratory failure followed by death in the first decade of life has been observed in 30% 
of patients with complete laminin-α2 deficiency.  
 
Dystrophic muscles are characterized by necrotic and regenerating fibers, centrally located 
myonuclei, increase in fiber size variation and non-muscle tissue as well as markedly elevated 
CK levels in the blood serum. Moreover, the muscle fiber regeneration capacity is markedly 
perturbed in MDC1A mice316,317. Since Evans blue dye upon injection does not accumulate inside 
the muscle fibers of different mouse models, muscle membrane leakage seems not to be central 
to the pathogenesis of MDC1A318. The neuropathy manifests in form of reduced nerve conduction 
velocity mainly in motor nerves319. 
6.2 Strategies for Treatment of Muscular Dystrophies 
Muscular dystrophies are among the most difficult diseases to treat, even though most of the 
underlying molecular defects are now known. This is because skeletal muscle is the most 
abundant tissue of the body and is composed of large multinucleated fibers, the nuclei of which 
have permanently lost the ability to divide. Consequently, any cell or gene replacement must 
restore proper gene expression in hundreds of millions of postmitotic nuclei, which are embedded 
in a highly structured cytoplasm and surrounded by a thick basal lamina. Similarly, most 
pharmacological trials must overcome the complex as well as partly unknown biochemical 
mechanism of fiber degeneration that involves pathways, such as calcium fluxes and protease 
activity, for which inhibitors are associated with high systemic toxicity. Nevertheless, the results 
that have been accumulated during the last few years have opened new perspectives for different 
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treatment approaches. However, to date, there is no efficient treatment to prevent disability and 
death in muscular dystrophies. Treatments currently in use can only help to slow down the 
functional impairment of the disease. 
6.2.1 Pharmacological Approaches 
Several pharmacological strategies have been attempted to counteract the consequences of the 
dystrophic process, but only few of them have entered clinical trials.  
Corticosteroids are anti-inflammatory molecules, which can delay the loss of independent 
ambulation in patients by 2 to 4 years, significantly reduce the risk of developing skeletal defects 
and delay the onset of respiratory and cardiac failure320,321. However, their use is associated with 
significant side effects, such as weight gain and osteoporosis with the risk of bone fractures.  
 
Other pharmacological strategies include the stimulation of anabolic processes using insulin 
growth factor-1 (IGF-1), a known muscle growth factor, compensation of the mutated protein by 
pharmacological upregulation of a functionally related protein as well as blocking of proteasomes 
to protect degradation of proteins in dystrophic muscles322-324.  
6.2.2 Gene Therapy 
There are two types of gene therapy. Germline gene therapy alters the reproductive cells of an 
individual's body and therefore is inheritable. Somatic gene therapy has no effect on future 
offspring because it only alters non-reproductive (somatic) cells. Currently, somatic cell gene 
therapy has been done on a larger scale than germline gene therapy because there are less 
ethical and social concerns associated with it. Somatic gene therapy can be performed in two 
ways: ex vivo (out of the body) and in vivo (in the body).  
 
Ex vivo, somatic gene therapy involves two strategies. One is the use of cells obtained from a 
healthy donor, which express the normal copy of the mutated gene but induce an immune 
rejection unless the patient is permanently immune suppressed. The second one is the use of 
cells obtained from the patient, which do not require immune suppression but must be ‘genetically 
corrected’ in vitro to restore the expression of the mutated protein. The major problem still faced 
by this approach is the lack of dispersion of donor cells. 
 
In vivo somatic gene therapy targets cells within the body to be genetically altered. It necessitates 
that the vectors are able to deliver the genes to the correct area of the body, deliver enough 
altered genetic material to the cells to ensure effectiveness, and remain otherwise undetected by 
the body’s immune system. Disorders that arise from mutations in a single gene, as it is the case 
in muscular dystrophies, are the best candidates for gene therapy. The main strategies aim to 
replace the defective gene by introduction of a ‘normal’ copy or a compensatory gene by viral or 
non-viral delivery methods.  
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Moreover, current strategies also involve methods of gene modulation, such as antisense 
induced exon-skipping as well as endogenous correction of the defective gene using methods 
such as DNA–RNA chimeric oligonucleotides. However, these methods rely on exact mapping of 
the mutation in the individual patients. 
 
 In vivo Somatic Viral-based Gene therapy 
Viruses are naturally evolved vehicles, which efficiently transfer their genes into the host cells. 
For use in gene therapy, viruses are genetically modified to reduce expression of viral proteins, 
render them replication-deficient and to make space for insertion of the therapeutic transgene 
sequences. However, viruses still present a variety of problems to the patient, such as toxicity, 
immune responses, gene control and targeting issues as well as the potential recovery of the 
viruses to cause disease.  
 
In order to develop valuable gene therapies, both methodological advances in viral vector design 
as well as the evaluation of effective genes to be introduced is necessary. For the latter purpose, 
transgenic analysis of putative therapeutic genes in animal models for muscular dystrophies325,326 
is mandatory, enabling extensive pre-clinical studies on the safety and the functionality of various 
therapeutic approaches. Several transgenic approaches overexpressing the mutated gene or a 
structurally and functionally similar molecule in mouse models of muscular dystrophies resulted in 
a significant amelioration of the disease. However, replacing a mutated gene in all, or at least in a 
good proportion, of the post-mitotic nuclei of skeletal muscle is daunting. In addition, a major 
limitation of gene therapy is the large size of the genes to be compensated for in muscular 
dystrophies. An auspicious progress to overcome this problem, derive from approaches of 
transgenic overexpression of specifically designed molecules that are functionally but not 
structurally related to the disease-causing gene to be restored. Such rational design and the use 
of small mimetics of large proteins can be useful for gene therapy. 
 
For effective treatment of muscular dystrophies, local intramuscular injection is definitively not 
feasible but a systemic delivery modus is required for a clinical setting. However, systemic 
delivery favors unwanted gene transfer to other tissues than muscles, what may pose safety 
concerns because of the potential to increase germline transmission, immunoreactivity and 
toxicity. Adeno-associated viral (AAV) vectors are among the most promising transfer vehicles 
and a lot of effort has been put on development and improvement of their delivery properties. 
AAV are non-pathogenic replication-deficient parvoviruses, characterized by low immunogenicity, 
able to integrate into host genome allowing for permanent genetic correction and able to infect 
multiple cell types, including non-replicating cells such as mature myofibers. The major 
disadvantage of AAV is the limited capacity for insert size (< 5kb). Recently, new AAV serotypes 
capable of disseminating systemically and having a high infectivity in muscle were discovered 
and made systemic muscle gene delivery possible327, pointing to a possibly viable therapeutic 
option particularly for childhood diseases that can be decreased with early intervention, as it is 
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the case for MDC1A. Very recently, the feasibility of systemic mini-agrin gene delivery without 
additional pharmacological intervention leading to long-term transduction of whole body skeletal 
and cardiac muscle in MDC1A mice and resulting in a substantial amelioration of the MDC1A 
phenotype was demonstrated 328. 
 
In the clinics, gene therapy has experienced only few modest successes but suffered from many 
failures, because of the death of a participant in a trial due to acute toxicity329 and the occurrence 
of leukemia in children who were treated with retrovirus-mediated gene transfer330. 
These disappointing results from clinical trials imply the need of many more pre-clinical studies. 
In this respect, experiments on animal models will continue to provide crucial pieces of 
information in regard to issues such as the appropriate timing for intervention (the earlier the 
better seems to be a consensus), the risk–benefit ratio of current vectors and transgenes, and the 
assessment of functional benefit. 
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II THE TOPIC OF THE THESIS 
1 Introduction 
Laminin-α2 deficient congenital muscular dystrophy, classified as MDC1A, is a severe 
progressive muscle-wasting disease that leads to death in early childhood307. MDC1A is caused 
by mutations in lama2, the gene encoding the laminin-α2 chain being part of laminin-2 (α2, β1, 
γ1), the main laminin isoform present in the extracellular matrix of muscles and peripheral 
nerves57,62-64. The N-terminus of the laminin-α2 chain accounts for the formation of the primary 
laminin scaffold by self-polymerization while C-terminal globular domains bind with high affinity to 
α-dystroglycan providing a connection to the cytoskeleton via the transmembranous protein β-
dystroglycan. In laminin-α2 deficient muscle, the laminin-α4 chain is strongly upregulated to yield 
laminin-8 (α4, β1, γ1)60,246. Moreover, laminin-8 cannot self-polymerize and does not bind to α-
dystroglycan331, both properties that are likely to be important for the integrity of the muscle. Thus, 
in laminin α2-deficient muscle the chain of proteins linking the actin cytoskeleton via the 
sarcolemma to the basement membrane is interrupted (Fig. 1). As a consequence, muscle fibers 
loose their stability and degenerate. In addition, the regenerative capacity of muscle is 
substantially lower30,317. These deficiencies lead to the dystrophic phenotype characterized by 
high levels of creatine kinase in the blood, variations in fiber size and successive replacement of 
muscle by non-muscle tissue. As a mouse model, several laminin α2-deficient mice are available. 
For our studies we used the dyW-/- MDC1A mouse model306,309, which manifest a severe 
dystrophic phenotype becoming apparent at the age of two weeks. 
 
In a previous study, we have shown that a rationally designed miniaturized form of the 
extracellular matrix protein agrin, which is not related to the disease-causing lama2 gene, was 
sufficient to markedly improve muscle function and overall health of dyW-/- mice316. In brief, in dyW-/- 
mice constitutively expressing chick mini-agrin in skeletal muscles were analyzed in regard to 
their dystrophic phenotype. Due to its laminin- and α-dystroglycan-binding properties17,127,332, 
mini-agrin was supposed to reconnect the muscle fibers to the extracellular laminin network and 
thus restore the mechanical stability in MDC1A mice (Fig. 1). Indeed, such mice were clearly 
relieved from many of the pathological symptoms associated with the muscular dystrophy316. 
In a follow-up study we provided additional evidence that the mini-agrin-mediated amelioration is 
based on the direct linkage of muscle basal lamina with the sarcolemma, what in turn is important 
for proper muscle fiber regeneration after injury. Hence, mini-agrin both increases the tolerance to 
mechanical load but also improves the regeneration capacity of the dystrophic muscle. These 
findings suggest that treatment with mini-agrin might be beneficial over the entire spectrum of the 
MDC1A disease 317.  
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Figure 1: Innervated muscle fiber in wild-type- (a), MDC1A- (b), and MDC1A-mice treated with mini-
agrin (c) and potential mechanism involved in disease progression and treatment (lower panels). 
a. In wild-type mice, the peripheral nerve is well myelinated and the muscle fibers are healthy. This is based 
on the linkage of the basement membrane to the cytoskeleton (top panel). This is likely to be thanks to the 
tight connection of the basement membrane component laminin-2 with α-dystroglycan, which in turn is 
connected to the transmembranous component β-dystroglycan. β-Dystroglycan connects via linker 
molecules (not shown) to filamentous actin (f-actin). b. Dystrophic MDC1A muscle degenerates and 
peripheral nerve is demyelinated (top panel). Mutations in laminin-α2 prevent synthesis of laminin-2. 
Instead, laminin-α4 is synthesized in MDC1A muscle to form laminin-8. This isoform does not prevent the 
disease because it cannot link the basement membrane to α-dystroglycan and does not allow the formation 
of a proper basement membrane (symbolized by the interrupted line in the top panel). c. In MDC1A 
muscles treated with mini-agrin, both integrity of the muscle and the basement membrane is restored. In 
contrast, the peripheral nerve is still demyelinated (top panel). Mini-agrin binds via its amino-terminal region 
to laminin-8 and also stabilizes laminin-10 (α5, β1, γ1). The carboxy-terminal part of mini-agrin connects to 
α-dystroglycan and restores the connection to the f-actin. 
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2 Aim of the Thesis  
The underlying motivation of this study is to increase life quality and prolong life-span of MDC1A 
patients in the future. Hence, this investigation aims to contribute to the development of a feasible 
MDC1A treatment and additionally advance our knowledge of this disease. 
 
2.1 Evaluation of the potential of mini-agrin to slow down the disease 
progression of MDC1A muscular dystrophy when applied after onset of the 
disease 
This investigation further expands on the concept of the rationally designed mini-agrin able to 
ameliorate the dystrophic phenotype in mouse models of MDC1A substantially, and aims to make 
further steps in the evaluation of this strategy towards medical application.  
The experiments conducted in the two underlying studies317,316, all used the muscle-specific 
creatine kinase (MCK)-promoter to drive expression of mini-agrin. This promoter is activated 
during embryonic muscle development333,334 and consequently starts transgene expression 
before the onset of the disease. In respect to a future application of this approach in the treatment 
of human MDC1A patients, the main request of this thesis is to investigate the potential of mini-
agrin to slow down the disease progression when applied at birth or in advanced stages of the 
disease in the dyW-/- mouse model of MDC1A306.  
 
In summary, we have established the inducible tetracycline-regulated tet-off expression 
system335,336 in dyW-/- mice to temporally control mini-agrin expression in skeletal muscles. The 
tightly regulatable expression conditions enabled us to evaluate the amelioration of the dystrophic 
phenotype when mini-agrin was applied shortly after birth (at the age of 3 days), at the time point 
first dystrophic symptoms become apparent (at the age of 14 days) and in an advanced stage of 
the disease (at the age of 28 days).  
We provide strong evidence that mini-agrin applied at birth as well as in advanced stages of the 
disease significantly diminishes the progress of the dystrophy in dyW-/- mice. However, the 
dystrophic condition of the muscle at the time of mini-agrin application determines the extent of 
amelioration, since manifested dystrophic symptoms remain and can not be rescued by 
expression of mini-agrin. Moreover, start of mini-agrin expression stabilizes α-dystroglycan at the 
muscle membrane and hence profoundly increases the regeneration capacity of the remaining 
muscle fibers. Thus, the earlier mini-agrin is applied, the higher is the profit of its beneficial 
properties. 
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2.2 Evaluation of the Feasibility of Gene Therapy to Deliver Mini-agrin into the 
Diseased Muscles of MDC1A mice 
We intended to critically test whether adenoviral (AdV) or adeno-associated viral (AAV) vector-
mediated gene therapy could be used to introduce the mini-agrin into the skeletal muscles of dyW-
/- mice, in order to achieve a comparable amelioration of the dystrophic muscle pathology as in 
the transgenic approach. 
 
In summary, adenoviral vectors expressing mini-agrin under control of the MCK-promoter, were 
amplified in 293 cells337 to produce high titer virus stocks and were used for in situ infection of 
muscles of dyW-/- mice. The intramuscular injection presented reasonable transduction efficiencies 
but extensive necrosis at the site of injection.  
Very recently, Qiao and colleagues4, demonstrated successful AAV-mediated systemic mini-agrin 
gene delivery leading to long-term transduction of whole body skeletal and cardiac muscle in 
MDC1A mice and resulting in a substantial amelioration of the dystrophic phenotype (see also 
Appendix II: News and Commentary). This rendered our experiments unnecessary. 
2.3 Evaluation of the Potential of Full-length Muscle Agrin to Diminish the 
Disease Progression in MDC1A 
Full-length muscle agrin is present at low levels in the extracellular matrix of adult skeletal 
muscles. The increase of endogenous agrin expression levels in skeletal muscles by 
pharmacologically active compounds would be a safe and promising strategy for the treatment of 
MDC1A. To this end, we aimed to investigate the efficacy of full-length muscle agrin to diminish 
the disease progression in dyW-/- mice. 
 
In summary, we show that constitutive overexpression of chick full-length agrin significantly 
ameliorates the dystrophic phenotype in dyW-/- mice. However, the benefit of full-length agrin on 
the overall function of skeletal muscles, the slow-down of the disease progression, and the 
attenuation of ongoing degeneration was less pronounced compared to the effect attained by 
mini-agrin. 
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III MATERIALS AND METHODS 
 Generation of the constructs  
The mouse mini-agrin cDNA was obtained by two independent RT-PCRs on mRNA isolated from 
mouse skeletal muscle. The 0.75kb 5’ region encoding for the laminin binding and the 1.follistatin 
like domain was linked by Nhe I to the 2.2kb 3’ part of agrin encoding the α-dystroglycan binding 
domains. A 5x myc-tag was inserted in-frame as a 0.25kb Cla I - Sal I/SpeI fragment to the 3’ end 
of the construct. The mini-agrin-myc (m-mag) construct was sequenced and subcloned as a 
3.2kb EcoRV – Sal I fragment downstream of the tet-responsive promoter of a) the uni-directional 
pTRE-2 vector (Clontech) and b) the bi-directional pBI-G vector (Clontech) co-expressing LacZ. 
The Xho I site in the pTRE-2 vector was replaced by a Pac I site what allowed to linearize the 
construct as a 4.9kb Pac I –Ase I fragment for pronuclear injection. The pBI-G vector was 
linearized as a 9.58kb Ase I fragment. 
The chick full length agrin (c-FLag) construct was subcloned downstream the muscle-specific 
creatine kinase (MCK) promoter. 
 Protein production 
The mouse mini-agrin and the perlecan-agrin constructs both were subcloned into pCEP-Pu 
vector and were transfected into HEK 293 EBNA cells constitutively expressing the EBNA-1 
protein. Conditioned media was collected and tested by dot blots for its approximate content of 
protein. The supernatants were directly used for experiments. 
 
 Affinity binding assays 
96 well plates were coated with either chick α-dystroglycan or laminin-1 (0.5μg / well), followed by 
incubation with chick mini-agrin (50nM as start conc.) and supernatant containing mouse m-mag 
protein (pure sup. as start conc.) at descending concentrations (dilution ratio 1:6). The proteins 
were detected by polyclonal antibodies against chick respectively mouse C-terminal agrin as well 
as by monoclonal antibody against the myc-tag. 1q5 minutes after activation of HRP, 
absorbances were measured at 405nm and then normalized. Dose-response curves are shown in 
half-logarithmic diagrams. Binding data were fitted by non-linear regression analysis, assuming a 
single class of equivalent binding sites.  
 
 Overlay assays 
Protein extraction from wild-type chick and/or mouse skeletal muscles was separated on a 3-15% 
SDS gel. Proteins were blotted to nitrocellulose membrane and were incubated with supernatant 
containing mouse mini-agrin or perlecan-agrin protein. Protein bound to α-dystroglycan was 
detected by the monoclonal antibody against the myc-tag or the C-terminal part of agrin, 
respectively. 
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 Generation and genotyping of transgenic and dystrophic mice 
The tet-m-mag and the MCK-c-FLag constructs were injected into male pronuclei. The chimeric 
offspring of all lines was tested for the content of the insert by southern blot and PCR of tail 
biopsies. Chick mini-agrin (c-mag) transgenic mice were created as described316. MCK-tTA mice 
were obtained from Dr. Nina Raben338. DyW-/- mice309,339 containing a LacZ insertion in the lama2 
gene served as the mouse model for MDC1A. Genotyping of heterozygous and homozygous dyW-
/- mice was done by PCR with one primer within the LacZ insertion, (5'-
GTCGACGACGACAGTATCGGCCTCAG-3') and two primers specific for the exons in the lama2 
gene (5'-ACTGCCCTTTTCTCACCCACCCTT-3' and 5'-GTTGATGCGCTTGGGAC-3'). Primers 
for genotyping PCR of tet-m-mag mice were designed to amplify a 683bp fragment including the 
linkeage region of N25 and C95 part of the m-mag construct (5’-GCGGATCACTTTGCGGAACC-
3’ and 5’-TCGAACCTGAACTGTACATGACC-3’). C-FLAg as well as c-mag316 mice were 
genotyped with primers amplifying a 591bp fragment in the C-terminal part of agrin (5’-
ACCTGGATAAGCGTTTTGTT-3’ and 5’-CTTCTGTTTTGATGCTCAGC-3’). Genotyping of AgPerl 
mice was performed on the chick agrin part of the construct (5’-GTCCCTTGCTGATGACCTTGA-
3’, 5’-ACCCAGCCCCTCAGTACATGT-3’). Distinction of hemi- from homozygous MCK-tTA mice 
was done by quantitative TaqMan PCR (TaqMan™ PCR core reagent kit, Applied Biosystems) on 
the tTA-transgene (5’-GCCTACATTGTATTGGCATGTAAAA-3’, 5’-
CAAAAGTGAGTATGGTGCCTATCTAACA-3’, Probe 5’ FAM-
CTTTGCTCGACGCCTTAGCCATTGAG-TAMRA 3’) normalized to β-actin (5’-
CCACTGCCGCATCCTCTT-3’, 5’-GCTCGTTGCCAATAGTGATGAC-3’, Probe 5’ FAM-
CCCTGGAGAAGAGCTATGAGCTGCCTG-TAMRA 3’). 
 
 Breeding 
A mouse line heterozygous for the lama2 mutation and hemizygous for the tet-m-mag transgene, 
and another mouse line heterozygous for the lama2 mutation and homozygous for the MCK-tTA 
transgene were cross-bread to give rise to dyW-/- mice in which m-mag expression can be 
temporally regulated in skeletal muscles (dyW-/-/m-mag 3, 14, 28d). For the constitutively 
expressed transgenes (c-mag, c-FLag) mice heterozygous for the lama2 mutation and 
hemizygous for the c-FLAg or c-mag transgene were mated to mice heterozygous for the lama2 
mutation. 
 
 Transgene expression 
Expression levels of the different transgenic lines were evaluated by Northern blot assays 
(Northern Max, Ambion), immunoblots and immunostainings. For Northern blots total RNA 
extracted from skeletal muscle was processed according to the Northern Max (Ambion) protocol. 
For immunoblots muscles were homogenized in 1ml extraction buffer (75mM Tris-HCl, pH 6.8, 
3.8% SDS, 4 M urea, 20% glycerol and 5% -mercaptoethanol). After protein denaturation (95 °C 
for 5min), non-dissolved protein was removed by centrifugation (14,000g for 5min). Equal 
amounts of protein were loaded onto each lane, separated on 3–12% SDS–polyacrylamide gel 
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electrophoresis (PAGE) and immunoblotted. For quantification, mRNA and protein signals of the 
transgenes were normalized to corresponding β-actin or tubulin signals and referred to 
expression in wild-type animals. Quantification of immunostainings and antibodies are described 
below. 
For staining of the LacZ activity, fresh dissected muscles were fixed in 4% PFA/PBS. After 
washing (100mM sodium phosphate, 2mM MgCl2, 0.01% Na-deoxycholate,- 0.02% Nonidet P40) 
whole muscles were stained for 24hrs at 37°C using a freshly prepared stain solution comprised 
of 5mM K-ferricyanide, 5mM K-ferrocyanide and 1mg/ml X-gal in rinse buffer. Stained muscles 
were postfixed in 10% formalin and then were transferred to 70% ethanol for long time storage or 
were mounted for analysis by light microscopy. 
The inhibition of mini-agrin transcription after re-addition of doxycyline to mini-agrin expressing 
mice was tested by a quantitative TaqMan PCR (TaqMan™ PCR core reagent kit, Applied 
Biosystems) on the m-mag-transgene (5’- TGTGCCAATGTGACCGCTA -3’, 5’- 
GCTGAAACCCTTGCCAGAA-3’, Probe 5’ FAM- CCCCCAAAGTCCTGTGATTCCC -TAMRA 3’) 
normalized to β-actin (5’-CCACTGCCGCATCCTCTT-3’, 5’-GCTCGTTGCCAATAGTGATGAC-3’, 
Probe 5’ FAM-CCCTGGAGAAGAGCTATGAGCTGCCTG-TAMRA 3’). 
 
 Regulation of the tet-off system 
Temporal regulation of m-mag expression under the tetracycline-regulated expression system335 
was optimal by administration of 5ug doxycycline (Doxycycline hydrochloride, Sigma) per milli-
liter drinking water (enriched by 4% sucrose) in dimmed bottles. To repress the transgene after it 
was expressed, the concentration of doxycycline was increased to 50ug/mL.  
 Locomotion, muscle strength and creatine kinase assay 
Locomotive behaviour in animals of different genotypes was determined as described 
elsewhere316. In brief, mice were placed into a new cage and motor activity was measured for 10 
minutes. All movements such as walking, digging, or righting up were included. Muscle strength 
was evaluated by a modified grid test340. In brief, animals of the different genotypes were placed 
on a vertical grid and the time until they fell down was measured. After 3 minutes, the test was 
finished. The procedure was repeated 3 times with each animal and values were referred to 
values obtained from wild-type animals. The creatine kinase levels were measured in the blood 
collected from the mouse-tail vein. 2µl of serum was applied using the creatine kinase CK-NAC 
Liqui-UV kit (Rolf Greiner Biochemica). In all tests, at least four animals of each genotype were 
analyzed. 
 
 Histology, immunohistochemistry and antibodies 
Muscles were immersed in 7% gum Tragacanth (Sigma, St. Louis, MO, USA) and rapidly frozen 
in liquid nitrogen-cooled isopentane (–150°C). Cross sections of 12µm thickness were cut. 
General histology was performed using hematoxylin and eosin (H&E) (Merck, Rayway, NJ, USA). 
Membrane-bound and extracellular epitopes were visualized with Alexa-488-conjugated wheat 
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germ agglutinin (WGA; Molecular Probes, Eugene, OR, USA). Polyclonal rabbit anti-mouse 
laminin- α5 (Ab 405) was a kind gift from Dr. L. Sorokin, Lund University. Polyclonal sheep anti-
mouse α-dystroglycan was a kind gift from Dr. S. Kröger (University of Mainz). The remaining 
antibodies were produced in-house or purchased from commercial sources as follows: 
Monoclonal mouse anti-rat developmental myosin heavy chain (dMyHC; Novocastra), monoclonal 
rat anti-mouse laminin-γ1 chain (Chemicon), polyclonal rabbit anti-chick agrin (Ab 322810). Mouse 
monoclonal anti-Myc tag antibody (9E10) was produced and purified from hybridoma cell line 
9E10. It was biotinylated (D-Biotinoyl-E-Aminocapronsäure N-Hydroxysuccinimidester, Roche) to 
prevent cross-reaction of the secondary antibody with the mouse tissue. Depending on the 
source of the primary antibody, appropriate Cy3-conjugated (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) or Alexa-488-conjugated (Molecular probes) secondary 
antibodies were used. 4',6'-Diamidino-2-phenylindole hydrochloride (DAPI) was used to stain for 
nuclei. 
 Quantification of immunostainings 
For quantification of the muscle fiber size distribution, pictures of WGAs were collected using a 
Leica DM5000B fluorescence microscope, a digital camera (F-View; Soft Imaging System, 
Lakewood, CO, USA), and analySIS® software (Soft Imaging System). The muscle fiber size 
distribution was determined using the minimum distance of parallel tangents at opposing particle 
borders (minimal "Feret’s diameter") as described elsewhere341. Measurement of minimal Feret’s 
diameter of notexin-treated muscle was done on cross-sections stained for laminin- γ1 and 
dMyHC, whereas only regenerating (dMyHC-positive) fibers were considered. Normalization of 
the number of fibers in each fiber feret class was based on the total number of muscle fibers on 
each picture. In all quantification experiments, a minimum of 4000 muscle fibers per mouse and at 
least three mice of each genotype were analyzed.  
For quantification of the fibrosis, the fibrotic area of WGA-stained muscle cross-section was 
measured, normalized to the entire area of the cross-section and referred to wild-type animals. At 
least four cross-sections of triceps brachii were quantified for each genotype.  
To determine transgene expression levels as well as laminin α5 and α-dystroglycan protein 
expression in immunostainings, the primary antibodies were diluted such that the signal was not 
saturated. Images were collected and analyzed with a confocal microscope (Leica TCS-8P) and 
appropriate software. Specific intensity was calculated for each image as the signal intensity of 
the muscle circumference minus that of an adjacent, non-stained region342. Five different pictures 
were taken using the same parameters on each section, and four different sections were used for 
each individual mouse. 
 
 Muscle regeneration 
Skeletal muscle was injured by injection of the myotoxin notexin (Sigma) into the tibialis anterior 
of 35-day-old mice. DyW-/-/m-mag 28d, dyW-/- and WT mice were anesthetized and a 3mm-long 
incision into the skin was made at the proximal end of the muscle. A Hamilton micro syringe was 
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inserted and advanced to the distal end of the muscle. 15-20 microliters of notexin (50µg/mL) 
were injected slowly into the muscle while pulling the needle back to assure delivery of the 
myotoxin along the entire muscle. Mice were killed by CO2 asphyxiation 6 or 14 days later; 
muscles were isolated and processed as described above. 
 
 Intravenous injection of recombinant mini-agrin protein 
The mouse mini-agrin construct was subcloned into pCEP-Pu vector and was transfected into 
HEK 293 EBNA cells. Conditioned media was collected and the protein was purified by DEAE 
columns and concentrated to 1mg/ml. 0.1ml was slowly injected into the tail vein of a wild-type 
mouse. Muscles were collected 24 hours after injection. 
 
 Generation of adenovirus (AdV)   
Recombinant adenoviral vectors carrying the mini-agrin under the control of the muscle-specific 
creatine kinase (MCK) -promoter, were produced using a shuttle cloning strategy based on the 
AdEasy™ XL system (Stratagene, La Jolla, CA). In short, the subcloning part is performed in the 
pShuttle plasmid, where expression cassettes consisting of promoter, gene of interest and poly-
adenylation signal can be assembled prior to their transfer into an adenoviral backbone. In the 
transfer step one takes advantage of a homologous recombination in bacteria between the shuttle 
plasmid and the adenoviral backbone clone pAdEasy-1, which is initiated between ´left arm 
homologous (LAH)´ and ´right arm homologous (RAH)´ regions flanking the expression cassette 
and the corresponding LAH and RAH sequences in the adenoviral backbone. In a first step, a 
0.12kb SalI-XhoI fragment containing the beta-Globin poly-adenylation signal (pA) sequence was 
subcloned into the multiple cloning site (MCS) of the pShuttle plasmid. The MCK1350, a 1.35kb 
BglII - EcoRI fragment from the human muscle creatine kinase promoter was subcloned upstream 
of the pA sequence. The 3.2kb EcoRV -SalI fragment cDNA encoding mouse mini-agrin was put 
downstream of the respective promoter sequence. The following steps - linearization of the 
shuttle plasmid, transformation of each of the constructs into bacterial strain BJ5183-AD-1 (pre-
transformed with pAdEasy-1 vector) and selection for KanR clones - resulted in recombinant 
adenoviral plasmids containing mini-agrin expression cassettes in an adenoviral backbone. After 
bacterial amplification and single cut restriction digest, the linearized plasmid was transfected into 
293 cells to produce recombinant adenovirus. Positive clones have been selected on the basis of 
the cytotoxic effect on 293 cells after 48h, the absence of adenoviral E1 region in isolated 
adenoviral particles (as determined by PCR analysis with E1-specific primers) and the integrity of 
the genomic DNAs of the adenoviral constructs in isolated adenoviral particles (as determined by 
PCR and restriction digest analysis). Large-scale production of single constructs in 293 cells was 
done by repeated amplification (serial infection and lysis steps). Finally, 1-3 x 10E12 viral 
particles could be harvested from 10 l spinner cultures and were purified by CsCl step gradient 
centrifugation. In order to check the expression behavior of the respective mini-agrin constructs, 
we performed Western blot analyses on infected 293 cells using a myc-antibody confirmed proper 
mouse mini-agrin-myc expression. 
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 In situ infection of triceps brachii  
Two week-old wild-type and dyW-/- mice were anesthetized and the skin above the triceps brachii 
muscle was opened by minimal cut. A Hamilton micro syringe was introduced into the muscle and 
15μl of either adenoviruses expressing mini-agrin (1 x 1011 pfu/ml) or PBS were slowly injected 
while pulling the needle back to assure delivery along the entire muscle. The wound was closed 
post-injectionally.  Mice were killed by CO2 asphyxiation 16 days later, injected muscles were 
isolated and processed as described above. 
 
Statistical analysis 
To compare the different genotypes, P-values were calculated using the unpaired two-sample t-
tests, assuming equal variances. 
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IV RESULTS 
1 Therapeutic Potential of Mini-agrin in a Mouse Model for MDC1A 
at All Stages of the Disease 
Sarina Meinen and Markus A. Rüegg 
a. Cloning of the cDNA encoding the mouse mini-agrin-myc (m-mag) 
We aim to investigate the potential of mini-agrin to slow down the disease progression when it is 
applied at birth or in advanced stages of the disease in the dyW-/- mouse model of MDC1A. This 
project is based on the striking amelioration observed in dyW-/- mice constitutively overexpressing 
chick mini-agrin (c-mag) in skeletal muscles316. In this underlying study, a chicken-derived agrin 
mini-gene was used, mainly in regard to facilitate its detection in the transgenic mice. It is well 
known that postnatal application of extraneous transgenes eventually evokes immune responses 
in the host. To minimize the immunological rejection of the postnatally expressed mini-agrin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of the mouse mini-agrin-myc (m-mag) construct and its 
orthologue chick mini-agrin (c-mag) as described in Moll et al., 2001. Mini-agrin represents a fusion 
construct between the 0.75kb 5' region encoding the 25kDa N-terminal agrin (NtA) containing laminin-binding 
properties and the 1. follistatin-like (1.FS) domain, and the 2.2kb 3' region encoding the 95kDa C-terminus 
consisting of EGF-like and laminin G-like domains and containing α-dystroglycan binding properties. Mouse 
mini-agrin was generated out of mouse muscle-derived agrin cDNA. To allow specific detection in the 
transgenic mice, a 5x myc-tag was added to the 3' end of the mouse mini-agrin construct (m-mag). 
Restriction sites used to generate mouse mini-agrin are indicated. 
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we therefore decided to replace the chick mini-agrin by a mini-agrin deriving from the mouse 
muscle agrin isoform expressed at low levels in all skeletal muscles (Fig. 1).  
Mini-agrin represents a fusion protein between agrin’s laminin-binding N-terminus and its α-
dystroglycan binding C-terminus. The corresponding encoding cDNAs were obtained by two 
independent RT-PCRs on mRNA isolated from mouse skeletal muscle. After subcloning and DNA 
sequencing, the two cDNAs were fused. To distinguish the mouse mini-agrin from the 
endogenously expressed mouse agrin in the transgenic mice, we added a five times repeated 
myc-tag in-frame to the 3’ end of the mini-agrin construct giving rise to the 3.2kb mini-agrin-myc 
(m-mag) cDNA encoding a ~130kDa protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Binding of the transgenic mouse mini-agrin-myc (m-mag)  to laminin and a-dystroglycan. 
a. Solid-phase binding assays using 96-well plates coated with chick α-dystroglycan (A, C) or mouse 
laminin-1 (B, D).To detect chick mini-agrin, a polyclonal antiserum raised against chick agrin was used. 
Detection of mouse mini-agrin was done by using either polyclonal antibodies against C-terminal half of 
mouse agrin or the monoclonal  antibody 9E10 against the myc-tag. Both c-mag and m-mag proteins bind 
to α-dystroglycan and laminin-1 in a dose-dependent, saturable manner. Each data point represents the 
mean ±SD. (n=3). Binding data were fitted by non-linear regression analysis, assuming a single class of 
equivalent binding sites. b. Overlay binding assays using m-mag. Partially purified α-dystroglycan from 
chick (c-αDG) or mouse (m-αDG) skeletal muscle was separated by SDS-PAGE, transferred to 
nitrocellulose and incubated with supernatant from HEK 293 EBNA cells transfected with cDNA encoding 
m-mag. Bound protein was detected with 9E10 (anti-myc). 
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b. Testing of the function of the recombinant m-mag protein 
The addition of the myc-tag to the C-terminal end of mouse mini-agrin eventually influences the 
binding properties of the mouse compared to the proved and non-tagged chick mini-agrin316. To 
rule out major impairments we tested the binding of recombinant m-mag protein to laminin-1 and 
α-dystroglycan in affinity binding (Fig. 2 a) and overlay assays (Fig. 2 b) 
For this purpose, recombinant mouse m-mag protein was produced in human embryonic kidney 
(HEK) cells constitutively expressing the EBNA-1 protein. Dot blot assays allowed to estimate an 
approximate concentration of mini-agrin-myc protein in the conditioned media (not shown), which 
was further used for dose-response curves to either chick α-dystroglycan or mouse laminin-1 as 
well as for overlay assays to α-dystroglycan. Results indicate that m-mag protein has similar 
binding properties as its chick orthologue and that the addition of the myc-tag to the C-terminal 
end of mouse mini-agrin does not impair this binding. Furthermore, the myc-tag is detectable 
when mini-agrin is bound to α-dystroglycan or laminin and therefore will allow the distinction of 
the transgenic mini-agrin from endogenous agrin in the transgenic mice (Fig. 2 a + b). 
 
c. Generation of mice expressing m-mag under control of the inducible tetracycline-
regulated "tet-off" expression system 
Our aim to generate dyW-/- mice in which mini-agrin expression in skeletal muscles can be 
temporally controlled, prompted us to establish the inducible tetracycline-regulated ‘tet-off’ 
expression system335,336 (Fig. 3 a). This system is designed to express the target transgene only 
upon binding of the tetracycline-dependent transcription activator (tTA) to the tet-responsive 
promoter (tet), containing seven tTA binding sites and a cytomegalovirus (CMV)-promoter 
localized upstream of the target gene. This binding is suppressed in presence of the antibiotic 
doxycyline (Dox). Doxycycline is known to pass placenta as well as to be transferred by nursing, 
implying the ability of the tet-off system to regulate transgene expression in the offspring. 
 
In order to produce transgenic mice containing m-mag under the control of the tet-responsive 
promoter (tet-m-mag), we generated two independent constructs containing m-mag downstream 
of a uni-directional (Fig. 3 b) and a bi-directional (Fig. 3 c) tet-responsive promoter, the latter of 
which co-expresses nuclear localized LacZ as a reporter gene. The linearized constructs were 
injected into male pronucleus by the in-house "transgenic mouse core facility" to randomly insert 
into the genome. Male pronuclei later were implanted into pseudo-pregnant mice. Of the 69 and 
35 mice born of the uni- and the bi-directional injection series respectively, tail biopsies were 
tested by PCR using primers designed to amplify a fragment including the linkage region between 
the 1. follistatin-like domain and the C-terminal region of the m-mag construct (data not shown). 
We detected eight chimeric founder mice (5 males; 3 female) carrying the uni-directional 
promoter and seven founders (6 males; 1 female) carrying the bi-directional promoter upstream 
m-mag. This result was verified by Southern blot analysis using a probe spanning the linkage 
region of the m-mag fusion construct (data not shown). 
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All the chimeric founders were back-crossed to C57BL/6 mice and the F1 progeny was tested for 
the presence of the transgene. Four out of eight founders containing the uni-directional and all 
seven founders carrying the bi-directional tet-responsive promoter transmitted the transgene to 
the F1 progeny, giving rise to lines 1-4 for the uni-directional and 1-7 for the bi-directional tet-m-
mag strain. To prevent later segregation and eventual subsequent loss of transgene expression 
levels due to multiple insertion sites of tet-m-mag in the genome, the transgenic F1 progeny was 
back-crossed to C57BL/6 for an additional generation and a 1:1 ratio of transgene transmission 
was confirmed in the F2 progeny. 
 
Mice hemizygously carrying the tet-m-mag transgene (tet-m-mag+/-) were mated to mice 
homozygously expressing the tTA activator transgene under control of the muscle-specific 
creatine kinase (MCK)-promoter338,343 (MCK-tTA+/+). Skeletal muscles of offspring hemizygously 
carrying both transgenes (MCK-tTA+/-/ tet-m-mag +/-) were then tested for their m-mag expression 
levels in skeletal muscles (Fig. 4). In the uni-directional tet-m-mag strain, mRNA transcripts in 
Northern blot (Fig. 4 a) and protein levels in immunostaining (Fig. 4 c) and Western blot analysis 
herpes simplex protein VP16. The second transgene is the tet-responsive promoter (tet) containing binding 
sites for tTA, followed by a CMV-promoter and the target gene m-mag. Binding of tTA to these sequences, 
activates the CMV-promoter and drives expression of m-mag. In the tet-off system, this binding is 
suppressed in presence of the antibiotic doxycyline (Dox), leading to inhibition of mini-agrin expression. b. -
c. Constructs containing m-mag downstream the tet-responsive promoter. b. Uni-directional tet-responsive 
promoter (pTRE-2, Clonetech), solely expressing m-mag. c. Bi-directional tet-responsive promoter (pBI-G, 
Clonetech), co-expressing m-mag and LacZ. 
Figure 3: The inducible 
tetracycline-regulated “tet-
off” expression system. 
a. Functional elements of the 
inducible tetracycline-
regulated ‘tet-off’ expression 
system. Function of the 'tet-
off' system is composed of a  
team-work of two transgenes 
in response to the repressor 
agent doxycycline (Dox). 
The activator transgene, the 
tetracycline-dependent 
transcription activator tTA, is 
expressed under control of 
the muscle-specific creatine 
kinase (MCK-) promoter to 
target expression to skeletal 
muscles. It constitutes a 
fusion of the tet repressor of 
Transposon10 (tetR) and the 
transactivator domains of the 
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Figure 4: Analysis of m-mag expression activity in MCK-tTA+/-/ tet-m-mag+/-  mice expressing m-mag 
driven by the uni- (a, c, e, h) and the bi-directional (b, d, f, g, h) tet-responsive promoter. 
a. + b.  Northern blot analysis of quadriceps muscle, c. + d. immunostaining of triceps brachii cross-sections 
and e. + f.  Western blot analysis (e + f) of triceps brachii muscle. Analysis of m-mag mRNA transcription 
activity (a + b) and m-mag protein expression levels (d - f) both suggest mouse line 3 followed by line 1 and 2 
of the uni- (a, c, e, h) and mouse line 2 and 7 followed by line 1 and 5 of the bi-directional (b, d, f, h) MCK-
tTA+/-/ tet-m-mag+/- strain to express the transgene in a decreasing manner, respectively. g. Nuclear beta-
galactosidase activity in the bi-directional strain reliably reflects m-mag transgene expression. h. Quantification 
of the m-mag expression levels in the different lines as determined by the analysis described in a.-f. For 
quantification, mRNA levels in Northern blot and protein levels in Western blot analysis were normalized to 
corresponding β-actin signals. Based on these results we decided to continue our experiments with mouse line 
3 of the uni- and with mouse line 2 of the bi-directional tet-m-mag+/- strain. 
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(Fig. 4 e) suggest mouse line 3 followed by line 1 and 2 to have the highest m-mag expression 
activity. Nearly no m-mag expression was detected in line 4. In the bi-directional tet-m-mag strain, 
mRNA signals of m-mag in Northern blot analysis (Fig. 4 b) and protein levels  visualized in 
immunostaining (Fig. 4 d) and Western blot analysis (Fig. 4 f), revealed highest  transgene 
expression levels in line 2 and 7, followed by lines 1 and 5. No transcripts and proteins were 
detected in line 3, 4 and 6. In addition, m-mag expression activity in the bi-directional tet-m-mag 
strain correlated well with the nuclear expression of the reporter gene beta-galactosidase (Fig. 4 
g). Moreover, muscles of mice only carrying the tet-m-mag transgene did not show any m-mag 
expression activity in none of the tests. 
Based on these results, non-expressing lines were eliminated. Mouse line 7 of the bi-directional 
tet-m-mag strain represented health impairment and poor mating behavior (probably due to 
transgene incorporation into the genome at an important gene locus) and was eliminated as well. 
We decided to continue our experiments with mouse line 3 of the uni-directional and mouse line 2 
of the bi-directional tet-m-mag strain, both showing a good overall health and mating behavior. 
 
d. Tight spatial and temporal regulation of mouse mini-agrin-myc expression in dyW-/- 
mice 
Muscle-specific expression of the mini-agrin transgene relies on the expression of the tTA 
activator transgene driven by the muscle-specific creatine kinase promoter (MCK-tTA). To ensure 
the targeted expression of m-mag to muscles and thus prevent eventual side effects due to a 
widespread unspecific expression pattern, we evaluated the spatial regulation of tTA and 
consequent m-mag expression in the two MCK-tTA+/-/ tet-m-mag+/- mouse lines shown to express 
high levels of m-mag in skeletal muscles (Fig.5 a - c). Western blot analysis of different tissues of 
the uni-directional line 3 (Fig. 5 a) and the bi-directional line 2 (Fig. 5 b) revealed high mini-agrin 
expression levels in skeletal and cardiac muscle. Only minimal amounts of m-mag were detected 
in liver and kidney, whereas no protein was present in lung and brain. In the bi-directional MCK-
tTA+/-/ tet-m-mag+/- line 2, this spatial expression pattern was confirmed by the exact conformance 
of LacZ activity in the corresponding tissues (Fig. 5c). In summary, these results suggest tTA 
expression, and thus subsequent m-mag expression, to be specifically targeted to skeletal and 
cardiac muscle where the MCK-promoter is known to be active. 
 
In a next step, we optimized the temporal regulation of m-mag expression by administration of the 
repressor agent doxycycline. For this purpose, different concentrations of doxycycline were 
permanently administered to the drinking water of pregnant and gestating females (0.5mg/l; 
5mg/l; 20mg/l; and 50mg/l). After 2 weeks of gestation, the antibiotic was withdrawn and the 
double transgenic offspring (MCK-tTA+/-/tet-m-mag+/-) was tested for induction of m-mag 
expression. In both of our double transgenic mouse strains, application of 5μg doxycycline per 
milli-liter drinking water to pregnant and gestating females, was found to completely inhibit mini- 
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agrin transcription and translation in the offspring and additionally allowed a rapid induction (Fig. 
6). Northern blot analysis (Fig. 6 a + d) as well as immunostaining (Fig. 6 b + e), Western blot 
(Fig. 6 c) and LacZ activity (Fig. 6 f) all demonstrate a tight repression of m-mag expression in the 
offspring of gestating females permanently treated with doxycycline (Dox). As short as three days 
after withdrawal of the antibiotic (wd 3d) m-mag mRNA expression in the uni-directional MCK-
tTA+/-/ tet-m-mag +/- strain was detected by Northern blot analysis (Fig. 6 a). At this time, in the bi-
directional strain m-mag transcription has not yet started (Fig. 6 d). Correspondingly, the protein 
started to be translated in the uni- (Fig. 6 b + c) but not yet in the bi-directional (Fig. 6 e + f) line, 
as visualized by immunostaining (Fig. 6 b + e) and Western blot analysis (Fig. 6 c) or LacZ 
expression activity (Fig. 6 f). Six days after doxycycline withdrawal (wd 6d), in both strains m-mag 
expression activity reached levels as when no doxycycline has ever been applied (no Dox, Fig. 6 
a - f). Thus, both double transgenic mouse lines expressing m-mag either under control of the 
uni- or the bi-directional tetracycline-regulated ‘tet-off’ expression system, allowed precise and 
efficient spatial and temporal regulation of m-mag expression, verified by quantification of the 
different analysis (Fig. 6 g). 
 
Figure 5: Spatial expression pattern of mini-agrin (m-mag) in the uni- (a) and the bi-directional (b, c) 
MCK-tTA+/-/tet-m-mag+/- mice. 
a. + b. Western blot analysis of various tissues  (as indicated) suggest high m-mag protein expression in 
skeletal and cardiac muscle of both the uni- and the bi-directional line 3 (a) and 2 (b), respectively. Residual 
m-mag was detected in liver and kidney. No expression was detected in lung and brain. c. LacZ activity in 
the different tissues of the bi-directional line 2 exactly corresponds to the results obtained by Western blot 
(b). These results confirm tTA and subsequent mini-agrin expression to be targeted to skeletal and cardiac 
muscle as expected from tTA expression driven by the MCK-promoter. 
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Figure 6: Temporal regulation of m-mag expression in the offspring from females permanently treated 
with doxycycline during pregnancy followed by withdrawal after 2 weeks of gestation. 
a. - c. Analysis of the uni-directional line 3 and d. - f. of the bi-directional line 2 MCK-tTA+/-/ tet-m-mag+/- 
mouse strain. Northern blot analysis of tricpes brachii, (a + d) immunostaining of tricpes brachii cross-sections 
(b. + e.) as well as Western blot analysis of quadriceps muscle (c) and LacZ staining (f) of calf muscles all 
indicate that addition of 5μg doxycyline (Dox) per milli-liter drinking water is capable to completely repress m-
mag expression in both the uni- (a - c) and the bi-directional (d - f) MCK-tTA+/-/ tet-m-mag+/- strain. 3 days 
after withdrawal of the antibiotic (wd 3d), transcription and translation is induced in the uni-directional line 3 (a 
- c). 6 days after withdrawal (wd 6d) in both strains m-mag expression activity reaches equal levels as when 
no doxycycline (no Dox) was applied. g. For quantification, mRNA and protein levels of mini-agrin were 
normalized to corresponding β-actin signals. Analysis confirm the virtual results, suggesting a tight, rapid and 
reliable regulation of m-mag expression under control of the inducible tet-off expression system.  
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In order to generate dyW-/- mice in which mini-agrin expression in skeletal muscles can be 
temporally controlled, we first generated mouse lines heterozygous for the lama2 mutation and 
hemizygous for either the uni- or the bi-directional tet-m-mag transgene (dyW+/-/tet-m-mag+/-). In 
parallel, another mouse line heterozygous for the lama2 mutation plus homozygous for the MCK-
tTA transgene was generated (dyW+/-/MCK-tTA+/+). Mating of these two mouse lines (dyW+/-/ MCK- 
tTA+/+ X dyW+/-/ tet-m-mag+/-) eventually give rise to dyW-/- mice in which m-mag expression can be 
temporally regulated in skeletal muscles (Fig. 7). Using this breeding strategy the probability to 
get dyW-/-/MCK- tTA+/-/ tet-m-mag+/- mice, the genotype desired for further analysis, is one out of 
eight newborns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the course of producing dyW-/-/MCK-tTA+/-/ tet-m-mag+/- mice, it became clear that the construct 
containing m-mag downstream the bi-directional tet-responsive promoter and giving rise to line 2, 
has inserted on the same chromosome as the lama2 gene is located. This was concluded from 
the complete absence of the dyW-/- genotype containing the tet-m-mag transgene in the offspring. 
This fact rendered the bi-directional tet-m-mag line 2 useless for our further experiments. Thus, 
for all further investigations we focused on the uni-directional tet-m-mag line 3.  
Figure 7: Breeding strategy. 
Generation of dyW-/- mice in which mini-agrin expression in skeletal muscles can be temporally controlled. 
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e. The disease progression is slowed down upon start of mini-agrin expression after 
birth 
We decided to evaluate the amelioration of the dystrophy in 4 and 6 week-old dyW-/- mice upon 
start of mini-agrin expression at different ages after birth. To this end, we induced mini-agrin 
expression by the removal of doxycycline at birth (dyW-/-/m-mag 3d), at the age of 11 days (dyW-/-
/m-mag 14d) when first dystrophic symptoms become apparent, and at the age of 25 days (dyW-/-
/m-mag 28d) representing an advanced stage of the disease.  
 Physiological analysis  
We first compared the physical shape of the different genotypes and in average noticed the body 
size of dyW-/- mice to be larger the earlier their muscles started to express the mini-agrin 
transgene. However, physiological tests elucidate the overall function of skeletal muscles in the 
dyW-/- mice starting mini-agrin expression at the different stages of the disease. The muscle 
strength of the different genotypes was evaluated by measuring the time the animals performed 
on a vertical grid before falling down (Fig.  8 a). The difference in the muscle strength of dyW-/- 
mice starting m-mag expression at any age after birth compared to their dyW-/- littermates was 
striking. However, in both 4 and 6 week-old animals, the duration of performance significantly and 
continuously increased the earlier mini-agrin started to be expressed.  
Locomotive activity was estimated in an open-field walking test (Fig. 8 b) by placing the mice into 
a new cage and measuring the time over 10 minutes they spent exploring the unknown 
environment. As described316, dyW-/- mice constitutively overexpressing chick mini-agrin (dyW-/-/c-
mag) presented near normal locomotion behavior, whereas the activity slightly decreased the 
later m-mag started to be expressed. However, in 4 week-old dyW-/- animals starting m-mag 
expression at the age of 3 days, the time of activity was still doubled compared to dyW-/- 
littermates.  
In summary, both physiological tests indicate a slight decrease of the overall function of skeletal 
muscles the later mini-agrin was applied in the dyW-/- mice. However, in all cases muscle strength 
and locomotory activity were significantly higher compared to age-matched dyW-/- mice. 
Additionally, in 6 week-old animals inducing mini-agrin expression at the age of 4 weeks, muscle 
strength and locomotory behavior was significantly increased compared to 6 week-old but was 
maintained compared to 4 week-old dyW-/- mice. 
Creatine kinase (CK) is normally localized in the cytosol. It catalyzes the reversible exchange of 
high-energy phosphate bonds between creatine phosphate and ADP to provide a quick source of 
energy during contraction. In the course of MDC1A, muscles pass through degenerative 
processes, during which muscle cells break open, release their contents into the bloodstream and 
thus give rise to an increased amount of CK in the blood serum. Hence, elevated CK levels in the 
blood reliably indicate the extent of ongoing muscle fiber degeneration occurring at the time of 
measurement. Independent of the age, CK levels in dyW-/- mice were 5-times elevated compared 
to wild-type littermates. In dyW-/- mice constitutively expressing c-mag or starting m-mag 
expression at the age of 3, 14 or 28 days, CK levels were reduced to half of the amount 
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measured in dyW-/- mice (Fig. 8 c).  Thus, mini-agrin clearly decreases ongoing degeneration, 
independent of the damage that had occurred before mini-agrin expression has started.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Histological analysis  
The severe dystrophic phenotype of dyW-/- muscles is characterized by presence of many small 
and rounded fibers, replacement of muscle by fibrotic tissue, infiltration and central nucleation. 
Haematoxylin & Eosin (H&E) staining of triceps brachii deriving from 4 (Fig. 9 a) and 6 (Fig. 9 b) 
week-old mice, revealed that these pathological changes are continuously less pronounced the 
earlier mini-agrin expression was induced in the muscles of dyW-/- mice. Quantification of this 
improvement was assessed by measuring the muscle fiber size distribution, reflecting muscle de-  
Figure 8: Overall function of skeletal 
muscles in 4 and 6 week-old dyW-/- 
mice starting mini-agrin expression 
3, 14 and 28 days after birth. 
For each genotype at least 3 animals 
were analyzed. a. Muscle strength was 
evaluated by placing the mice on a 
vertical grid and measuring the time 
they were able to hold themselves. The 
earlier mini-agrin started to be 
expressed, the longer the mice could 
stay on the grid indicating increased 
muscle strength. Histogram represents 
average performance time ±SD. b. 
Locomotive activity was estimated by 
an open-field walking test, measuring 
the time of activity over 10 minutes. In 4 
and 6 week-old animals, dyW-/-  mice 
starting mini-agrin expression any time 
after birth showed a significant higher 
locomotive activity compared to dyW-/- 
littermates. Histogram represents 
average moving time ±SD. c. Creatine 
kinase (CK) levels detected in the blood 
of 4 and 6 week-old mice of the 
different genotypes. In all dyW-/- mice 
starting mini-agrin expression at any 
age, we observed a similar decrease of 
the CK levels to less than half of the 
amount measured in dyW-/- mice. This 
result indicates that presence of mini-
agrin clearly decreases ongoing muscle 
degeneration. Histogram represents 
average CK levels ±SEM. P-values (t 
test) are as follows: **, P < 0.01; *, P < 
0.05; ns, P > 0.05. 
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Figure 9: Phenotype analysis of triceps brachii cross-sections of 4 and 6 week-old dyW-/- mice starting 
mini-agrin expression 3, 14 or 28 days after birth. 
For each genotype at least 3 mice were analyzed. a. - b. Haematoxylin & Eosin (H&E) staining of 4 (a) and 6 
(b) week-old mice revealed infiltration, central nucleation, many small fibers and extensive fibrosis in dyW-/- 
muscle. The earlier mini-agrin was present in dyW-/- muscle, the less pathological changes were observed. c. - 
d. The muscle fiber size distribution of 4 (c) and 6 (d) week-old animals was quantified using the minimal ‘fiber 
feret’s diameter’. Values were grouped into size classes of 5 μm per class and represent the average 
percentage ±SEM. The different genotypes are represented as followed: dyW-/- (red squares), dyW-/-/m-mag 3d 
(dark blue circles), dyW-/-/m-mag 14d (blue triangles), dyW/m-mag 28d (light blue squares), dyW-/-/c-mag (green 
circles), WT (triangles, interrupted line). Muscles of dyW-/- mice show a significant higher percentage of small 
fibers than age-matched muscles of dyW-/- mice starting mini-agrin expression at any age. Note that the number 
of small fibers decreases the earlier mini-agrin expression was induced. e. - f. Fibrotic tissue was visualized (e) 
and quantified (f) from wheat germ agglutinin (WGA) staining, which detects membrane-bound and 
extracellular epitopes. (e) represents the condition of triceps brachii of the different genotypes at the age of 4 
weeks. In dyW-/- mice more than 25% of a muscle cross-section is replaced by fibrotic tissue (f), while the 
abundance of fibrotic areas significantly decreases the earlier mini-agrin starts to be expressed. P-values (t 
test) are as follows: **, P < 0.01; *, P < 0.05; ns, P > 0.05.
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and regeneration. To this end, we evaluated the minimal fiber feret diameters in triceps brachii 
cross-sections of each genotype from 4 (Fig. 9 c) and 6 (Fig. 9 d) week-old mice. In a wild-type 
triceps brachii muscle cross-section the majority of the fibers represent a minimal diameter 
around 20-40μm or 30-50μm in 4 or 6 week-old mice respectively, whereas small fibers (< 15μm) 
represent a clear minority. Compared to wild-type, the fiber size distribution in dyW-/- muscle was 
obviously shifted towards smaller fibers, since many of them did not exceed a minimal diameter 
of 15μm. The earlier mini-agrin expression has started, the more the fiber size distribution was re-
shifted towards wild-type distribution.  
Moreover, endomysial fibrosis is a general feature in MDC1A muscles and arises from 
replacement of muscle by non-muscle tissue. Fibrosis additionally limits the function of a muscle. 
Large parts of triceps brachii muscles from 4 and 6 week-old dyW-/- mice revealed to be affected 
by fibrosis, whereas the abundance of fibrotic areas significantly decreased the earlier mini-agrin 
started to be expressed at the membrane (Fig. 9 e + f). 
 
 Restoration of the regenerative capacity  
In contrast to dyW-/- muscles, laminin-α5 and α-dystroglycan protein but not mRNA levels are 
increased in dyW-/- muscles constitutively overexpressing chick mini-agrin. We confirmed the 
posttranslational stabilization of these two proteins in the remaining intact muscle tissue of dyW-/- 
mice starting mini-agrin expression 3, 14 and 28 days after birth, since we found the amounts of 
both proteins to be comparable in dyW-/- mice constitutively overexpressing c-mag or starting m-
mag expression at any age (Fig. 10 a + b). 
In addition to the decreased mechanical stability in laminin α2-deficient muscle, the capability to 
regenerate is markedly impaired317,339. In muscle of dy3K-/- mice, another mouse model for 
MDC1A, overexpression of mini-agrin successfully restored the regeneration capacity. This 
activity was attributed to the high affinity binding of mini-agrin to α-dystroglycan317. Thus, we 
hypothesized that in co-incidence with the posttranslational stabilization of α-dystroglycan, the 
regenerative capacity in dyW-/- muscle should be similarly restored upon mini-agrin expression 
after onset of the disease. To asses this question, we made use of the myotoxin notexin, a snake 
venom compound with phospholipase A2 activity that provokes transient necrosis of mature 
muscle followed by extensive myofiber regeneration. Inflammatory response and mononuclear 
cell proliferation is known to be most active within 1–4 days upon injection. Myogenic cell 
differentiation and new myotube formation is observed ~5–6 days post-injection. By 10 days post-
injection, the overall architecture of the muscle is restored, although most regenerated myofibers 
are smaller and display central myonuclei. A morphologically and histochemically normal mature 
muscle is seen at ~3–4 week postinjection344,345.  
We injected notexin into the tibialis anterior muscles of 5 week-old wild-type, dyW-/- and dyW-/- mice 
who started mini-agrin expression at the age of 4 weeks (dyW-/-/m-mag 28d) and analyzed the 
muscles 6 (Fig. 10 c) and 14 (Fig. 10 d) days post-injection (Fig. 10 c - f). 6 days after injury only 
few regenerating (dMyHC-positive) fibers were found in dyW-/- muscle. In contrast, dyW-/-/m-mag  
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Figure 10: Stabilization of laminin-α5 and α-dystroglycan and regeneration capacity after injury. 
a. - b. Posttranslational stabilization of laminin-α5 and α-dystroglycan at the membrane of triceps brachii of 6 
week-old dyW-/- mice starting mini-agrin expression after birth. Amounts of both proteins were comparable in dyW-
/-/c-mag and dyW-/-/m-mag mice starting expression at any age. c. - d. Recovery of tibialis anterior muscle 
analyzed 6 (c) and 14 (d) days after injury by injection of notexin. Upper panels represent staining of cross-
sections with DAPI (blue), an antibody against developmental myosin heavy chain (dMyHC, green) which is re-
expressed in regenerating muscle fibers and laminin γ1 (red) to visualize the membranes. Lower panels reveal 
the muscle pathology by H&E staining. c. 6 days after notexin injection only a few very small regenerating 
(dMyHC-positive) fibers were found in dyW-/- muscle. In contrast, start of mini-agrin expression 7 days before 
injury (dyW-/-/m-mag 28d) could restore the regeneration capacity to a level indistinguishable from wild-type 
muscle as represented by the presence of many dMyHC-positive muscle fibers. d. 14 days after notexin 
injection, dyW-/- muscle is drastically affected by degenerative processes, while dyW-/-/m-mag 28d and WT 
muscles obviously are recovering from the injury. e. - f. Quantification of the muscle fiber size distribution of 
tibialis anterior 6 (e) and 14 (f) days after injury revealed the significantly enhanced regenerative capacity of 
muscle upon start of mini-agrin expression after onset of the disease. The different genotypes are indicated as 
followed: dyW-/- (red squares), dyW-/-/m-mag 28d (blue circles) and wild-type (grey triangles, interrupted line). P-
values (t test) are as follows: **, P < 0.01; *, P < 0.05. 
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28d muscles showed a comparable amount of regenerating muscle fibers as injured wild-type 
muscles, represented by the presence of many dMyHC-positive muscle fibers. Thus, start of mini-
agrin expression shortly before injury (dyW-/-/m-mag 28d) could restore the regeneration capacity 
to a level indistinguishable from wild-type mice. 14 days after muscle injury, dyW-/- muscle was 
fatally affected by degenerative processes whereas in dyW-/-/m-mag 28d and wild-type muscle the 
overall architecture was restored. 
Quantification of the muscle fiber size distribution (Fig. 10 e + f) additionally revealed the 
significantly enhanced regenerative capacity of muscle upon start of mini-agrin expression after 
onset of the disease. 6 days after notexin injection the majority of regenerating (dMyHC-positive) 
dyW-/- muscle fibers were very small, while there was no statistically significant difference between 
the distribution of regenerating fibers of dyW-/-/m-mag 28d and wild-type muscle (Fig. 10 e). 14 
days after injury (Fig. 10 f), the majority of the fibers in dyW-/-/m-mag 28d and wild-type muscles 
had a diameter of 10-20μm, which is supposed to increase during the next few weeks. In 
contrast, in dyW-/-muscles fibers with a diameter of 10-20μm were less abundant than fibers 
smaller than 10μm or bigger than 20μm, indicating insufficient regeneration as well as ongoing 
degeneration. 
These results confirm our hypothesis, that start of mini-agrin expression stabilizes α-dystroglycan 
at the muscle membrane (Fig. 10 a + b) and hence profoundly increases the regeneration 
capacity of the remaining muscle fibers at all stages of the disease, independent of the condition 
of the rest of the muscle. 
 
In summary, we show under tight controlled conditions (tet-off-system) that mini-agrin can slow 
down the progression of the disease in dyW-/- mice when it is applied at different stages of the 
disease. The earlier mini-agrin expression is induced, the more pronounced is the amelioration of 
the dystrophic phenotype. We report that the extent of amelioration depends on the condition of 
the muscle at the time of mini-agrin induction, since mini-agrin diminishes the disease 
progression by restoring the mechanical stability and the regenerative capacity of intact muscle 
tissue. 
 
f. Stability of mini-agrin at the muscle fiber membrane 
To further profit from the inducible tet-off system tightly regulating m-mag expression in skeletal 
muscles of our mice, we aimed to evaluate the stability of the m-mag protein bound to the 
basement membrane after a temporally limited expression (Fig. 11). To this end, we started m-
mag expression in healthy animals (dyW+/+) by withdrawal of doxycycline at the age of 3 weeks 
and repressed production at the age of 4 weeks by re-application of a 10-times increased amount 
of doxycycline (50μg/ml). A complete repression was rapidly achieved as confirmed by real-time 
PCR quantification of m-mag mRNA transcripts in triceps brachii (Fig. 11 a). 24 hours (Dox 1d) 
after re-application of doxycycline m-mag transcription was reduced to 10% and after >48 hours 
(Dox 2d, 3d, 4d) was decreased to less than 1%. In order to evaluate the stability of m-mag at the 
RESULTS 
 
 57
muscle fiber membrane, the protein was assessed by Western blot (Fig. 11 b) and by 
immunostaining (Fig. 11 c). Results indicate that upon repression, there is a continuous decrease 
of the m-mag protein bound to the basement membrane, which is halved within 5 days and has 
completely disappeared 9 days after re-application of the antibiotic.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 11: Stability of the mini-agrin protein in skeletal muscle after a temporal expression modus.  
a. Real-time PCR quantification of mini-agrin mRNA transcripts in triceps brachii before repression (no Dox) 
and 1-4 days (Dox 1d, Dox 2d, Dox 3d, Dox 4d) after re-addition of doxycycline (50μg/ml). Values were 
processed according to the delta-Ct method and were referred to mRNA levels present in the muscle before 
repression has started (no Dox). Results suggest mRNA transcription to be reduced to 10% and less than 
1%, within 24 hours (Dox 1d) and >48 hours (Dox 2d, 3d, 4d) after re-application of doxycycline, 
respectively. b. - c. Mini-agrin protein detected by Western blot using quadriceps (b) and by immunostaining 
using triceps brachii (c). Upon repression, the amount of mini-agrin protein bound to the basement 
membrane continuously decreased, was halved within 5 days and has completely disappeared after 9 days.  
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g. A preliminary attempt of a systemic mini-agrin protein application  
Our studies proved mini-agrin to diminish the MDC1A disease progression when applied after 
birth and to remain stably bound to membrane for several days. Direct delivery of the mini-agrin 
protein to the skeletal muscles of diseased individuals would rule out several problems faced with 
viral-based gene therapy. Due to more than 600 muscles harbored in a human body, 
intramuscular injections are definitely ruled out as an application method. This prompted us to 
perform a preliminary approach of the most obvious way to systemically deliver m-mag to the 
extracellular matrix of skeletal muscles, namely intravenous injection of recombinant mini-agrin 
protein. 24 hours after protein application, mini-agrin was found co-localized with laminin-α5 at 
the microvascular walls but did not exit the vascular system (Fig. 12), implying the requirement of 
further pharmacological intervention to succeed in this application modus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Detection of m-mag in triceps brachii  cross-sections 24 hours after intravenous 
injection of the recombinant protein.  
Mini-agrin co-localizes with laminin-α5 at the microvascular walls but did not exit the vascular system. 
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2 Gene Therapy as a Means to deliver Mini-agrin into the diseased 
Muscles of MDC1A mice 
Sarina Meinen, Rolf Stucka, Hanns Lochmüller and Markus A. Rüegg 
 
In a parallel study to the conceptual approach of testing the mini-agrin for its effects after 
application in advanced stages of the disease, we aimed to critically test whether gene therapy 
could be used to introduce the mini-gene for agrin into skeletal muscles of diseased individuals. 
For this purpose, we intended to use adenoviral (AdV) and adeno-associated viral (AAV) vectors 
as delivery tools for mini-agrin.  
 
Mini-agrin harbors several advantages for being successfully used in gene therapy. First, its 
cDNA is small enough to be incorporated into AAV vectors, the currently most promising viral-
based delivery tool. Second, the notoriously low efficacy in the infection of muscle is not a 
problem since mini-agrin protein is secreted from infected muscle fibers and thus can also act on 
neighboring, non-infected fibers. Third, because MDC1A patients express agrin endogenously, 
the immunological rejection of the protein will be minimal346.  
 
a. Generation of high titer stocks of adenoviral (AdV) vectors expressing mouse mini-
agrin-myc (m-mag) 
In a first step, our collaborators (Rolf Stucka and Hanns Lochmüller, Munich) subcloned the 
mouse mini-agrin-myc (m-mag) cDNA (see Fig. 1) into a 1. generation AdV vector. This virus can 
be easily produced to high titer concentrations, efficiently can infect replicating as well as 
differentiated cells and is safe for use in gene therapy since no malignancy is associated with it. 
However, AdV DNA does not integrate into the host genome and thus results only in a transient 
transgene expression and additionally may induce a host immune reaction to viral gene 
products347. 
In order to generate recombinant AdV vectors carrying the mini-agrin under the control of the 
muscle-specific creatine kinase (MCK)-promoter (AdV-MCK-m-mag), a shuttle cloning strategy 
was followed, based on the AdEasy™ XL system (Stratagene, Fig 13 a). This system uses 
special competent cells that are pre-transformed with the AdEASY plasmid giving rise to the 
adenoviral backbone. The m-mag construct was subcloned downstream the MCK-promoter into a 
shuttle vector which was transformed to the AdEASY-pre-transformed cells. This allows 
homologous recombination in bacteria between the shuttle vector and the adenoviral genome. 
The linearized construct containing the MCK-promoter, m-mag and the adenoviral backbone (Fig. 
13 b) then was transferred into 293 cells337, which complement for the E1 and E3 deficiency of 
the viral genome and thus allow amplification of the recombinant AdV. 
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Figure 13: Generation of adenoviral (AdV) vectors expressing mouse mini-agrin-myc (m-mag). 
a. The AdEasy™ XL system (Stratagene) was used to produce recombinant adenoviral vectors (AdV) carrying m-
mag downstream the MCK-promoter. The AdEASY plasmid provides for the adenoviral backbone and was 
transformed to special competent cells. The m-mag construct was subcloned downstream the MCK-promoter into 
a shuttle vector, which then was transformed to the AdEASY-pre-transformed competent cells. This allows 
homologous recombination in bacteria between the shuttle vector and the adenoviral genome. b. The linearized 
construct containing the MCK-promoter, m-mag and the adenoviral backbone then was transferred into 293 cells, 
which complement for the E1 and E3 deficiency of the viral genome and thus allow amplification of the 
recombinant AdV. c. Western blot analysis revealed that infected cells express high amount of the m-mag protein. 
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Figure 14: In situ infection of triceps brachii  with AdV-m-mag.
AdV-m-mag-injected dyW-/- muscle presented reasonable transduction efficiencies as detected by immunostaining 
of mini-agrin localized at the muscle fiber membranes using an antibody against the myc-tag (first panel, first 
column). In contrast, in WT muscle transduction of AdV-m-mag was much less efficient (third panel, first column). 
The site of injection site of AdV-m-mag-injected dyW-/- muscle was inflicted by extensive necrosis (first panel, 
second and third column), whereas by far less necrosis was observed in AdV-m-mag-injected WT muscle (third 
panel, second and third column). PBS-injected muscles of both genotype (second and fourth panel for dyW-/- and 
WT muscle, respectively) were only affected by minimal necrosis at the site of injection. 
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Large scale production of single constructs in 293 cells was done by repeated amplification, 
including serial infection and lysis steps. Finally, 1-3x10E12 viral particles could be harvested 
from 10 l spinner cultures. Using this system a high titer stock of AdV-MCK-m-mag was produced 
and purified by cesium chloride step gradient centrifugation. Finally, an infectious titer of 1x10E11 
particles/ml was achieved. In order to check the correct expression behavior of m-mag, Western 
blot analyses of lysates of infected 293 cells was performed. The m-mag protein was visualized 
as a single band of ~130kDa, consistent with its calculated molecular mass (Fig. 13 c). 
b. Infection of dyW-/- muscle in situ 
AdV harbors high transduction efficiencies upon local application and was previously shown to 
deliver mini-dystrophin to the diseased skeletal muscles of mdx mice where it could ameliorate 
the dystrophy348. Of course, local injections are definitely not feasible in the treatment of muscular 
dystrophies, since there is need to treat several hundred of muscles repeatedly. Nevertheless, in 
our approach local intramuscular injection can confirm the assumption that mini-agrin, which is 
secreted from infected muscle fibers and thus can also act on neighboring non-infected fibers, is 
able to efficiently transduce the muscle. Furthermore, we aimed to evaluate whether delivery of 
mini-agrin by means of adenoviral-based gene therapy efficiently could ameliorate the dystrophic 
phenotype of skeletal muscles in dyW-/- mice. 
For this purpose, we injected triceps brachii muscle of 2 week-old wild-type and dyW-/- mice using 
AdV-MCK-m-mag. 16 days after virus injection, muscles were dissected for analysis (Fig. 14). 
The in situ infection of dyW-/- muscle with AdV-MCK-m-mag represented reasonable transduction 
efficiencies (first panel, first column) as well as extensive necrosis at the site of injection (first 
panel, second and third column). Lower transduction efficiency and less necrosis were observed 
in virus-treated muscles of wild-type animals (third panel). Almost no necrosis was produced in 
PBS-injected muscles of both genotypes (second and fourth panel). Therefore, we attributed the 
extensive necrosis in AdV-MCK-m-mag -treated dyW-/- muscle to an immune reaction to viral 
proteins. This problem could be overcome by administering immune-suppressants to the treated 
mice. 
 
In parallel to our work, the feasibility of systemic mini-agrin gene delivery leading to long-term 
transduction of whole body skeletal and cardiac muscle has been demonstrated and was shown 
to result in a substantial amelioration of the disease in dyW-/- mice328 (see Discussion and 
Appendix II: News and Commentary). Due to this impressive study328 we stopped further 
investigation following this approach and focused on the advantages provided by our conceptual 
approach using the tet-off system to regulate mini-agrin expression in dyW-/- mice.  
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3 Full-length muscle agrin ameliorates the dystrophic phenotype in 
dyW-/- mice 
Sarina Meinen1, Patrizia Barzaghi1, Shuo Lin and Markus A. Rüegg 
1 equal contribution 
 
Another promising strategy for the treatment of MDC1A would be to screen for pharmacologically 
active compounds that increase the expression of endogenous agrin in skeletal muscles. Full-
length muscle agrin is a highly glycosylated 400-600kDa heparan sulfate proteoglycan and 
served as a template for the generation of mini-agrin. It acts as an organizer and stabilizer of 
protein arrangements in the muscle basal lamina136,137,332 and is expressed at very low levels in 
matured muscle. However, before screening for such agents, it will be important to investigate the 
beneficial effects of full-length agrin on the dystrophic MDC1A phenotype. 
a. Generation of dyW-/- mice constitutively expressing chick full-length agrin in skeletal 
muscles 
In a transgenic approach, we determined whether overexpression of full-length muscle agrin 
ameliorates the dystrophic symptoms in dyW-/- mice as efficiently as constitutive expression of 
chick mini-agrin (c-mag) does. For this purpose, we generated mice constitutively overexpressing 
chick full-length muscle agrin (c-FLag) driven by the muscle-specific creatine kinase (MCK)-
promoter (Fig. 15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Schematic representation of the full-length agrin protein and construct. 
The full length agrin protein (upper panel) contains laminin and α-dystroglycan binding sites at its N- and C-
terminus, respectively. Full-length agrin is a heparan sulfate proteoglycan and thus is highly glycosylated. 
Its core protein represents ~225kDa, whereas glycosylations give rise to an apparent molecular weight of 
400—600kDa. The ~ 6.3kb full-length agrin cDNA was gained out of muscle-specific chick full-length agrin 
and was subcloned downstream the MCK-promoter. This construct was used for generation of the 
transgenic mice overexpressing chick full-length agrin in skeletal muscles. 
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Evaluation of the transgene expression levels by Northern blot (Fig. 16 b), immunostaining (Fig. 
16 a) and Western blot (not shown) analysis suggested three different mouse lines (L2, L4 and 
L9) to express the transgene at detectable levels. However, in all these mouse lines, expression 
levels of full-length agrin were substantially lower than those reached for c-mag using the same 
promoter (Fig. 16 a - c). Line 4, which was evaluated to achieve the highest expression activity on 
mRNA as well as on protein level (Fig. 16 c) and therefore was used to generate a mouse line 
heterozygous for the lama2  mutation and hemizygous for chick full-length agrin (dyW+/-/c-FLag). 
An additional round of mating gave rise to laminin-α2 deficient mice overexpressing chick full-
length agrin in skeletal muscles (dyW-/-/c-FLag). 4 week-old animals of this genotype were used 
for our comparative analysis of the dystrophic phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Evaluation of the expression levels in the transgenic mouse lines 2, 4 and 9 (L2, L4, L9) 
overexpressing chick full-length agrin (c-FLag) in skeletal muscles. 
a. Immunostaining of c-FLag present at the membrane in the different transgenic mouse lines. b. Northern 
blot analysis of mRNA transcription levels of c-FLag in direct comparison to chick mini-agrin. c. 
Quantification of the mRNA (NB) and protein (IHC, WB) expression levels of the c-FLag in the different. c-
FLag L4 was found to express the highest amount of the transgene, even though levels were substantially 
lower than  in c-mag mice. Line 4 was used for further experiments. 
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Figure 17: Phenotype analysis of 4 week-old dyW-/- mice constitutively overexpressing chick full-length agrin (dyW-
/-/c-FLag) in skeletal muscles. 
a. Locomotion. Data represent average moving time ±SD in an open-field walking test. DyW-/-/c-FLag mice performed 
significantly longer than dyW-/- mice. b. Evaluation of CK levels ±SEM. DyW/c-FLag mice showed significantly decreased 
CK levels compared to dyW-/- mice. However, c-FLag was not able to half the CK levels as it was the case using c-mag. c. 
Haematoxilin & Eosin staining of triceps brachii cross-sections visualized reduced pathological symptoms in dyW-/-/c-FLag 
mice compared to dyW-/- mice. The amelioration was not as prominent as observed in muscles of dyW-/-/c-mag mice. d. 
Muscle fiber size distribution on cross-sections of triceps brachii of 4 week-old mice using the minimal ‘fiber feret’s 
diameter’. Values were grouped into size classes of 5μm per class and represent the average percentage ±SEM. The 
different genotypes are represented as follows: dyW-/- (red squares), dyW-/-/c-FLag (dark blue triangles), dyW-/-/c-mag 
(green circles), WT (triangles, interrupted line). Muscles of dyW-/- mice represent a significant higher percentage of small 
fibers than muscles of dyW-/-/c-FLag mice. Results suggest a slightly increased de- and regeneration in dyW-/-/c-FLag 
compared to dyW/c-mag muscle. e.- f. Posttranslational stabilization of laminin-α5 (e) and α-dystroglycan (f) in triceps 
brachii. g. Quantification suggest an equal elevation of laminin-α5 but a slightly decreased expression οφ α-dystroglycan 
in dyW/c-FLag muscles when compared to dyW/c-mag muscle. P-values (t test) are as follows: **, P < 0.01; *, P < 
0.05; ns, P > 0.05. 
 
RESULTS 
 
 66
b. Phenotype analysis of dyW-/-/c-FLag mice 
The general appearance, such as the shape, the size and hygienic maintenance of dyW-/- mice 
overexpressing the chick full-length agrin was obviously improved when compared to dyW-/- mice, 
but the amelioration was not as striking as in dyW-/-/c-mag mice. The open-field walking test 
revealed dyW-/-/c-FLag mice to be almost twice as active as age-matched dyW-/- mice. However, 
dyW-/-/c-FLag mice did not reach the near normal locomotion behavior presented by dyW-/- mice 
overexpressing chick mini-agrin (Fig. 17 a).  
 
Creatine kinase (CK) levels in the blood serum indicate ongoing degeneration in dystrophic 
muscles. DyW-/-/c-FLag mice showed significantly decreased CK levels compared to dyW-/- mice, 
indicating the ability of full-length agrin to effectively decrease the susceptibility of the muscle. 
Nonetheless, ongoing degeneration was less extensively diminished than in dyW-/-/c-mag mice 
(Fig. 17 b). 
In line with these findings, the histological haematoxilin-eosin staining (Fig. 17 c) of triceps brachii 
cross-sections revealed that the dystrophic phenotype such as infiltration, increased number of 
small fibers and fibrosis in dyW-/-/c-FLag muscle is less pronounced but more progressed in 
muscles of age-matched dyW-/- and dyW-/-/c-mag mice, respectively.  
A hallmark of dystrophic muscle is the marked shift of the fiber size distribution towards smaller 
muscle fibers. We used the minimal ‘fiber feret’s diameter’ for quantification of the muscle fiber 
size distribution on cross-sections of triceps brachii of 4 week-old mice of the different genotype 
(Fig. 17 d). A significant higher percentage of small fibers were determined in muscles of dyW-/- 
mice in comparison to muscles deriving from dyW-/-/c-FLag. Again, results suggest a slightly 
decreased amelioration of the dystrophy in muscles dyW-/-/c-FLag compared to dyW-/-/c-mag mice.  
Both, laminin-α5 and α-dystroglycan were shown to be posttranslationally stabilized at the muscle 
fiber membranes of dyW-/-/c-mag mice316,317.  In dyW-/-/c-FLag mice, quantification of laminin-α5 
protein detected at the membrane of triceps brachii cross-sections (Fig. 17 e + g), suggested 
equal amounts of the protein as observed in dyW-/-/c-mag muscles, whereas α-dystroglycan 
protein levels stabilized at the muscle fiber membranes were slightly but not significantly 
decreased compared to dyW-/-/c-mag  Fig. 17 f + g).  
 
In summary, overexpression of chick full-length agrin ameliorates the dystrophic phenotype in 
dyW-/- mice, but the amelioration is less pronounced than in the dyW-/-/c-mag mice. This effect 
might be due to the lower expression levels achieved for the chick full-length than for the chick 
mini-agrin. Moreover, full-length muscle agrin might provide a sterically less functional 
reconnection of α-dystroglycan to the laminin network. 
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V DISCUSSION AND PERSPECTIVES 
1 Discussion 
a. Artificial restoration of the linkage between laminin and dystroglycan ameliorates the 
disease progression of MDC1A muscular dystrophy at all stages 
Seemingly, the embryonic development of muscle in MDC1A mice is normal, but a severe 
muscular dystrophy is manifested postnatally303-305,311. In the dyW-/- mouse model, the disease 
starts to manifest shortly after birth and the animals stop gaining weight at the age of 2–3 weeks, 
when muscle degeneration becomes acute306,316. This fact implies the possibility to diminish the 
disease progression by postnatal therapeutic intervention. Thus, we assumed application of mini-
agrin at birth to be nearly as effective as when application was started during embryonic 
development, as it was the case in dyW-/- mice constitutively overexpressing mini-agrin316. 
 
 Tight regulation of the "tet-off" system enables reliable evaluation 
To reliably determine the potential of mini-agrin to slow down the disease progression when it is 
applied at birth or in advanced stages of the disease, we have established the tetracycline-
regulated ‘tet-off’ expression system335,336 in the dyW-/- mice, to temporally control mini-agrin 
expression in skeletal muscles (Fig. 3 and 7). Previous studies using the tet-off system in 
conjunction with the MCK-tTA mice338 as its regulatory part, suggested an application of 50μg up 
to 1mg doxycycline per milli-liter drinking water to achieve a tight transgene repression343,349-352. 
However, in our MCK-tTA+/-/tet-m-mag+/- mice application of 50μg doxycycline/ml drinking water 
tightly inhibited mini-agrin protein production, but took around 4 weeks to induce m-mag 
expression upon withdrawal of the antibiotic (data not shown), what definitively was not feasible 
for our approach. In purpose to achieve a reliable repression and a rapid induction of mini-agrin, 
we substantially decreased the amount of doxycycline. We provide evidence that administration 
of 5μg doxycycline per milli-liter drinking water to pregnant and gestating females completely 
inhibits mini-agrin transcription and translation in the offspring. Moreover, within less than one 
week upon withdrawal of the antibiotic, mini-agrin expression has recovered to levels 
indistinguishable from expression levels exhibited without administration of doxycyline (Fig. 6). 
Thus, we have adjusted the regulation of the tet-off system to be suitable for our approach and 
hence paved the way to reliably evaluate the amelioration of the dystrophic phenotype in dyW-/- 
mice when mini-agrin expression was induced after birth or after onset of the disease under 
tightly controlled temporal (Fig. 6) and spatial (Fig. 5) regulation. 
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 Mini-agrin decreases the degeneration of intact muscle tissue of dyW-/- mice 
Indeed, we could demonstrate that mini-agrin significantly slows down the disease progression in 
dyW-/- mice when applied shortly after birth (at the age of 3 days), at the time point first dystrophic 
symptoms become apparent (at the age of 14 days) and in an advanced stage of the disease (at 
the age of 28 days; Fig. 8 and 9). However, the improvement of the overall health, the increase in 
muscle strength (Fig. 8 a) and locomotion activity (Fig. 8 b) as well as the amelioration of the 
histological pathology of the skeletal muscles (Fig. 9) was more pronounced the earlier mini-agrin 
started to be expressed. This result indicates that the manifested dystrophic symptoms in the 
muscle at the time of mini-agrin application determine the extent of amelioration. This assertion 
was additionally confirmed by 6 week-old animals inducing mini-agrin expression at the age of 4 
weeks (dyW-/-/m-mag 28d), whose dystrophic phenotype was significantly alleviated compared to 
6 week-old, but was maintained at the disease stage of 4 week-old dyW-/- mice (Fig. 8 a + b and 
Fig. 9 e - f). We therefore suggest that the benefit exerted by mini-agrin depends on the amount 
of the remaining muscle fibers able to be accessed by the therapeutic mini-agrin protein. In such 
intact muscle tissue, mini-agrin exerts its beneficial effects by reducing the susceptibility of the 
muscle fibers to injury316. This is underlined by the statistically equal decrease of the immediate 
ongoing muscle degeneration as represented by the blood serum creatine kinase levels 
measured in dyW-/- mice starting mini-agrin expression at different time points (Fig. 8 c). In detail, 
dyW-/- mice starting mini-agrin expression at any time, all represented an equal reduction of the 
creatine kinase levels to half of the amount observed in dyW-/- mice. Hence, mini-agrin is able to 
decrease the muscle fiber degeneration in the remaining muscle tissue, independent of the 
damage that had occurred before mini-agrin expression has started.  
In contrast to dyW-/- muscles, laminin-α5 and α-dystroglycan protein but not mRNA levels are 
increased in dyW-/- muscles constitutively overexpressing chick mini-agrin316,317. We confirmed the 
posttranslational stabilization of these two proteins in the remaining intact muscle tissue of dyW-/- 
mice starting mini-agrin expression at later stages of the disease (Fig. 10 a + b). In the muscle 
basement membrane, laminin-α5 chain assembles with the β1 and the γ1 chain to laminin-10, 
and is supposed to self-polymerize and form a laminin network. However, laminin-10 does not 
strongly bind to α-dystroglycan317. Therefore, posttranslational stabilization of both laminin-α5 and 
α-dystroglycan might be due to the high-affinity binding of mini-agrin.  This connection of the 
muscle fiber to the laminin network is likely to be important for the mini-agrin-mediated 
amelioration of the dystrophic phenotype in MDC1A, since it maintains the binding and/or 
signalling to α-dystroglycan and stabilizes laminin-10 in the basement membrane. 
In summary we showed that mini-agrin reduces the degeneration of intact dyW-/- muscle tissue 
due to an increase of the tolerance of muscle fibers to mechanical demands and/or the recovery 
of ligands-mediated signalling317 at all stages of the disease. 
 
 Mini-agrin increases the regeneration capacity of intact muscle tissue in dyW-/- mice  
In addition to the enhanced degenerative processes occurring in laminin α2-deficient muscle, the 
initial capability to regenerate is markedly impaired306,317. Secondarily, in advanced stages of 
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muscle disease with abundant fibrosis, the basement membranes of necrotic muscle fibers are 
removed before they have a chance to act as scaffolds for generation of new muscle fibers353,354. 
Hence, regeneration results in fibrotic muscle tissue with abnormal muscle fiber arrangement.  
 
Another study arising from our laboratory, provided evidence that mini-agrin both increases the 
tolerance to mechanical load but also improves the regeneration capacity of the dystrophic 
muscle317. The restoration of the regeneration capacity was attributed to the high affinity binding 
of mini-agrin to α-dystroglycan, whose protein but not mRNA levels were found to be increased 
by constitutive overexpression of chick mini-agrin in laminin α2-deficient muscle316,317. We 
showed that start of mini-agrin expression in dyW-/- mice at different ages after birth, results in a 
comparable posttranslational stabilization of α-dystroglycan at the muscle fiber membranes (Fig. 
10 a + b). Co-incidentally we provide evidence that the regenerative capacity of the remaining 
muscle fibers is restored to almost wild-type levels upon start of mini-agrin expression in dyW-/- 
muscle (Fig. 10 c - f). Thus, in addition to the reduced degenerative processes, application of 
mini-agrin in dyW-/- muscle at different stages of the disease allows for successful regeneration of 
the remaining muscle fibers. 
 
In summary, we provide conceptual proof that the mini-agrin-mediated artificial restoration of the 
linkage between laminin and dystroglycan and/or the recovery of ligand-mediated signalling 
ameliorate the disease progression of MDC1A muscular dystrophy at all stages. We conclude 
that only intact laminin α2-deficient muscle tissue profits from the beneficial activity of mini-agrin 
but that the benefit is exerted by the same mechanism and effectiveness independent of the 
dystrophic condition of the rest of the muscle. Consequently, the dystrophic manifestation in 
muscle at the time of mini-agrin application determines the extent of amelioration, since 
manifested dystrophic symptoms remain and can not be rescued by expression of mini-agrin. 
 
 Limitations of a mini-agrin-based treatment of MDC1A 
MDC1A pathology involves other organs than skeletal muscles such as the peripheral nervous 
system (PNS) causing a severe neuropathy as well as the central nervous system (CNS) 
involving white matter changes. Hence, a holistic treatment would require an effective strategy 
targeting in particular the PNS in addition to the skeletal muscles. In our approach mini-agrin was 
specifically expressed in skeletal muscles (Fig. 1 and 5) what hindered the investigation of its 
effects on the progressive neuropathy caused by laminin-α2 deficiency in the PNS. However, in a 
recent study328 expression of mini-agrin in peripheral nerves failed to prevent the neuropathology 
in the hind limbs of MDC1A mice. Hence, a mini-agrin-based treatment of MDC1A provides for a 
substantially diminished progression of some pathological manifestations in the muscle, but does 
not prevent or alleviate pre-existing symptoms, not to mention the severe neuropathy in MDC1A 
patients. 
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b. Approaches to agrin-based application for the treatment of MDC1A 
 Advantages of mini-agrin for use in gene therapy of MDC1A 
Medicine currently offers no effective treatment for MDC1A patients. Therefore, high expectations 
are associated with the development of gene therapeutic applications of one of the transgenic 
approaches capable to diminish dystrophic symptoms in different mouse models of 
MDC1A306,316,317. A general challenge in the treatment of muscular dystrophies is to deliver the 
therapeutic molecules by a feasible, safe and efficient application modus to the more than 600 
skeletal muscles harbored in a human body.  
 
However, the aim to re-insert the laminin-α2 chain, which is missing in MDC1A patients, would 
face several problems. First, the large size (cDNA 9kb, protein 300kDa) of the protein 
complicates its delivery, second, the laminin-α2 chain has to be incorporated properly into the 
laminin heterotrimer that gives rise to laminin-2 and last, the de novo presence of the laminin-α2 
chain in the muscle might trigger immune responses in the patient. As several domains of 
laminin-α2 contribute to its functionality, it is also unfeasible to generate a miniaturized version 
without loosing its function.  
 
In contrast, part of these difficulties might be overcome by a treatment based on the functional but 
not structural related miniaturized form of the extracellular matrix molecule agrin. As outlined 
above, we provided strong evidence for the therapeutic efficacy of mini-agrin at all stages of the 
MDC1A muscular dystrophy (Fig. 8 - 10) and thus made a critical step towards medical 
application of mini-agrin in the treatment of MDC1A. Mini-agrin combines several advantages for 
application as a protein or in virus-based gene therapy. First, the notoriously low efficacy in the 
infection of muscle encountered in gene therapy trials is prevented because the mini-agrin protein 
is secreted from infected muscle fibers and thus could also act on neighboring, non-infected 
muscle fibers. Moreover, mini-agrin exerts its beneficial function by interacting with laminin and α-
dystroglycan in the extracellular matrix, a fact that additionally would facilitate and enhance 
efficiency of application of the protein. Second, mini-agrin derives from species-specific 
endogenously expressed muscle agrin346, what minimizes its immunological rejection by the host. 
Third, mini-agrin is a relatively small molecule with a cDNA size of 3.2kb and a globular protein 
structure with an estimated length of approximately 20nm332,355,356. Hence, the mini-agrin cDNA is 
small enough to allow the use of adeno-associated virus (AAV) vectors as a gene delivery tool. 
Moreover, the limited size of the mini-agrin protein raises the possibility of a protein delivery. 
 
 Delivery of mini-agrin protein to the skeletal muscles 
Direct delivery of the mini-agrin protein to the skeletal muscles of diseased individuals would rule 
out several safety problems faced with viral-based gene therapy (see below). Before undertaking 
this endeavor, we evaluated the stability of mini-agrin bound to the basement membrane after a 
temporal expression of 3 days in our transgenic animal model (Fig.11 a - c). Five days after 
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repression of the transcription (Fig. 11 a) the amount of mini-agrin bound to the membrane has 
halved and after 9 days has completely disappeared (Fig. 11 b + c). To further expand on this 
strategy, it would be important to compare the efficiency of the amelioration in dyW-/- mice that 
were discontinuously exposed to mini-agrin protein expression and dyW-/- mice continuously 
expressing mini-agrin in skeletal muscles.  
In a preliminary attempt, we tried to deliver recombinant mini-agrin protein by intravenous 
injection to the extracellular matrix of skeletal muscles. Capillaries running along the muscle 
fibers are characterized by low permeability357. This might account for the reason why mini-agrin 
despite its small structure (~20nm in diameter)332,355,356 was denied to exit the vascular system 
and instead remained localized to the capillary walls (Fig. 12). However, intravenous co-injection 
of mini-agrin protein and vascular endothelial growth factor (VEGF), known to transiently increase 
the microvascular permeability promptly after application348,358, may allow mini-agrin to exit the 
capillaries and reach the extracellular matrix of skeletal muscles where it could exert its beneficial 
effects.  
 
 Gene therapy as a means to introduce mini-agrin into the diseased skeletal muscles of dyW-/- mice 
In a parallel set of experiments, we aimed to introduce the mini-agrin gene by adeno-associated 
viral (AAV) or adenoviral (AdV) vector-mediated gene therapy into the skeletal muscles of dyW-/- 
mice. Since large-scale production of AAV is a time-consuming business, our collaborators in 
Munich first provided us with a 1.generation AdV vector serotype-2, expressing mini-agrin under 
control of the MCK-promoter (AdV-MCK-m-mag; Fig. 13). Adenoviral vectors can be produced to 
extremely high titer concentrations, are regarded to be safe for use in gene therapy since not 
malignant and are attributed to high transduction efficiencies in replication as well as 
differentiated cells. Despite deletion of the viral early genes E1 and E3, AdV may evoke a host 
immune reaction to viral proteins347. Moreover, adenoviral DNA does not integrate into the host 
genome, what on the one hand prevents eventual ablation of important genes due to virus 
insertion, but on the other hand causes only transient transgene expression and thus would 
involve the need for repetitive treatment. To date, no method is available allowing for efficient 
systemic delivery of AdV to muscles and local injections are definitely not the method of choice to 
treat muscular dystrophies, since several hundred of muscles would have been treated 
repeatedly. However, local application of AdV was previously shown to deliver mini-dystrophin to 
the diseased skeletal muscles of mdx mice where it was able to ameliorate the dystrophic 
phenotype348. In our preliminary approach, local intramuscular injection of AdV-MCK-m-mag was 
intended to confirm the ability of mini-agrin to achieve high transduction efficiency and to exert 
beneficial effects slowing down the progression of the dystrophy in the infected skeletal muscles 
of dyW-/- mice.  
Generally, transduction of immature, regenerating and dystrophic muscle fibers is favored 
compared to normal adult muscle fibers359, due by higher virus receptor expression and less tight 
extracellular matrix, allowing better adsorption and diffusion, respectively. Indeed, AdV-MCK-m-
mag in situ infection of dyW-/- muscle represented substantially higher transduction efficiencies 
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compared to infected wild-type muscle (Fig. 14). In contrast to wild-type, virus-infected dyW-/- 
muscle represented extensive necrosis in a wide area surrounding the injection site, whereas 
intramuscular injection of PBS did not result in necrosis in both genotypes. Therefore, we 
attributed the pathological effect in AdV-MCK-m-mag-treated dyW-/- muscle to an immune reaction 
to viral proteins. This may indicate the increased susceptibility of the dystrophic muscle to viral 
invasion360 and additionally may underline the impaired regeneration capacity. Mini-agrin was 
demonstrated to be present at the muscle fiber membranes in the intact part of the infected 
muscle, but as expected, was not present at sites of severe muscle damage (Fig. 14 first panel, 
first column), which hence can not profit from the benefit of mini-agrin. This corresponds to our 
findings in dyW-/- mice starting mini-agrin expression at later stages of the disease, suggesting that 
mini-agrin only acts on intact laminin α2-deficient muscle tissue and does not reverse manifested 
dystrophic symptoms (Fig. 8 - 10). Major immune responses to viral gene products might be 
suppressed by administration of immune-suppressants to the treated mice. 
 
Although gene therapy has initially been met with great enthusiasm, clinical gene therapy trials 
suffered many set-backs. Many trials have failed to correct the disease being treated, some have 
caused other diseases such as leukemia330, and some have resulted in patient deaths due to 
acute toxicity329. These disappointing clinical experiences have left the general impression that 
gene therapy will never fulfill its initial promise. However, these clinical trials may have been 
conducted before the technology was sufficiently matured to make the technology therapeutically 
feasible. 
 
Hitherto, most attempts of viral-based systemic gene delivery to muscles implicated complicated 
invasive surgical techniques or increasing of vessel leakiness by use of the inflammatory 
mediator histamine or vascular endothelial growth-factor (VEGF). Recently, VEGF-mediated 
delivery of an AAV-6 vector expressing “micro-dystrophin” was shown to result in body wide 
transduction of skeletal muscles in mdx mice348. Additionally, in a recent issue of PNAS, Qiao and 
colleagues4 presented the first study of a successful somatic gene therapy to treat laminin α2-
deficient congenital muscular dystrophy (MDC1A) in a mouse model. They delivered mini-agrin 
via a single intraperitoneal injection of AAV vectors serotype-1 (AAV1) into neonatal dyW-/- mice. 
Their work impressively demonstrates the feasibility of systemic gene delivery without additional 
pharmacological intervention that leads to long-term transduction of whole body skeletal and 
cardiac muscle and that results in a substantial amelioration of the disease. This work may thus 
offer a new entry point to envisage gene therapeutic treatment of patients suffering from MDC1A. 
Moreover, parallel methodological advances indicate that AAV6 in conjunction with VEGF348 and 
AAV8327 might even be more efficient than AAV1.  
 
All together, the potential of AAV-mediated, mini-agrin-based gene therapy of MDC1A is high but 
all the promising predictions must be carefully validated before this concept can be applied to 
human patients. Viruses still present a variety of problems to the patient, such as toxicity, immune 
DISCUSSION AND PERSPECTIVES 
 
 73
responses, gene control and targeting issues as well as the potential recovery of the viruses to 
cause disease. Importantly, much of our understanding of viral vectors is solely based on studies 
in mice, which tolerate treatment well. Humans might react differently and the efficacy of vector 
systems may be markedly different between the two species. 
 
 Upregulation of endogenous agrin expression 
Since gene therapeutic approaches in the treatment of muscular dystrophy still present a variety 
of problems, an alternative and safe approach to achieve expression of a possibly functional 
therapeutic molecule in the diseased muscles of MDC1A patients would be the upregulation of 
endogenous expression of full-length muscle agrin by pharmacological agents. Full-length muscle 
agrin is a highly glycosylated 400-600kDa heparan sulfate proteoglycan and served as a template 
for generation of mini-agrin. It acts as an organizer and stabilizer of protein arrangements in the 
muscle basal lamina17,136,137 and its expression is markedly decreased but continued at low levels 
upon muscle maturation. Several indispensable investigations would be necessary to implement 
this basic approach, including the identification of the promoter driving endogenous full-length 
agrin expression in muscles, screening for pharmacologically active agents specifically enhancing 
the activity of this promoter and first of all, the evaluation of full-length agrin’s benefit for the 
dystrophic MDC1A phenotype. To this end, we investigated the potential of the full-length muscle 
agrin to diminish the disease progression in dyW-/- mice and compared its benefit to the effects 
exerted by chick mini-agrin (c-mag). 
 
Constitutive overexpression of full-length agrin significantly ameliorated the dystrophic phenotype 
in every respect when referred to dyW-/- mice (Fig. 17). But the benefit of full-length agrin on the 
overall function of skeletal muscles (Fig. 17 a), the deceleration of the disease progression (Fig. 
17 c + d) and the attenuation of ongoing degeneration (Fig. 17 b) was less pronounced compared 
to the effect attained by mini-agrin. In contrast, posttranslational stabilization of laminin-α5 and α-
dystroglycan316,317 was similar in both genotypes  (Fig. 17 e - g).  
 
The decreased efficacy of full-length agrin might be attributed to the generally lower extent of 
overexpression when compared to chick mini-agrin, what might arise from the increased size and 
the posttranslational modifications attributed to the full-length agrin protein. The protein backbone 
of full-length agrin is 95±15nm long332 and contains a series of heparan sulphate 
glycosaminoglycan side chains that further enlarge the molecule. In contrast, mini-agrin protein 
misses the glycosylated domains and is supposed to fold into a globular protein structure with an 
estimated length of approximately 20nm332,355,356. However, we showed evidence that the mini-
agrin protein remains stably bound at the muscle fiber membrane for several days (Fig. 11). 
Therefore, perpetual overexpression of chick full-length agrin is likely to saturate the muscle fiber 
membrane with time. Indeed, the difference of the full-length and mini-agrin protein levels is less 
pronounced than on the mRNA level (Fig. 16) and decreases more in older mice (data not 
shown). This saturation might account for the comparable amount of stabilized laminin-α5 and α-
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dystroglycan protein in dyW-/-/c-FLag and dyW-/-/c-mag mice (Fig. 17e - g). Thus, it is likely possible 
that the decreased efficacy of full-length agrin is due to its size and glycosylation, both providing 
for a sterically less effective reconnection of α-dystroglycan to the laminin network and promoting 
interactions with several other proteins in vivo.  
 
Support for this assumption comes from a study that was performed in parallel in our laboratory 
(mainly by Patrizia Barzaghi). This additional approach aimed to elucidate the mechanism 
enabling mini-agrin to prevent muscle degeneration and to improve regeneration. Both processes 
are based on the mechanical re-establishment of the linkage of α-dystroglycan to muscle 
basement membrane and/or the recovery of ligand/mediated signalling317. We generated a 
chimeric fusion protein consisting of the laminin-binding domain of agrin fused to the functionally 
but not structurally related α-dystroglycan binding domain of perlecan331 (AgPerl, ~110kDa). 
Results showed that overexpression of AgPerl in dyW-/- mice, exerts a comparable benefit as 
attained by mini-agrin. This provides strong evidence that the mechanical stabilization of the 
muscle fiber by reconnection of the sarcolemma to the extracellular matrix, via a transgene 
containing laminin and α-dystroglycan binding domains, is the major benefit exerted by mini-agrin 
and agrin-perlecan in dyW-/- mice. These two miniaturized molecules are similar in size (~20nm in 
length) and thus lead to a similar sterical proximity of laminin and α-dystroglycan. This finding 
supports the assumption that full-length agrin due to its almost 5 times larger backbone 
(95±15nm), may provide only for a looser linkage of α-dystroglycan and laminin and thus a 
decreased mechanical stability what at least partly may account for the less pronounced 
amelioration in the dyW-/-/c-FLag mice (Fig. 17). 
2 Conclusion 
All together, our findings constitute a critical step towards medical application of approaches that 
restore the tight linkage between laminin and dystroglycan in the treatment of MDC1A. We 
demonstrate the therapeutic efficacy of mini-agrin at all stages of the disease. Via its tight re-
connection of the muscle fiber to the extracellular matrix, mini-agrin diminishes degeneration and 
improves the regeneration capacity of muscle fibers. Although both mechanisms are efficient and 
beneficial at all stages of the disease, successful restoration requires intact laminin α2-deficient 
muscle tissue. Hence, the dystrophic condition of the muscle at the time of therapeutic 
intervention is critical for the extent of the amelioration, since manifested dystrophic symptoms 
can not be rescued. In conclusion, mini-agrin can substantially slow down the progression of 
MDC1A muscular dystrophy at all stages, but is not able to rescue the disease or to reverse 
manifested symptoms. Therefore, the earlier the linkage between laminin and dystroglycan is 
restored, the higher is the benefit for the diseased patient.  
 
These data might help to improve the safety and efficacy of MDC1A treatment and definitely 
encourage to further expand on this therapeutic concept, especially in respect to combinational 
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treatment using functionally different approaches, such as preventing apoptosis361-363 in diseased 
muscles and aiming to ameliorate the peripheral neuropathy. Moreover, these experiments set 
the basis for further developing clinically feasible and relevant application methods such as gene 
therapy4 and/or the screening of small molecules able to upregulate production of agrin in muscle. 
3 Future Perspectives 
As outlined above, laminin- 2 deficiency disrupts the mechanical linkage of the muscle fiber to 
the extracellular matrix. We provided evidence that this pathological feature can be effectively 
treated at all stages of the disease, by reconnection of laminin and α-dystroglycan via mini-agrin. 
In addition, laminin- 2 deficiency interrupts several signalling pathways, dependent on laminin 
binding to both α-dystroglycan and α7β1 integrin on the muscle membrane361. For instance, 
disruption of the interactions of α-dystroglycan with laminin-α2 leads to disrupted PI3K/AKT 
signalling and apoptotic death of myotubes. Moreover, disruption of laminin-2/4 binding to α7β1 
integrin leads to apoptosis involving Src tyrosine kinase signalling (p60Fyn) and a p38α SAPK-
dependent pathway. In short, signalling from laminin- 2 may provide a survival signal for muscle, 
and its absence in MDC1A is associated with particularly high levels of apoptosis30,361. Therefore, 
prevention of apoptosis constitutes an additional promising strategy to ameliorate the muscular 
dystrophy in MDC1A. Indeed, overexpression of BCL-2, an inhibitor of apoptosis, in MDC1A mice 
was shown to substantially ameliorate the dystrophic phenotype361-363. Taken together, a 
combination of these two functionally different approaches may provide an improved strategy for 
the treatment of the muscle pathology in MDC1A. 
MDC1A pathology involves other organs than skeletal muscles, in particular the peripheral 
nervous system causing a severe neuropathy as well as the central nervous system involving 
white matter changes. Hence, a holistic MDC1A treatment would require a therapeutic strategy 
that is effective in several tissues. However, restoration of the muscle fiber membrane by mini-
agrin as well as prevention of apoptosis by application of BCL-2, both are supposed to act solely 
on the muscle pathology but do not prevent the severe neuropathy caused by demyelination in 
the peripheral nervous system. Therefore, further understanding of the functions of laminin-α2 in 
brain and peripheral nerve are indispensable to clarify the reason underlying the reduced nerve 
conduction velocity and the brain white matter changes and may help to develop a holistic 
treatment of MDC1A. 
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Gene Therapy (2006) 13, 869–870. doi:10.1038/sj.gt.3302668;
published online 13 October 2005
In a recent issue of PNAS, Qiao et al.1
present the first study of a successful
somatic gene therapy to treat laminin
a2-deficient congenital muscular
dystrophy (MDC1A) in a mouse
model.
The researchers from the Univer-
sity of Pittsburgh used a state-of-the-
art adeno-associated viral (AAV) vec-
tor to systemically deliver mini-agrin,
whose efficacy for the treatment had
been demonstrated earlier in trans-
genic mice.2,3 Their work impress-
ively demonstrates the feasibility of
systemic gene delivery for long-term
transduction of skeletal and cardiac
muscle and subsequent substantial
amelioration of the disease without
any additional pharmacological inter-
vention. This work points the way to
a new approach to gene therapy for
patients suffering from MDC1A.
MDC1A is an autosomal recessive
muscle wasting disease that often
leads to death in early childhood. It
is caused by mutations in LAMA2,
the gene encoding laminin a2, which
assembles with the b1 and the g1
chain to laminin-2, the main laminin
isoform present in the basement
membrane of muscle fibers and
peripheral nerves (Figure 1a). Base-
ment membranes are highly struc-
tured sheets of extracellular matrix
molecules that surround many cells.
Although other laminin isoforms are
synthesized in the muscle of MDC1A
patients, they do not form a proper
basement membrane that is con-
nected to the muscle sarcolemmal
membrane (Figure 1b). Hence, the
chain of proteins linking the actin
cytoskeleton via the sarcolemma to
the basement membrane is inter-
Figure 1 Innervated muscle fiber in (a) wild-type, (b) MDC1A, and (c) MDC1A mice treated with mini-agrin, and the potential mechanism
involved in disease progression and treatment (lower panels). (a) In wild-type mice, the peripheral nerve is well myelinated and the muscle
fibers are healthy. This is based on the linkage of the basement membrane to the cytoskeleton (top panel). This link is likely to be due to the
tight connection of the basement membrane component laminin-2 with a-dystroglycan, which in turn is connected to the transmembrane
component b-dystroglycan. b-Dystroglycan connects via linker molecules (not shown) to filamentous actin (f-actin). (b) Dystrophic MDC1A
muscle degenerates and the peripheral nerve is demyelinated (top panel). Mutations in laminin a2 prevent synthesis of laminin-2. Instead,
laminin a4 is synthesized in MDC1A muscle to form laminin-8. This isoform cannot link the basement membrane to a-dystroglycan and does
not allow the formation of a proper basement membrane (symbolized by the interrupted line in the top panel). (c) In MDC1A muscles treated
with mini-agrin, both integrity of the muscle and the basement membrane are restored. In contrast, the peripheral nerve is still demyelinated
(top panel). Mini-agrin binds via its amino-terminal region to laminin-8 and also stabilizes laminin-10 (a5, b1, g1). The carboxy-terminal part
of mini-agrin connects to a-dystroglycan and restores the connection to the f-actin.
Gene Therapy (2006) 13, 869–870
& 2006 Nature Publishing Group All rights reserved 0969-7128/06 $30.00
www.nature.com/gt
NEWS AND COMMENTARY
rupted. As a consequence, muscle
fibers lose their stability and degen-
erate. In addition, the regenerative
capacity of muscle is substantially
lower.3,4
Gene therapy has recently suf-
fered from major setbacks because
of the death of a participant in a trial
due to acute toxicity5 and the occur-
rence of leukemia in children who
were treated with retrovirus-
mediated gene transfer.6 Gene thera-
pies for muscle dystrophies are also
hampered by the fact that more than
600 muscles must be reached to
warrant optimal therapy. Thus, local
intramuscular injection is defini-
tively not a feasible strategy in a
clinical setting. In this case the
authors’ major achievement came
by using AAV1 vectors that allowed
long-term (at least 4 months) expres-
sion of the transgene in all skeletal
muscles examined and in the heart
by a single intraperitoneal injection
into neonatal mice. Recent methodo-
logical advances indicate that AAV6
in conjunction with vascular en-
dothelial growth factor (VEGF)7 and
AAV88 might be even more efficient
than AAV1.
The second important change was
the use of mini-agrin instead of
laminin a2. Re-insertion of laminin
a2 would be extremely difficult
because of the large size of the cDNA
(9 kb), which prevents its packaging
into AAV vectors. Moreover, laminin
a2 must become incorporated into
the laminin heterotrimer to be func-
tional. As several domains of lami-
nin a2 contribute to its functionality,
it is also unfeasible to generate a
miniaturized version without losing
its function. Moreover, de novo ex-
pression of laminin a2 might trigger
immune responses in patients. In
contrast, the mini-agrin used by Qiao
et al.1 has several advantages. Firstly,
its cDNA is small enough to be
incorporated into AAV vectors. Sec-
ondly, because MDC1A patients
express agrin endogenously, the
immunological rejection of the pro-
tein will be minimal.
Agrin, well known for its role in
the organization of the nerve-muscle
synapse,9 shares with laminin a2 the
ability to bind to a-dystroglycan, a
protein that is involved in the link-
age of basement membranes to the
muscle sarcolemma (Figure 1). More-
over, an amino-terminal domain of
agrin confers binding to all laminins.
Transgenic overexpression of a mini-
agrin consisting solely of the lami-
nin-binding and the a-dystroglycan-
binding domain markedly improved
the stability, function and regenera-
tive capacity of muscle in mouse
models for MDC1A.2,3 As a conse-
quence, the mice had greatly pro-
longed lifespan and improved
locomotion. As in the transgenic
study, Qiao et al.1 restored the struc-
ture of the muscle basement mem-
brane, decreased dystrophy-related
muscle fibrosis and significantly
improved body growth, locomotor
functions and lifespan. Mini-agrin
expressed in nonmuscle tissue
seemed to have no adverse effects
during the time window examined.
Although mini-agrin was present
in the basement membrane of the
peripheral nerve, it could not pre-
vent demyelination.1 This might
arise either from insufficient levels
of mini-agrin or from the different
function of laminin a2 not using
a-dystroglycan but integrins as a
receptor in peripheral nerve.
In summary, the potential of AAV-
mediated, mini-agrin-based gene
therapy of MDC1A is high, but all
the promising results from the
mouse studies must be carefully
validated before they can be applied
to human patients. Viruses still
present a variety of problems for
patients since much of our under-
standing of viral vectors is solely
based on studies in mice, which
tolerate treatment well. Humans
might react differently and the effi-
cacy of vector systems may be
markedly different between the two
species. Moreover, MDC1A pathol-
ogy involves also organs other than
skeletal and cardiac muscles, and a
perfect treatment would also require
infection of the peripheral and cen-
tral nervous system. Since expres-
sion of mini-agrin in peripheral
nerves failed to prevent neuropathol-
ogy, it is unlikely that this treatment
could alleviate all symptoms.
Although the current study by Qiao
et al.1 applied mini-agrin at a later
stage than the previous transgenic
study,2 it will be important to test the
efficacy of mini-agrin that is applied
when the symptoms of the dystro-
phy are apparent. Finally, more
detailed information about the mo-
lecular mechanisms involved in the
beneficial effect of mini-agrin might
help to improve the safety and
efficacy of MDC1A treatment, espe-
cially in combination with treatment
using functionally different ap-
proaches, such as the prevention of
apoptosis.10,11 ’
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Introduction
Congenital muscular dystrophies (CMDs) represent a clinically 
and molecularly heterogeneous group of autosomal recessive 
neuromuscular disorders with a typical early onset of symp-
toms. Estimates in Italy suggest an incidence rate of 4.65 × 
10−5 (Mostacciuolo et al., 1996). Thus, after Duchenne muscu-
lar dystrophy (DMD), CMDs represent the second most fre-
quent neuromuscular disorder. Laminin-α2–defi cient CMD, 
classifi ed as MDC1A, accounts for 30–40% of all CMD pa-
tients. MDC1A is a severe progressive muscle-wasting disease 
that leads to death in early childhood (Miyagoe-Suzuki et al., 
2000; Muntoni and Voit, 2004; Ruegg, 2005). It shows a rather 
homogenous clinical picture, with severe neonatal hypotonia 
associated with joint contracture and inability to stand or walk. 
Moreover, MDC1A is accompanied by a peripheral neuropathy 
that is caused by demyelination in the peripheral and central 
nervous system. However, no mental retardation is observed in 
most patients.
Laminins are cruciform-like molecules formed by α, β, 
and γ chains (Fig. 1 A). There are 5 α, 3 β, and 3 γ chains de-
scribed so far that give rise to 15 isoforms (Aumailley et al., 
2005). The central role of laminins can be explained by their 
dual function in organizing a structured basement membrane 
through interaction with other basement membrane proteins 
and connecting basement membranes to adjacent cells via cell 
surface receptors. Inactivation of different laminin chains in 
mice causes distinct phenotypes (for review see Miner and 
Yurchenco, 2004). The laminin-α2 chain assembles to laminin-211 
(LM-211; α2, β1, and γ1) and LM-221. LM-211 is the main 
isoform in the basement membrane of muscle and peripheral 
nerve, whereas laminin-221 is restricted to neuromuscular junc-
tions (Patton et al., 1997). In the basement membrane, LM-211 
and -221 bind to other laminins, to nidogen (which in turn binds 
to collagen IV and perlecan), and to agrin (Fig. 1 A). The self-
polymerization activity of LM-211 is thought to be p articularly 
Linker molecules between laminins and dystroglycan 
ameliorate laminin-α2–defi cient muscular dystrophy 
at all disease stages
Sarina Meinen,1 Patrizia Barzaghi,1 Shuo Lin,1 Hanns Lochmüller,2 and Markus A. Ruegg1
1Biozentrum, University of Basel, CH-4056 Basel, Switzerland
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Mutations in laminin-α2 cause a severe congeni-tal muscular dystrophy, called MDC1A. The two main receptors that interact with laminin-α2 
are dystroglycan and α7β1 integrin. We have previously 
shown in mouse models for MDC1A that muscle-specifi c 
overexpression of a miniaturized form of agrin (mini-
agrin), which binds to dystroglycan but not to α7β1 
 integrin, substantially ameliorates the disease (Moll, J., 
P. Barzaghi, S. Lin, G. Bezakova, H. Lochmuller, E. Engvall, 
U. Muller, and M.A. Ruegg. 2001. Nature. 413:302–307; 
Bentzinger, C.F., P. Barzaghi, S. Lin, and M.A. Ruegg. 
2005. Matrix Biol. 24:326–332.). Now we show that 
late-onset expression of mini-agrin still prolongs life 
span and improves overall health, although not to the 
same extent as early expression. Furthermore, a chimeric 
protein containing the dystroglycan-binding domain of 
perlecan has the same activities as mini-agrin in amelio-
rating the disease. Finally, expression of full-length agrin 
also slows down the disease. These experiments are 
 conceptual proof that linking the basement membrane 
to dystroglycan by specifi cally designed molecules or 
by endogenous ligands, could be a means to counteract 
MDC1A at a progressed stage of the disease, and thus 
opens new possibilities for the development of treatment 
options for this muscular dystrophy.
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important for the formation of a proper muscle basement 
 membrane. The main receptors for laminin-α2 in adult muscle 
are dystroglycan and α7β1 integrin (Fig. 1 A, green). Dystro-
glycan is cleaved into the peripheral α-dystroglycan and the 
transmembranous β-dystroglycan. In the membrane, dystro-
glycan associates with the sarcoglycans and sarcospan and 
 intracellularly binds to dystrophin, which in turn links the 
complex to the f-actin cytoskeleton. The complex between 
LM-211, dystroglycan, sarcoglycans, and dystrophin, which is 
called the dystrophin–glycoprotein complex (DGC), has been 
shown to be of utmost importance for the maintenance of 
muscle integrity, as mutations in these components cause dif-
ferent types of muscular dystrophies (for review see Davies 
and Nowak, 2006). Similarly, mice or humans that are defi cient 
of α7 integrin display a mild muscular dystrophy (Mayer et al., 
1997; Hayashi et al., 1998), and muscle-specifi c inactivation 
of β1 integrins has a major impact on muscle development 
(Schwander et al., 2003). Thus, the evidence is strong that both 
receptor systems contribute to the linking of basement mem-
brane to the f-actin cytoskeleton, and it is likely that the two 
systems act synergistically.
MDC1A is among the most severe muscle dystrophies, 
which may be based on the observation that the absence of lam-
inin-α2 leaves both receptor systems unoccupied by its ligand. As 
a compensatory mechanism, muscle fi bers of MDC1A patients 
and laminin-α2–defi cient mice increase synthesis of  laminin-α4 
(Patton et al., 1997; Ringelmann et al., 1999; Moll et al., 2001; 
Bentzinger et al., 2005). However, LM-411 is truncated at the 
N-terminal end, which prevents its self-polymerization, and it 
also does not bind to α-dystroglycan or α7β1 integrin with 
high affi nity (Kortesmaa et al., 2000; Talts et al., 2000). There is 
also evidence that muscle fi ber membranes of MDC1A patients, 
and mice models thereof, contain signifi cantly lower levels of 
α7β1 integrin (Vachon et al., 1997) and α-dystroglycan (Moll 
et al., 2001; Bentzinger et al., 2005). In addition, the ability of 
muscle to regenerate is greatly impaired (Kuang et al., 1999; 
Bentzinger et al., 2005). These defi ciencies lead to the dystrophic 
phenotype characterized by high levels of creatine kinase (CK) in 
the blood, large variation in fi ber size, successive replacement of 
muscle by fi brous tissue, and infi ltration of adipose tissue. Good 
models for the disease are dyW/dyW mice generated by homo-
logous recombination (Kuang et al., 1998). Like human patients, 
dyW/dyW mice have an early onset and severe dystrophic pheno-
type, which is often lethal between 6 and 16 wk. They grow at 
a slow rate, the histology of muscles is very similar to that of 
 human patients, and they have a prominent peripheral neuropathy 
based on defective myelination of the peripheral nerve.
There is no curative treatment for MDC1A. However, a 
“replacement therapy” using a miniaturized form of the base-
ment membrane component agrin (mini-agrin) was shown to 
markedly lower muscle degeneration and mortality in dyW/dyW 
mice (Moll et al., 2001). This is caused by both increasing the 
tolerance to mechanical load and improving the regenerative 
capability of the muscle (Bentzinger et al., 2005). These stud-
ies left several questions unanswered that were addressed in 
the current study. First, an effi cacious treatment also needs to 
work after the onset of the disease. Second, a requisite to envis-
age pharmacological treatment options that aim at increasing 
synthesis of endogenous agrin is to show that full-length agrin 
can also have a benefi cial effect. Finally, although it is highly 
suggestive that the benefi cial effect of mini-agrin is based on 
the linking of the up-regulated LM-411 with α-dystroglycan 
Figure 1. Interactions of laminin-211 and 
scheme of constructs used in the study. 
(A) Structure and binding sites of LM-211. Lam-
inins form by coiled-coil interactions of α, β, 
and γ chains. Interactions of LM-211 and -221 
with extracellular matrix components are indi-
cated in red and italics. The main receptors 
are indicated in green and include different 
 integrins and α-dystroglycan. (B and C) Sche-
matic representation of nonneuronal agrin 
(B) and perlecan (C). Domain structures and 
abbreviations are adopted from previous stud-
ies (Bezakova and Ruegg, 2003; Iozzo, 
2005). The domains included in the constructs 
used in this study are color-coded, and relevant 
binding partners are indicated. (D) Schematic 
presentation of constructs used in the study. 
Promoters (green), domains (see color code in 
B and C), and tags are indicated for each con-
struct. MCK represents the 1.3-kb fragment of 
the human MCK promoter. TetO7-CMV repre-
sents the tetracycline-responsive promoter (Fig. 
S1 A). Fig. S1 is available at http://www.jcb
.org/cgi/content/full/jcb.200611152/DC1.
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(Moll et al., 2001), other mechanisms (e.g., via integrins) may 
also contribute.
In an attempt to answer these open questions, we prepared 
a panel of constructs to generate different transgenic mouse lines 
(Fig. 1, B–D). First, we used the tet-off system (Fig. S1 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200611152/DC1) 
to generate dyW/dyW mice in which expression of mini-agrin 
can be temporally controlled (Gossen and Bujard, 1992). Se-
cond, we generated transgenic dyW/dyW mice that overexpress 
chick full-length muscle agrin (c-FLag) in muscle (Fig. 1, B and D). 
Third, we generated dyW/dyW mice that overexpress a fusion 
construct in which we replaced the α-dystroglycan binding re-
gion of chick mini-agrin (c-mag) with that of mouse perlecan 
(AgPerl; Fig. 1, C and D). Domain V of perlecan (also called 
endoreppelin; Iozzo, 2005) binds to α-dystroglycan (Talts et al., 
1999), but not to integrins that are expressed in muscle. In this 
study, we show that mini-agrin can slow down the progression 
of MDC1A at any stage of the disease, full-length agrin is capa-
ble of improving muscle function, and the fusion construct 
between agrin and perlecan also counteracts the disease. In 
summary, our results are conceptual proof that linkage of lam-
inin isoforms with α-dystroglycan is a means to treat MDC1A 
also at progressed stages of the disease.
Results
The most important questions for developing a treatment are to 
determine the effi cacy of therapy at a progressed stage of the 
disease, to establish a molecular understanding of how the treat-
ment interferes with disease progression, and to establish possi-
ble routes of applying the treatment. To this end, we generated 
a set of transgenic animals that overexpress artifi cially designed 
proteins in skeletal muscle. All the constructs, including their 
promoters, are listed in Fig. 1 D.
Tight spatial and temporal regulation 
of mini-agrin expression
To test whether mini-agrin is also capable of ameliorating the 
disease when the phenotype is already apparent, we generated 
mice in which expression of mini-agrin can be controlled by 
 removal of doxycycline (Gossen and Bujard, 1992). To minimize 
immune responses and for detection, we constructed mini-agrin 
from mouse cDNA and fused a c-myc tag to its C terminus (Fig. 
1 D). Like c-mag, the tagged mouse mini-agrin (m-mag) bound 
to LM-111 and α-dystroglycan (Fig. S2, available at http://
www.jcb.org/cgi/content/full/jcb.200611152/DC1). Double 
transgenic mice in which expression of m-mag could be con-
trolled by doxycycline (Gossen and Bujard, 1992; Ghersa et al., 
1998) were generated (for details see Fig. 1 D, Fig. S1, and 
 Materials and methods). When they were examined for the ex-
pression of m-mag, the highest levels on the mRNA and protein 
level were detected in line L3 (Fig. 2, A and B; Table I for quan-
tifi cation) which was used in all further experiments. Expres-
sion of m-mag was highest in skeletal muscle and heart, whereas 
only little or no m-mag was detected in liver, lung, kidney, or 
brain (Fig. 2 C). Next we determined the concentration of doxy-
cycline needed to suppress expression of m-mag throughout 
embryonic development and to allow fast induction. We found 
that 5 μg/ml doxycycline in the drinking water of pregnant and 
gestating females was suffi cient to completely inhibit m-mag 
transcription (Fig. 2 D) and translation (Fig. 2, E and F). 3 d 
after withdrawal of doxycycline, m-mag was already expressed 
at high levels, and it reached a maximum after 6 d (Fig. 2, D–F; 
Table I for quantifi cation).
Figure 2. Expression of m-mag in transgenic lines. (A) Northern 
blot analysis of quadriceps and (B) immunostaining of triceps 
brachii cross sections from transgenic mouse lines 1–4 (L1–L4) 
and WT mice. Highest expression of m-mag mRNA (3.6 kb) 
and protein was detected in L3. (C) Western blot analyses 
from different tissues of L3. High levels of m-mag (130 kD) 
were detected in skeletal muscle (triceps brachii) and the heart. 
Very low levels of m-mag were observed in liver and kidney, 
but not in lung or brain. (D–F) Expression of m-mag in mouse 
line L3 is regulated by doxycycline. 5 mg/l doxycycline (Dox) 
in the drinking water suppresses the expression of m-mag at the 
transcriptional (D) and protein level (E and F). After withdrawal 
of doxycycline for 3 d (wd 3d), m-mag is detected, and levels 
similar to nontreated transgenic mice (no Dox) can be reached 
after 6 d (wd 6d). Note the lower molecular weight protein 
bands in (C and F), which are indicative of proteolytic degra-
dation/processing. For normalization, probes for β-actin were 
used in Northern blot analyses (A and D) and antibodies 
against β-tubulin and -actin in Western blots (C and F). For quan-
tifi cation see Table I. Bars, 50 μm.
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Late onset of mini-agrin expression 
ameliorates disease progression 
in dyW/dyW mice
To generate laminin-α2–defi cient mice that allowed controlling 
expression of m-mag, we mated line L3 with mice heterozygous 
for the laminin-α2 mutation. This breeding eventually resulted 
in dyW/dyW mice that contained all the necessary genetic ele-
ments (see Fig. S1 B for the breeding scheme). In such mice, 
which are called dyW/m-mag, we removed doxycycline at birth, 
which resulted in expression of m-mag at postnatal day 3 
(henceforth called dyW/m-mag 3d), at day 11 (dyW/m-mag 14d), 
or at day 25 (dyW/m-mag 28d). Muscular dystrophy was always 
evaluated in 4- and 6-wk-old mice. In a grip test, dyW/m-mag 
mice always performed better than dyW/dyW controls, irrespec-
tive of when expression of m-mag was started (Fig. 3 A). In the 
4- and 6-wk-old animals the improvement was less pronounced 
if m-mag expression was started late (dyW/m-mag 28d). In an 
open fi eld test, locomotory activity in 4-wk-old m-mag trans-
genic mice was signifi cantly higher than in dyW/dyW mice, 
whereas in 6-wk-old mice, statistical signifi cance could only be 
reached in mice expressing the transgene early (Fig. 3 B). To get 
a direct measure for ongoing muscle fi ber damage, we mea-
sured the CK activity in the blood (Fig. 3 C). CK activity was 
5 times higher in dyW/dyW than in wild-type (WT) mice. Ex-
pression of m-mag lowered CK activity in dyW/dyW mice by ap-
proximately half (Fig. 3 C). In contrast to the behavioral tests, 
the lowering of the CK activity was not dependent on when 
mini-agrin expression started. Although the improvement in the 
capability of moving is certainly important to determine the 
benefi t of a treatment, the strongest endpoint in such a severe 
disease is life expectancy. As shown in Fig. 3 D, treatment that 
started only after 4 wk substantially increased survival proba-
bility. In accordance with this, the mean lifespan of dyW/m-mag 
28d mice was approximately tripled compared with dyW/dyW 
mice (Fig. 3 E).
Another hallmark of the severe muscular dystrophy in 
dyW/dyW mice is the presence of many small fi bers and of fi brotic 
tissue as visualized by hematoxylin and eosin (HE, Fig. 4 A) 
and Masson’s Trichrome staining (Fig. 4 B) of cross sections 
from triceps brachii. In 6-wk-old dyW/dyW mice, muscle showed 
strong signs of degeneration and replacement of muscle with 
nonmuscle tissue (Fig. 4 A, top right). The nonmuscle cells 
Figure 3. Mini-agrin improves overall performance, lowers 
muscle damage, and prolongs lifespan. Parameters were 
measured in 4- or 6-wk-old WT, laminin-α2–defi cient (dyW/
dyW), and laminin-α2–defi cient mice expressing m-mag (dyW/
m-mag) or c-mag (dyW/c-mag). (A) In grip strength, all 
mini-agrin–expressing mice show a signifi cant improvement 
compared with dyW/dyW mice. The improvement is less in mice 
expressing mini-agrin late (dyW/m-mag 14d or dyW/m-mag 
28d). (B) Locomotive activity within 10 min. In 4-wk-old mice, 
all mini-agrin–expressing mice show a signifi cant improve-
ment compared with dyW/dyW mice. In 6-wk-old mice, only 
early treatment (dyW/c-mag and dyW/m-mag 3d) is signifi -
cant. (C) CK levels in the blood. All values are normalized to 
WT mice. CK activity is reduced to approximately half of that 
measured in dyW/dyW mice in all mini-agrin–expressing mice, 
irrespective of the onset of expression. (D and E) Survival 
curves of mice with different genotypes. Late start of mini-agrin 
expression (dyW/m-mag 28d) increases the survival probabil-
ity (D; n ≥ 29) and the mean survival (E; n ≥ 16) more than 
twice in comparison to dyW/dyW mice. Note that late expres-
sion of mini-agrin is signifi cantly less effective than constitutive 
expression of c-mag (dyW/c-mag mice). All values represent 
the mean ± the SEM. n ≥ 3. P-values (t test) are as follows: 
**, P < 0.01; *, P < 0.05; ns (not signifi cant), P > 0.05.
Table I. Quantifi cation of mRNA and protein levels of m-mag in dif-
ferent transgenic lines, and induction by withdrawal of doxycycline
Line Dox NB WB IHC
L1 65 63 ± 12 70 ± 8
L2 40 57 ± 14 68 ± 3
L3 100 100 ± 7 100 ± 4
L4 1 3 ± 1 5 ± 2
L3 Dox 1 0 1 ± 1
L3 wd 3d 72 92 ± 6 56 ± 7
L3 wd 6d 102 96 ± 9 97 ± 6
Quantifi cation of Northern blot analysis (NB), immunohistochemistry (IHC), and 
Western blot analysis (WB). Values show expression levels of m-mag in skeletal 
muscles of mouse lines L1–L4. Data of line L3 after suppression of expression 
by doxycycline (Dox) and subsequent withdrawal for 3 (wd 3d) or 6 d (wd 6d) 
are relative to levels measured in mouse line L3. Values represent the mean ± 
the SEM. n ≥ 3.
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represented mainly fi brotic tissue, as suggested by the blue 
color in the Masson’s Trichrome staining (Fig. 4 B). Moreover, 
muscle fi bers in dyW/dyW mice often lost their characteristic 
 polygonal shape, which is indicative of impaired nerve conduc-
tion. Although expression of the m-mag transgene prevented 
much of the fi brosis (Fig. 4, A and B), it did not affect the shape 
of the muscle fi bers. The extent of fi brosis depended on the time 
point of the transgene expression. It was, however, compelling 
that a treatment of only 2 wk was still suffi cient to improve the 
histological picture of the muscle. To measure these parameters 
more quantitatively, we determined the muscle fi ber size distri-
bution in 4-wk- (not depicted) and 6-wk-old mice (Fig. 4 C). 
Compared with WT mice, the fi ber size distribution was obvi-
ously shifted toward smaller fi bers in dyW/dyW mice, as many 
did not exceed a minimal diameter of 15 μm (Fig. 4 C). This 
shift was prevented by the expression of m-mag. To quantify 
 fi brosis, we determined fi rst the relative percentage of the area 
covered by nonmuscle tissue in a series of muscle cross sec-
tions. As shown in Fig. 4 D, expression of the m-mag transgene 
prevented the fi brotic phenotype of dyW/dyW muscle to a great 
extent. As an independent measure of fi brosis, we also deter-
mined the amount of hydroxylated proline in muscles of the dif-
ferent genotypes (Fig. 4 E). Hydroxyproline is a main constituent 
of collagens whose expression is high in fi brotic tissue. This 
quantifi cation also showed the benefi cial effect of m-mag. In 
contrast to the counting of nonmuscle tissue, the amount of hy-
droxyproline was at least twice as high in all mini-agrin trans-
genic dyW/dyW mice compared with WT controls, and this increase 
was independent of the time point of expression (Fig. 4 E).
Several lines of evidence strongly indicate that muscles 
of MDC1A patients, and animal models thereof, have a reduced 
capacity of regenerating upon damage (Miyagoe et al., 1997; 
Kuang et al., 1999). In dy3K/dy3K mice, another mouse model 
for MDC1A, this pathology is reversed by constitutive expres-
sion of mini-agrin (Bentzinger et al., 2005). To test whether the 
onset of expression of m-mag infl uences the outcome of the re-
generation process, we induced degeneration by injection of 
notexin into the tibialis anterior muscle of dyW/m-mag 28d 
mice 1 wk after induction of the mini-agrin. Muscles were then 
examined 6, 14, and 28 d after injection and compared with 
WT and dyW/dyW mice. As shown in Fig. 5 A, 6 d after injec-
tion, many muscle fi bers had already reformed in both WT and 
dyW/m-mag 28d mice. Indicative of ongoing regeneration, these 
muscle fi bers expressed high levels of developmental myosin 
heavy chain (dMyHC; Fig. 5 B). In contrast, muscle of dyW/dyW 
mice contained mainly cells with a very small cytoplasmic sur-
round and only a few dMyHC-positive fi bers (Fig. 5, A and B). 
The difference between dyW/dyW and WT or dyW/m-mag 28d 
mice was highly signifi cant in the quantitative assessment of 
the fi ber size distribution (Fig. 5 C). 14 d after notexin injec-
tion, the muscle fi ber size had further increased, and fi bers 
no longer expressed dMyHC in both WT and dyW/m-mag 
28d mice (Fig. 5 A). Myonuclei still had a central position, which 
was indicative of the recent regeneration (Fig. 5 A, arrows). 
Figure 4. Phenotype analysis in triceps 
brachii muscle of 6-wk-old mice. HE (A) 
and Masson’s Trichrome (B) staining of 
cross sections. Pathological changes in the 
muscle of dyW/dyW mice, i.e., fi brosis, vari-
ation in muscle fi ber diameters, infi ltration of 
nonmuscle tissue, and collagen-containing 
tissue (blue in B), are less pronounced in 
mice expressing mini-agrin, but are de-
pendent on the time point of mini-agrin ex-
pression. Note that mini-agrin expression 
does not prevent appearance of polygo-
nally shaped muscle fi bers. (C) Muscle fi ber 
size distribution. Values represent relative 
numbers of fi bers in a given diameter class. 
Muscle fi bers of dyW/dyW mice are signifi -
cantly smaller than age-matched fi bers 
of dyW/dyW mice expressing mini-agrin. 
(D) Relative contribution of fi brotic regions 
to the total area in cross sections. In 6-wk-old 
dyW/dyW mice, the fi brotic tissue represents 
>30% of the entire muscle. In all the mini-
agrin transgenic dyW/dyW mice, the fi bro-
sis is signifi cantly reduced. (E) Relative 
amount of hydroxyproline (OH-Pro) in mus-
cles of the different genotypes. The amount 
of OH-Pro is signifi cantly reduced by mini-
agrin (dyW/m-mag 3d and 14d, >50%; 
dyW/m-mag 28d, >30%). Values represent 
the mean ± the SEM. n ≥ 3. P-values (t test) 
are as follows: **, P < 0.01; *, P < 0.05; 
ns, P > 0.05. Bar, 50 μm.
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In contrast, cross sections from dyW/dyW mice contained large 
regions with mononucleated cells (Fig. 5 A, arrowheads), and 
the few muscle fi bers did not express dMyHC (Fig. 5 B). This 
defi ciency in regenerative capacity of dyW/dyW mice was also 
eminent in the fi ber size distribution (not depicted). 4 wk after 
notexin injection, muscles had almost completely recovered. 
Figure 5. Expression of mini-agrin enhances regeneration of skeletal muscle after notexin-induced injury of tibialis anterior muscle. Notexin injection was 
performed in 5-wk-old mice in which mini-agrin expression had been started 1 wk before. Muscles were analyzed 6 (A and B, notexin 6d; C), 14 (A and B, 
notexin 14d), and 28 d (A and B, notexin 28d; D–F) after injection. (A) HE-stained cross sections. (B) Staining with the nuclear marker DAPI (blue), anti-
bodies to dMyHC (green), and laminin-γ1 (red) were used to determine the state of regeneration. 6 d after notexin injection, muscle fi bers are regenerating 
in WT and dyW/m-mag 28d mice, while regeneration is poor in dyW/dyW mice; this is indicated by large regions containing mononucleated cells (arrow-
heads). 14 d after notexin injection, dyW/dyW muscle still contains many mononucleated cells (arrowhead) and little dMyHC is expressed. In WT and dyW/
m-mag 28d mice, regeneration has progressed and most of the muscle fi bers have lost expression of dMyHC. 28 d after notexin injection, muscle is restored 
in WT and dyW/m-mag 28d, although centralized nuclei are still present. In dyW/dyW mice, large regions of the muscle fail to regenerate and are replaced 
by nonmuscle tissue. (C) Fiber size distribution 6 d after notexin injection. Quantifi cation of fi brosis (D) and fi ber size distribution 28 d after injection (E). 
There is a signifi cant difference between dyW/dyW mice and the other two genotypes. (F) HE staining of longitudinal sections of muscles 28 d after notexin 
injection. DyW/dyW muscle is characterized by extensive fi brosis, and most of the remaining muscle fi bers are smaller and thinner than in the other two genotypes. 
Values represent the mean ± the SEM. n ≥ 3. P-values (t test) are as follows: **, P < 0.01; *, P < 0.05; ns, P > 0.05. Bars, 50 μm.
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Muscle of dyW/dyW mice still contained large regions that were 
reminiscent of fi brotic tissue (see Fig. 5 D for quantifi cation), 
and the diameter of the muscle fi bers was often <15 μm (Fig. 
5 E). To see whether the regenerated muscle fi bers spanned the 
entire length of the muscle, we also examined longitudinal sec-
tions of tibialis anterior muscle. In contrast to WT mice, most 
of the regenerated muscle fi bers were rather short and thin, and 
large parts of the muscle of dyW/dyW mice still contained mono-
nucleated cells (Fig. 5 F). Muscle from dyW/m- mag 28d and 
WT mice showed a homogenous fi ber size distribution and only 
little fi brosis. These experiments show that mini-agrin is suffi -
cient to restore the regenerative capacity of muscle from dyW/dyW 
mice to almost WT levels. Importantly, 1 wk of m-mag expression 
is suffi cient for this effect.
We have previously shown that constitutive overexpres-
sion of mini-agrin in dyW/dyW mice leads to increased levels of 
laminin-α5 and α-dystroglycan (Moll et al., 2001), and that this 
is based on posttranscriptional effects (Bentzinger et al., 2005). 
The protein levels of laminin-α5 were also increased in all dyW/
m-mag mice, irrespective of the onset of m-mag expression 
(Fig. S3 A, available at http://www.jcb.org/cgi/content/full/
jcb.200611152/DC1; and Table II). Similarly, using antibodies 
directed to the core protein (Herrmann et al., 2000), we found 
increased levels of α-dystroglycan in all the transgenic mice 
(Fig. S3 A; Table II). In contrast, we could not detect any 
changes in the levels of α7 integrin (not depicted), which is in 
agreement with earlier fi ndings (Moll et al., 2001). Because re-
cent experiments showed that transgenic expression of laminin-α1 
is highly benefi cial in dy3K/dy3K mice (Gawlik et al., 2004), we 
also stained for this laminin chain. Basement membranes sur-
rounding skeletal muscle did not contain detectable levels of 
laminin-α1 (Fig. S3 B), which is consistent with published 
 results (Patton et al., 1997). Our data thus show that an increase 
in the amount of laminin-α1 is unlikely the mechanism of how 
mini-agrin ameliorates the disease in dyW/dyW mice.
Full-length agrin or an agrin-perlecan fusion 
protein ameliorate disease progression
Another treatment option for MDC1A patients is the up-regulation 
of the expression of endogenous agrin in muscle, similar to 
what has been proposed for utrophin in DMD patients (for re-
view see Miura and Jasmin, 2006). Because full-length agrin is 
a large, highly glycosylated protein, its effi cacy in ameliorating 
the disease might differ from mini-agrin. To test this, we gener-
ated transgenic mice that overexpress c-FLag in muscle (Fig. 1, 
B and D). In another set of experiments, we wanted to test our 
initial hypothesis that the benefi cial effect of mini-agrin is based 
on the linking of the up-regulated laminin isoforms containing 
laminin-α4 to α-dystroglycan (Moll et al., 2001) and not to the 
integrins. To this end, we generated a fusion construct in which 
we replaced the 95-kD, C-terminal half of agrin with domain V/
endorepellin of mouse perlecan (Fig. 1, C and D). Like mini-
agrin, this fusion protein (AgPerl) bound to α-dystroglycan 
(Fig. S2 C). These data are consistent with the fi nding that 
Figure 6. Transgenic expression of c-FLag and an AgPerl fusion protein improves muscle function and lifespan in dyW/dyW mice. (A) Immunostaining of 
transgenes in triceps brachii muscle of transgenic mouse lines for c-FLag (L2, L4, and L9) or AgPerl (L1, L2, L4, and L5). L4 (c-FLag L4) and L1 (AgPerl L1) ex-
press the highest levels for c-FLag and AgPerl fusion construct, respectively. For quantifi cation see Table III. Improvement in locomotion (B) or CK values in 
the blood (C) is evident for all the transgenic mice at an age of 4 wk. (D and E) Life expectancy. The survival probability (D; n ≥ 29) and the mean survival 
(E; n ≥ 23) are more than doubled in the transgenic compared with the dyW/dyW mice. Note that in most of the parameters measured there is a trend that 
the amelioration is less pronounced in dyW/c-FLag mice than in dyW/c-mag or dyW/AgPerl mice. Values in all quantifi cations represent the mean ± the 
SEM. n ≥ 3. P-values (t test) are as follows: **, P < 0.01; *, P < 0.05; ns, P > 0.05. Bar, 50 μm. 
Table II. Quantifi cation of laminin-𝛂5 and 𝛂-dystroglycan detected 
at the membrane of triceps brachii
Strain Laminin-𝛂5 𝛂-Dystroglycan
WT 100 ± 17 100 ± 13
dyW/dyW 138 ± 9 27 ± 6
dyW/c-mag 373 ± 33 71 ± 14
dyW/m-mag 3d 365 ± 17 64 ± 18
dyW/m-mag 14d 409 ± 17 61 ± 10
dyW/m-mag 28d 368 ± 16 63 ± 17
Expression levels of laminin-α5 and α-dystroglycan were compa-
rable in dyW/c-mag and dyW/m-mag mice starting expression in 
advanced stages of the disease. Values are relative to WT mice and 
represent the mean ± the SEM. n ≥ 3.
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 domain V/endorepellin binds to α-dystroglycan with similar af-
fi nity as laminin-α2 (Talts et al., 1999) or agrin (Gesemann 
et al., 1998).
Between the different mouse lines, the mRNA levels of 
the transgenes varied substantially, whereas the amount of pro-
tein detected in muscle was similar (Fig. 6 A; Table III). To as-
sess the capability of the transgenes to ameliorate the disease in 
dyW/dyW mice, the mouse lines with the highest expression lev-
els were crossbred and analyzed (i.e., c-Flag L4 and AgPerl 
L1). In the locomotory test, all the transgenic lines showed a 
highly signifi cant improvement compared with dyW/dyW mice 
(Fig. 6 B). Moreover, CK levels in the blood were signifi cantly 
lower (Fig. 6 C). Most importantly, the survival probability and 
the mean survival of the transgenic mice were higher than in 
dyW/dyW mice (Fig. 6, D and E).
Muscle histology was substantially improved as shown by 
HE staining of triceps brachii from 4-wk-old mice (Fig. 7 A), 
and the size distribution of the muscle fi bers was shifted to 
larger fi bers (Fig. 7 B). Consistent with the hypothesis that the 
mechanism of amelioration by the transgenes is the same as in 
mini-agrin transgenic mice, protein levels for both laminin-α5 
and α-dystroglycan were elevated (Fig. 7 C; Table IV for quanti
fi cation). Our experiments thus show that full-length agrin and 
a fusion protein of agrin and perlecan ameliorate the disease 
phenotype in dyW/dyW mice. In most measurements, mice ex-
pressing the AgPerl transgene showed a better improvement 
than those expressing c-FLag.
If human patients were to be treated, an appropriate route 
of application must be defi ned. Such routes for mini-agrin could 
be viral vectors (Qiao et al., 2005), but also injection of recom-
binant protein, as done for other muscle diseases (Bogdanovich 
et al., 2002; Raben et al., 2003). To test the feasibility of protein 
application, we determined the turnover rate of mini-agrin in 
our mouse model. To this end, mice were raised in the presence 
of doxycycline (i.e., m-mag not expressed), followed by 1 wk 
without doxycycline (m-mag expressed). Thereafter, doxy-
cycline was reapplied and m-mag expression was followed on 
the mRNA and the protein level over time. 1 d after readdition 
of doxycycline, the mRNA encoding mini-agrin had already 
dropped to 10%, and it could not be detected anymore after 
2 d (Fig. 8 A). Concomitantly, with the repression of transcrip-
tion, m-mag protein steadily declined, as determined by Western 
blot analysis (Fig. 8 B) and immunohistochemistry (Fig. 8 C). 
Quantifi cation of the amount of mini-agrin after suppression of 
its transcription indicates a half-life of 4.5 d (Fig. 8 D).
To get an estimate of how high the levels of agrin must be 
to achieve an improvement, we compared the levels of endoge-
nous mouse agrin found in other tissues to the levels of the 
transgenes expressed in muscles of our mice. We fi rst compared 
the levels of the transgenic protein for mini- and full-length 
agrin using antibodies that recognize chick, but not mouse, 
agrin (Fig. 8 E, left column). The amount of c-mag was 20% 
higher than c-FLag (Fig. 8 F; left column). We then compared 
staining intensity of the transgenic m-mag in muscle with that 
for endogenous agrin in kidneys using antibodies directed to 
mouse agrin (Fig. 8 E, right column). Expression levels of the 
transgenic m-mag were 13% lower than the levels of endoge-
nous agrin detected in kidney (Fig. 8 F, right columns). To com-
pare levels of endogenous agrin in kidney and the amount of 
c-FLag in muscle, we assumed that the amount of c- and m-mag 
were the same. This assumption is based on the fact that the 
overall improvement in the phenotype is the same in dyW/c-mag 
and dyW/m-mag mice. Expression levels of c- and m-mag trans-
genes were therefore set as being equal. Based on this, the pro-
tein level of the transgenic c-FLag (81% of c-mag) is substantially 
lower than the amount of endogenous agrin found in kidney 
(113% of m-mag). Thus, expression levels of endogenous agrin 
in kidney are even substantially higher than the levels of the 
transgenic c-FLag in the muscle. Thus, agents that increase the 
amount of agrin in muscle to the amount in kidney are suffi cient 
to be of benefi t for dyW/dyW mice.
Discussion
In our previous work (Moll et al., 2001; Bentzinger et al., 2005), 
we provided in vivo evidence that mini-agrin could be a means 
to prevent muscular dystrophy in MDC1A patients. The work 
described in this study approaches both therapeutic and mecha-
nistic aspects of how mini-agrin ameliorates the phenotype in 
dyW/dyW mice. It provides strong evidence that mini-agrin also 
decelerates disease progression when applied at late stages, and 
it shows that full-length agrin, if expressed at a level similar to 
that in kidney, is capable of ameliorating the disease. Finally, 
our evidence that the fusion construct between the laminin-
binding domain of agrin and the α-dystroglycan–binding do-
main of perlecan has the same ameliorating activity in dyW/dyW 
Table III. Quantifi cation of mRNA levels by Northern blot analysis (NB) and protein levels by immunohistochemistry (IHC) or Western blot 
analysis (WB) in different transgenic lines expressing c-FLag or AgPerl
Strain Line NB WB IHC
c-mag 100 100 ± 6 100 ± 5
c-FLag L2 57 89 ± 19 84 ± 6
L4 63 97 ± 10 87 ± 5
L9 42 67 ± 24 78 ± 9
AgPerl L1 210 79 ± 2 84 ± 5
L2 72 70 ± 5 78 ± 6
L4 42 69 ± 1 87 ± 3
L5 50 60 ± 9 85 ± 6
Values show the expression in skeletal muscles of c-FLag in mouse lines L2, L4, and L9 and of AgPerl in mouse lines L1, L2, L4, and L5. Data are relative to levels 
measured in mice transgenic for c-mag (Moll et al., 2001). Values represent the mean ± the SEM. n ≥ 3.
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mice as mini-agrin clearly indicates that the amelioration is 
based on the linking of muscle basement membrane to the DGC, 
and not to integrins.
Mini-agrin slows down MDC1A 
disease progression
In MDC1A patients, the disease is often diagnosed in the fi rst 
year of life because of the fl oppy appearance of the infants. How-
ever, muscular dystrophy has already started to manifest at the 
time of diagnosis, and treatment of infants faces diffi culties. 
Therefore, it is important to evaluate the potential of mini-agrin 
treatment at progressed stages of the disease. To test this, we 
generated dyW/dyW mice that allow the temporal control of the 
expression of mini-agrin in muscle using the tet-off system (Gossen 
and Bujard, 1992; Ghersa et al., 1998). We show that mini-agrin 
is of clear, but attenuated, benefi t when applied at progressed 
disease stages. Importantly, expression of mini-agrin after 4 wk, 
when the disease is already far progressed, still tripled the mean 
survival. Our evidence indicates that mini-agrin mainly acts on 
the tissue that has not yet been destroyed in the course of the dis-
ease. This is best manifested by the fi nding that late expression 
of mini-agrin seems not to affect already existing fi brosis (Fig. 4), 
and that early treatment is superior in the behavioral tests (Fig. 3, 
A and B). There is also evidence that the time point of transgene 
expression is not relevant for parameters that measure acute 
 responses, such as CK activity in the blood (Fig. 3 C) or the 
 regeneration upon injury (Fig. 5). Our experiments are thus evi-
dence that even late application of mini-agrin is highly benefi cial, 
but that treatment is most successful if initiated early.
Mini-agrin combines several advantages 
for a feasible treatment of MDC1A patients
Our proof-of-concept experiment using transgenic mice is a 
crucial step toward devising ways of treating MDC1A patients. 
Similar to mini-agrin, transgenic expression of laminin-α1 
also improves muscle function (Gawlik et al., 2004). Although 
this approach may be interesting for therapy, the use of  laminin-α1 
seems less feasible than that of mini-agrin. First, the size of 
its cDNA (>9 kb) prevents its packaging into AAV vectors. 
Second, laminin-α1 must also become incorporated into the 
laminin heterotrimer to be functional, which makes it diffi cult 
to generate a miniaturized version of laminin-α1 because 
Figure 7. Characterization of muscles from mice 
transgenic for c-FLag or the AgPerl fusion protein. 
Animals were analyzed at 4 wk of age. (A) HE 
staining of triceps brachii cross sections. (B) Mus-
cle fi ber size distribution. Values are given as rela-
tive number of fi bers in each diameter class. 
Muscles of dyW/dyW mice contain a signifi cantly 
higher percentage of small fi bers. (C) Levels of 
laminin-α5 (left column) and α-dystroglycan (right 
column) are increased in muscles of dyW/c-FLag or 
dyW/AgPerl mice relative to dyW/dyW mice. See 
Table IV for quantifi cation. Values in all quantifi ca-
tions represent the mean ± the SEM. n ≥ 3. P- values 
(t test) are as follows: **, P < 0.01; *, P < 0.05; 
ns, P > 0.05. Bars, 50 μm.
Table IV. Quantifi cation of laminin-𝛂5 and 𝛂-dystroglycan in triceps 
brachii of dyW/dyW mice expressing dyW/c-FLag or dyW/AgPerl
Strain Laminin-𝛂5 𝛂-Dystroglycan
WT 100 ± 16 100 ± 11
dyW/dyW 138 ± 20 28 ± 3
dyW/c-FLag 263 ± 64 60 ± 6
dyW/AgPerl 266 ± 39 61 ± 6
dyW/c-mag 264 ± 40 69 ± 12
Both transgenes increase the concentration of laminin-α5 and α-dystroglycan in 
dyW/dyW mice. Similar values were observed in dyW/c-mag mice. Values are 
relative to WT mice and represent the mean ± the SEM. n ≥ 3.
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 several domains contribute to its functionality. In contrast, 
mini-agrin combines several advantages, and thus might be a 
promising strategy for the treatment of MDC1A patients. As 
the next step will be the defi ning of a route of application, we 
determined the half-life of mini-agrin in the transgenic mice. 
We found that it was 4.5 d, which is substantially less than 
what has been estimated for full-length agrin when injected 
into rat muscle (Bezakova et al., 2001). One of the reasons for 
this difference could be the lack of any O-glycosylation in 
mini-agrin. Moreover, mini-agrin also seems to be targeted by 
proteases of unknown identity, as the protein displays distinct 
bands in Western blots (Moll et al., 2001; this study). Never-
theless, the good stability of mini-agrin, in combination with 
the fact that it acts extracellularly, makes it a valuable candidate 
gene for gene therapy. Indeed, recent experiments in dyW/dyW 
mice showed that transduction of skeletal and heart muscle by re-
combinant adeno-associated virus that express mini-agrin restored 
muscle function (Qiao et al., 2005; Meinen and Ruegg, 2006). 
An alternative way of treating patients might also be the 
use of recombinant protein and its targeting to the affected 
tissue. Examples for the successful targeting of recombinant 
enzymes and antibodies to muscle are the treatment of lyso-
somal storage diseases (Desnick, 2004) and muscle wasting 
(Bogdanovich et al., 2002), respectively. The major obstacle 
for mini-agrin’s reaching muscle is, however, its laminin-
 binding, as laminins line the endothelial wall of blood vessels 
(Hallmann et al., 2005). Thus, it will be important to reduce 
the size of the injected protein (e.g., the binding of agrin to 
α-dystroglycan requires only two laminin G–like domains) 
and to apply enhancers of endothelial permeability, such as 
VEGF or histamine.
Up-regulation of endogenous agrin provides 
an alternative treatment option
An alternative treatment option is the use of molecules that 
 increase the expression of the endogenous agrin protein in 
Figure 8. Feasibility for the use of mini-agrin or up-
 regulation of endogenous agrin expression as a treatment 
option. (A–D) Stability of mini-agrin in skeletal muscle of 
4-wk-old transgenic mice. (A) Time course of m-mag tran-
scripts in triceps brachii after repression by 50 mg/liter 
doxycycline in the drinking water, as determined by quan-
titative real-time PCR. After 2 d, m-mag transcripts cannot 
be detected anymore. Concomitantly, mini-agrin protein is 
lost from the muscle basement, as determined by Western 
blot analysis from quadriceps (B) and quantitative immuno-
staining of cross sections from triceps brachii muscle (C). 
(D) Quantitative immunohistochemistry indicates a half-
life of mini-agrin protein of 4.5 d. Values are expres-
sed as percentages of staining relative to values before 
suppression by doxycycline. (E) Staining of transgenic 
c-mag and c-FLag (left) in triceps brachii muscle using anti-
bodies recognizing chick, but not mouse agrin. Staining 
using antibodies against mouse agrin in triceps brachii 
muscle of mice transgenic for m-mag or in kidneys of WT 
mice (WT kidney; right). Note that staining in green (left) 
detects only the transgenes, whereas staining in red (right) 
can detect both the m-mag and endogenous agrin. (F). 
Quantifi cation of staining intensity. Protein expression lev-
els of c-FLag reach 81% of c-mag (left). Endogenous agrin 
expression in kidney is 13% higher than the levels of trans-
genic m-mag in muscle (right). For details see the text and 
the Materials and methods. Values represent the mean ± 
the SEM. n ≥ 3. Bar, 50 μm. 
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MDC1A patients. In mdx mice, which are mouse models of 
DMD, up-regulation of the endogenous utrophin, which is the 
autosomal homologue of dystrophin, has been shown to amelio-
rate the dystrophic phenotype (Miura and Jasmin, 2006). Re-
cently, intraperitoneal injection of a peptide derived from 
heregulin was shown to increase expression of utrophin and 
thereby ameliorate the disease in mdx mice (Krag et al., 2004). 
We show that c-FLag, indeed, ameliorates the disease and pro-
longs lifespan in dyW/dyW mice. This is experimental proof that 
the aforementioned strategy might be promising for the treat-
ment of MDC1A patients. We found that the improvement with 
c-FLag is less effective than with mini-agrin. This difference 
might arise from a distinct orientation of the domains important 
for laminin and α-dystroglycan binding caused by the size dif-
ference or differences in glycosylation. Full-length agrin is 95 nm 
long (Denzer et al., 1998), whereas mini-agrin folds into a 
 globular structure with an estimated length of 20 nm. Moreover, 
the high carbohydrate content of full-length agrin may impose 
a different orientation of the two functional domains, and the 
presence of heparan sulfate glycosaminoglycan side chains may 
lower its apparent binding affi nity to α-dystroglycan, as binding 
of agrin to α-dystroglycan is inhibited by heparin (Gee et al., 
1994; Gesemann et al., 1996). Finally, the amount of full-length 
agrin expressed in our transgenic mice is lower than that of 
mini-agrin. However, the difference in the protein concentration 
between the two transgenes became smaller the older the mice 
were (unpublished data). Thus, it is likely that the slow turnover 
rate of full-length agrin in the basement membrane allows it to 
accumulate over time and to eventually reach saturation, despite 
being less strongly expressed. Accumulation of agrin would be 
highly desirable in a pharmacological approach because even a 
moderate increase in agrin transcripts would then result in high 
concentrations of the protein over time. Moreover, the levels of 
transgenic agrin necessary for its ameliorative effect are even 
lower than those found in kidney. Thus, such an approach may 
indeed be feasible.
A mechanistic explanation 
of agrin’s activity
We also provide conceptual proof that mini-agrin’s benefi cial 
effect on the disease progression in dyW/dyW mice arises from 
the reconnection of muscle basement membrane with the cyto-
skeleton via the DGC, as a chimeric fusion protein between 
 AgPerl has the same effi cacy in ameliorating the disease as 
mini-agrin. Both mini-agrin and AgPerl bind to laminins and 
α-dystroglycan, and they compete for the same binding sites 
(unpublished data). Our experiments therefore indicate that 
 integrins do not contribute to the ameliorating activity because 
the C-terminal proportions of AgPerl bind to different integrins 
(Brown et al., 1997; Burgess et al., 2002). In addition, the α2β1 
integrin receptor of domain V/endorepellin is not even ex-
pressed in muscle. Our model that reconnection of laminins and 
α- dystroglycan is the underlying mechanism for the benefi cial 
 effect of mini-agrin and AgPerl is also corroborated by the 
fact that CMDs with phenotypes similar to those of MDC1A 
are based on mutations in glycosyltransferases that have 
α- dystroglycan as their main substrates (Muntoni and Voit, 2004).
One of the most striking fi ndings is that mini-agrin, ir-
respective of the onset of its expression, increases the regene ra tive 
capacity of muscle fi bers in dyW/dyW mice. After notexin-induced 
muscle damage, many fi bers in the WT and the dyW/m-mag 
mice regenerate within the fi rst week, as indicated by the ex-
pression of dMyHC. In contrast, in dyW/dyW mice, dMyHC was 
expressed only marginally in the early phase, but was also not 
up-regulated later. Moreover, muscle fi bers that had formed in 
dyW/dyW mice were shorter, and the muscle contained large re-
gions with mononucleated cells (Fig. 5). This is evidence that 
muscle regeneration in dyW/dyW mice is not simply delayed, 
but that some of the crucial steps cannot be accomplished. The 
mechanism behind how LM-211 infl uences regeneration is not 
known. For example, expression of LM-211 in satellite cells 
themselves may improve proliferation or survival. Alterna-
tively, satellite cells may depend on LM-211 bound to muscle 
basement membrane for adhesion and/or survival, which, in 
turn, would allow their fusion. These events may even be in-
terdependent, as muscle fi bers are known to undergo detach-
ment- induced apoptosis, which is termed anoikis, during 
regenera tion (Kuang et al., 1999). The fact that only 1 wk of 
mini-agrin expression can restore muscle regeneration to lev-
els indistinguishable from WT mice suggests that its binding 
to α-dystroglycan may activate pathways that prevent anoikis. 
Indeed, disruption of the binding of laminin with α-dystroglycan 
induces cell death in cultured muscle cells because of the per-
turbation of the phosphoinositide 3-kinase–protein kinase B 
pathway. Thus, we favor a mechanism in which mini-agrin 
bound to muscle basement membranes allows the survival of 
satellite cells and early myotubes.
We also fi nd that the level of laminin-α5, but not laminin-α1, 
is increased in all mice that express a transgene. The increase in 
laminin-α5 is not based on changes in transcription (Bentzinger 
et al., 2005), but may be based on its immobilization in the 
 muscle basement membrane. As laminin-α5 does not bind to 
α-dystroglycan (Ido et al., 2004), it probably does not contribute 
to linking α-dystroglycan to basement membrane. However, 
laminin-α5 is not truncated at the N-terminal end, a site impor-
tant for the formation of the primary laminin scaffold. Thus, 
the increased concentration of LM-511 in the transgenic mice 
may be important for the restoration of muscle basement 
 membrane. We also observed a restoration of the amount of 
α-dystroglycan in mice that express the transgene (Fig. 7 and 
Fig. S3). This change was very striking when we used an affi nity-
purifi ed antiserum directed against the protein backbone of 
α-dystroglycan (Herrmann et al., 2000), but was not seen with 
the antibody IIH6 directed to the carbohydrate moiety (Gawlik 
et al., 2004; unpublished data). It may be possible that altera-
tions in the proteolytic processing of dystroglycan, may lead to 
the loss of the epitope recognized by the antipeptide antibody, 
whereas glycosylation is not affected.
Future directions in the development 
of a MDC1A treatment
We and others (Qiao et al., 2005) noticed that mini-agrin does 
not remove all of the symptoms. Laminin-α2 defi ciency in 
nonmuscle tissue, particularly in the peripheral nerve, clearly 
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contributes to the pathology in dyW/dyW mice, and because our 
transgenes are only expressed in muscle, the pathology in non-
muscle cells is not reversed. Interestingly, some symptoms are 
still present in dyW/dyW mice that express human laminin-α2 in 
skeletal muscle (Kuang et al., 1998), whereas amelioration is 
more complete in mice that express laminin-α1 under the con-
trol of the ubiquitously expressed chicken β-actin promoter 
(Gawlik et al., 2004). Thus, the exclusive expression of all our 
transgenes in muscle does contribute to the incompleteness of 
the amelioration. In addition, it is also probable that mini-
agrin cannot substitute all of the functions of laminin-α2. For 
example, mini-agrin is not known to bind to those integrins that 
are expressed in muscle, and thus, any function mediated by the 
binding of laminin-α2 to integrins cannot be compensated for. 
Several lines of evidence strongly suggest that binding of 
 laminin-α2 to α7β1 integrin is important to prevent anoikis 
(Vachon et al., 1996, 1997). As recent fi ndings indicate that pre-
vention of apoptosis by genetic manipulation is also benefi cial 
for dyW/dyW mice (Girgenrath et al., 2004; Dominov et al., 
2005), it might be possible that antiapoptotic agents act syner-
gistically with mini-agrin. Several apoptosis inhibitors are used 
in clinical development. Thus, the combination of antiapoptotic 
drugs with the expression of mini-agrin in muscle, and/or the 
up-regulation of endogenous agrin, might be a promising ap-
proach to help MDC1A patients. Future experiments will be 
aimed at critically testing such a strategy.
Materials and methods
Generation of the constructs and transgenic mice
The m-mag cDNA was obtained by two independent RT-PCRs on mRNA 
isolated from mouse skeletal muscle. The 0.75-kb cDNA encoding the 
25-kD N-terminal agrin and the 2.2-kb cDNA encoding the 95-kD C-terminal 
half were ligated, and a 5× myc-tag (0.25 kb) was added to the 3′ end to 
yield the m-mag–myc (m-mag) construct. The 3.2-kb m-mag construct was 
sequenced and subcloned downstream of the uni-directional pTRE2 tet-
 responsive promoter (tetO7-CMV; BD Biosciences; pTRE2, 3.8 kb). A PacI 
site was inserted into the pTRE2 vector to allow linearization of the con-
struct as a 4.9-kb PacI–AseI fragment for injection into mouse oocytes. All 
transgenic mouse lines in which the cDNA was stably inserted into the ge-
nome were mated with transgenic mice expressing the tetracycline-dependent 
transcription activator (tTA) under the control of a 3.3-kb fragment of the 
human muscle CK (MCK) promoter (Fig. S1). MCK-tTA mice were obtained 
from N. Raben (National Institutes of Health, Bethesda, MD; Ghersa et al., 
1998) and were shown to drive expression of transgenes in skeletal and 
heart muscle (Ghersa et al., 1998; Raben et al., 2001). The AgPerl fusion 
protein was created by fusing the cDNA encoding the 0.75-kb 5′ region 
of chick agrin (Mascarenhas et al., 2003) with a cDNA coding for domain 
V of mouse perlecan (full-length cDNA encoding mouse perlecan was a gift 
from T. Sasaki, Max-Planck-Institut for Biochemistry, Martinsried, Germany). 
Both the 6.2-kb c-FLag and the 3.1-kb AgPerl were subcloned downstream 
of the 1.3-kb MCK promoter (Fig. S1, B–D). Constructs were linearized 
and injected into male pronuclei. C-mag transgenic mice (c-mag) were 
 created as previously described (Moll et al., 2001). dyW/dyW mice (Kuang 
et al., 1998) containing a LacZ insertion in the LAMA2 gene served as the 
mouse model for MDC1A.
Genotyping
Genotyping of heterozygous and homozygous dyW/dyW mice was done 
as previously described (Kuang et al., 1998). M-mag mice were geno-
typed by primers designed to amplify a 683-bp-long fragment, including 
the linker region of the N- and C-terminal parts of the m-mag construct 
(5′-G C G G A T C A C T T T G C G G A A C C -3′ and 5′-T C G A A C C T G A A C T G T A C A-
T G A C C -3′). Both c-FLag and c-mag mice were genotyped with primers 
amplifying a 591-bp-long fragment coding for the C-terminal part of agrin 
(5′-A C C T G G A T A A G C G T T T T G T T -3′ and 5′-C T T C T G T T T T G A T G C T C A G C -3′). 
Genotyping of AgPerl transgenic mice was performed on the chick agrin 
portion of the construct (5′-G T C C C T T G C T G A T G A C C T T G A -3′, 5′-A C C C-
A G C C C C T C A G T A C A T G T -3′). To distinguish hemi- from homozygous 
MCK-tTA mice, we performed quantitative TaqMan PCR (TaqMan PCR 
core reagent kit; Applied Biosystems) on the genomic DNA. The following 
primers were used: tTA-transgene, 5′-G C C T A C A T T G T A T T G G C A T G T A A A A -3′, 
5′-C A A A A G T G A G T A T G G T G C C T A T C T A A C A -3′, and Probe 5′-FAM-
C T T T G C T C G A C G C C T T A G C C A T T G A G -TAMRA 3′. For normalization of 
copy number, the following probes for β-actin were used: 5′-C C A C T-
G C C G C A T C C T C T T -3′, 5′-G C T C G T T G C C A A T A G T G A T G A C -3′, and Probe 
5′-FAM-C C C T G G A G A A G A G C T A T G A G C T G C C T G -TAMRA-3′.
Regulation of the tet-off system
For temporal regulation of m-mag expression under the tetracycline-regulated 
tet-off expression system (Gossen and Bujard, 1992), 5 μg doxycycline 
(doxycycline hydrochloride; Sigma-Aldrich) per milliliter of drinking water 
(enriched by 4% sucrose) was administered in dimmed bottles. For repres-
sion after transgene expression, 50 μg of doxycycline per milliliter of drink-
ing water was applied.
Protein production
The cDNAs encoding m-mag or AgPerl were subcloned into the pCEP-Pu 
vector (Kohfeldt et al., 1997) and transfected into HEK 293 EBNA cells. 
Conditioned medium was collected, and the relative amount of the protein 
was determined by dot blot assays. Such supernatants were directly used 
for experiments.
Solid-phase binding assays
96-well plates were coated with either chick α-dystroglycan enriched from 
skeletal muscle as previously described (Gesemann et al., 1998) or with 
laminin-111 (0.5 μg/well), which was a gift from J. Engel (Biozentrum, 
University of Basel, Switzerland). Proteins were coated in 50 mM sodium 
carbonate buffer, pH 9.6, and incubated overnight at 4°C. After blocking 
with PBS containing 0.05% Tween-20, 1 mM CaCl2, 1 mM MgCl2, and 
3% BSA (blocking buffer), wells were incubated with a dilution series (1:6) 
of supernatant containing m-mag (pure supernatant as the starting concen-
tration) or of purifi ed c-mag (50 nM as the starting concentration). The 
wells were washed with blocking buffer. Bound protein was detected with 
polyclonal antibodies raised against the C-terminal, 95-kD part of chick or 
mouse agrin. Alternatively, the monoclonal antibody 9E10 (Evan et al., 
1985) directed against the myc-tag was used. For detection, appropriate 
horse radish peroxidase–conjugated antibodies, followed by McEvans so-
lution, ABTS, and H2O2, were used. The absorbance was measured on an 
ELISA reader at 405 nm after 15 min.
Overlay assays
Lysates enriched for α-dystroglycan were obtained from chick or mouse 
skeletal muscles, as previously described (Gesemann et al., 1998). Pro-
teins were separated on a 3–15% SDS gel and blotted to nitrocellulose 
membrane. Blots were blocked for 2 h with PBS containing 0.05% Tween-20, 
1 mM CaCl2, 1 mM MgCl2, and 5% dry milk powder (blocking buffer). 
 Supernatants containing recombinant proteins were added and incubated 
overnight at 4°C. After several washes with blocking buffer, bound m-mag 
was detected with the anti-myc antibody 9E10, whereas  detection of 
 AgPerl was done using a polyclonal antiserum raised against the N-terminal 
part of agrin. For detection, appropriate horse radish  peroxidase–
 conjugated antibodies were used, and immunoreactivity was visualized by 
the ECL detection method (Pierce Chemical Co.).
Immunoblots
Tissues were homogenized in protein extraction buffer (75 mM Tris-HCl, 
pH 6.8, 3.8% SDS, 4 M urea, 20% glycerol, and 5% β-mercaptoethanol). 
Equal amounts of protein were separated on a 3–12% SDS–PAGE and 
 immunoblotted. Protein signals were normalized to β-actin (Santa Cruz 
Biotechnology; sc-8432) or β-tubulin (BD Bioscience).
Northern blot analysis and quantitative TaqMan PCR
Northern blot assays were performed on total RNA extracted from skel-
etal muscles using Northern Max Kit (Ambion). Signals were normal-
ized to corresponding β-actin signals. Quantitative TaqMan PCR was 
performed on the m-mag transgene (5′-T G T G C C A A T G T G A C C G C T A -3′, 
5′-G C T G A A A C C C T T G C C A G A A -3′, and Probe 5′-FAM-C C C C C A A A G T C-
C T G T G A T T C C C -TAMRA 3′) and was normalized to β-actin (5′-C C A C T G-
C C G C A T C C T C T T -3′, 5′-G C T C G T T G C C A A T A G T G A T G A C -3′, and Probe 
5′-FAM-C C C T G G A G A A G A G C T A T G A G C T G C C T G -TAMRA-3′).
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Locomotion, muscle strength, and CK assay
Locomotive behavior was determined as previously described (Moll et al., 
2001). In brief, mice were placed into a new cage and motor activity 
(walking, digging, and standing upright) was measured for 10 min. Grip 
strength was evaluated by placing the animals onto a vertical grid and 
measuring the time until they fell down. The cut-off time was 3 min. Blood 
for CK assays was collected from the tail vein. 2 μl of serum was applied 
using the CK CK-NAC Liqui-UV kit (Rolf Greiner Biochemica). In all tests, at 
least three animals of each genotype were analyzed, and values were nor-
malized to values obtained from WT animals.
Histology, immunohistochemistry, and antibodies
Muscles were immersed in 7% gum tragacanth (Sigma-Aldrich) and rap-
idly frozen in liquid nitrogen–cooled isopentane (–150°C). 12-μm-thick 
cross sections or longitudinal sections were cut and collected on Super-
Frost Plus slides (Menzel-Glaser). In the case of longitudinal sections, the 
slides were pretreated with 3% aqueous EDTA. General histology was 
performed using HE (Merck). Masson’s Trichrome staining (Luna, 1968) 
was used to visualize collagenous tissue. Membrane-bound and extracel-
lular epitopes were visualized with Alexa Fluor 488 –conjugated WGA 
(Invitrogen). Polyclonal rabbit anti–mouse laminin-α5 (Ab 405) and mono-
clonal rat anti–mouse laminin-α1 (Ab 198; Sorokin et al., 1992) were a 
gift from L. Sorokin (Lund University, Lund, Sweden). Polyclonal sheep 
anti–mouse α-dystroglycan was a gift from S. Kröger (University of Mainz, 
Mainz, Germany). The remaining antibodies were produced in-house or 
obtained as follows: monoclonal mouse anti–rat dMyHC (Novocastra), 
monoclonal rat anti–mouse laminin-γ1 chain (CHEMICON International, 
Inc.), polyclonal rabbit anti–chick (produced in-house; Gesemann et al., 
1995), and anti–mouse agrin (produced in-house). Mouse monoclonal 
anti-myc antibody (9E10) was produced and purifi ed from hybridoma cell 
line 9E10 and was biotinylated (D-Biotinoyl-E-aminocaproic acid-N-
 hydroxysuccinimidester; Roche). Depending on the source of the primary 
antibody, appropriate Cy3-conjugated (Jackson ImmunoResearch Labora-
tories) Alexa Fluor 488–conjugated secondary antibodies (Invitrogen) or 
TRITC-labeled streptavidin were used for visualization. DAPI was used to 
stain nuclei.
Quantifi cation of immunostainings
The muscle fi ber size was quantifi ed using the minimum distance of parallel 
tangents at opposing particle borders (minimal “Feret’s diameter”), as pre-
viously described (Briguet et al., 2004). Pictures of WGA-stained cross 
sections were collected using a fl uorescence microscope (DM5000B; 
Leica), a digital camera (F-View; Soft Imaging System), and analySIS soft-
ware (Soft Imaging System). Measurement of minimal Feret’s diameter of 
notexin-treated muscle was done on cross sections stained for laminin-γ1 
and dMyHC. Normalization of the number of fi bers in each fi ber Feret 
class of 5 μm was based on the total number of muscle fi bers in each pic-
ture. Fibrosis was quantifi ed by measuring the fi brotic area of WGA-
stained muscle cross section and normalizing it to the entire area of 
the cross section. For quantifi cation of immunostainings of m-mag, c-mag, 
c-FLag, laminin-α5, or α-dystroglycan, images were collected and ana-
lyzed by a confocal microscope (TCS-8P; Leica) and appropriate software. 
InSpeck Microscope Image Intensity Calibration kit (Invitrogen) was used to 
determine the linear range of the laser. Specifi c intensity was calculated for 
each image as the signal intensity of the muscle circumference minus that 
of an adjacent, nonstained region (Turney et al., 1996). Five different pic-
tures were taken using the same parameters on each section, and four dif-
ferent sections were used for each individual mouse. In all quantifi cation 
experiments, at least three mice of each genotype were analyzed.
Evaluation of full-length agrin expression
Transgenic c-mag and c-Flag were detected by the polyclonal rabbit anti–
chick agrin (Gesemann et al., 1995). For comparison of the transgenic 
m-mag and the endogenous agrin, an antiserum recognizing the 95-kD, 
C-terminal half of mouse agrin was used. Chick and mouse agrin immuno-
stainings were quantifi ed separately, as described in the previous section. 
Under the premise that c- and m-mag ameliorate the disease phenotype to 
the same extent, the relative expression levels of both were set to 100%. 
This clearly shows that levels of endogenous agrin expressed in kidney 
(expression level, 113% of m-mag) are suffi cient to at least produce the 
ameliorating effect of c-Flag (expression level, 81% of c-mag).
Notexin-induced muscle damage
Tibialis anterior of 5-wk-old mice was injured by injection of 15–20 μl 
notexin (50 μg/ml; Sigma-Aldrich), as previously described (Bentzinger 
et al., 2005). Mice were killed 6, 14, or 28 d after injection, and mus-
cles were isolated and processed as described in Quantifi cation of 
immunostainings.
Hydroxyproline assay
Fibrosis in triceps brachii muscles was measured by assaying for the 
exclusive collagen-specifi c modifi ed aminoacid hydroxyproline (Woessner, 
1961; Edwards and O’Brien, 1980). Tendons were carefully removed be-
fore muscles were vacuum-speed dried and sent to Analytical Research 
Services (Bern, Switzerland) for amino acid analysis. There, each muscle 
was hydrolyzed under vacuum in 50 μl of 6 N HCl for 22 h at 115°C. 
 Hydrolysates were evaporated to dryness and resuspended in 0.1% trifl uoro-
acetic acid. Aliquots were diluted 1:100 for determination of amino acids 
by a routine method (Cohen et al., 1986), including derivatization with 
phenylisothiocyanate, followed by HPLC, identifying, and quantifying 
the collagen-related amino acid hydroxyproline. Relative hydroxyproline 
amount was assessed in reference to the total amount of amino acids.
Statistical analysis
To compare the different genotypes, p-values were calculated using the 
 unpaired two-sample t-tests, assuming equal variances.
Online supplemental material
Fig. S1 represents the regulation of expression by the inducible tetra cycline-
regulated tet-off expression system (Gossen and Bujard, 1992) and the 
breeding scheme to obtain dyW/dyW mice with a tight spatial and tempo-
ral regulation of mini-agrin expression. Fig. S2 shows the binding of the 
transgenic m-mag and the fusion protein AgPerl to laminin and α-dystroglycan 
in both solid-phase and overlay binding assays. In Fig. S3, immunohisto-
chemical staining of cross sections visualizes the regulation of different 
agrin-binding proteins, including laminin-α5, α-dystroglycan, and laminin-α1 in 
dyW/m-mag mice. The online version of this article is available at http://
www.jcb.org/cgi/content/full/jcb.200611152/DC1.
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